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ABBREVIATIONS
AUC total area under the blood drug concentration-time
curve
C drug concentration
C concentration of drug in the blood at zero timeo
concentration of drug in the blood at time t.
C concentration of drug in the blood entering the
liver (systemic)
C, concentration of drug in the emergent venous bloodhv /I. . V(hepatic vein )
C_^ drug concentration in the blood at steady state
concentration of drug in the blood entering the liver
concentration of drug in the blood leaving the liver
CL drug clearance
CL^ hepatic drug clearance
CL^ total body drug clearance
CL^^^ intrinsic hepatic drug clearance
C L . . intrinsic hepatic free drug clearanceint(free) ^
C L . ... .. total intrinsic hepatic drug clearanceint(tot)
D dose
E hepatic extraction ratio
F systemic availability of drug given orally
fg * ratio of the unbound drug concentration in plasma
water to the whole drug blood concentration
K Michaelis-Menten constantm
first order rate constant for elimination of drug
by all processes from central compartment
kĵ 2 first order rate constant for transfer of drug
from central compartment to peripheral compartment
k ^ 2 first order rate constant for transfer of drug














first order rate constant for absorption
overall first order elimination rate constant 
for drug disposition
number
hepatic blood flow 
time
dosing interval
apparent volume of distribution 
volume of central compartment
apparent volume of distribution by extrapolation
apparent volume of distribution by area
apparent volume of distribution at steady state
maximum velocity of enzvrae action
subscripts 
i.v., p.o intravenous and oral routes
subscripts 
O, t at time = O and t
SUMMARY
The investigation was undertaken to observe the effects of alteration 
of liver blood flow and of liver metabolism on the kinetics of two 
antiarrhythmic drugs, lignocaine, a highly hepatic cleared drug and 
tocainide, a drug with low hepatic clearance in intact rats.
An initial study was undertaken to investigate the basic kinetics 
of both drugs following oral and intravenous administration at differ­
ent dosage levels. Lignocaine was found to be the subject of "first 
pass" effect with a systemic availability of 0.019. Tocainide was 
found to be approximately 8 0 % eliminated by the liver and approximately 
20% by the kidneys. Systemic availability of tocainide was 0.94. The 
tq of lignocaine was found to be the same after intravenous and oral 
administration. The t^ of tocainide was found to be longer after oral 
than intravnous administration.
From this preliminary work the dose range in which the kinetics of 
lignocaine and tocainide showed first order kinetics was established.
Doses within this range were chosen for the study of the effects of 
alterations of liver blood flow and liver enzyme activity on the kinetics 
of both drugs. Two enzyme inducing agents were used, 3,4 benzpyrene 
which induces hepatic enzymes without altering liver blood flow and 
phenobarbitone which induces hepatic enzymes and increases hepatic blood 
flow. Sotalol, a g-adrenoceptor antagonist was found to decrease cardiac 
output and liver blood flow. Liver blood flow was measured by the 
radioactively labelled microsphere method. By this method flow to other 
organs and fractional distribution of cardiac output can also be observed.
Changes in kinetics of lignocaine and tocainide at selected doses 
after intravenous and oral administration were observed in rats treated 
with either, 3,4 benzpyrene, phenobarbitone or sotalol.
The results were compared with those obtained from the two mathe­
matical models, the "well-stirred" and the "parallel tube" models which 
predict change in kinetics when these major determinants of hepatic drug 
elimination, blood flow and metabolism are changed.
For tocainide, a metabolism dependent drug, both models gave a 
satisfactory prediction of changes in hepatic extraction ratio, systemic 
availability and AUC when blood flow and metabolism are altered.
Reasonably close prediction of kinetic changes of lignocaine a high 
hepatic clearance drug is obtained when hepatic enzymes are induced.
For changes in liver blood flow with lignocaine the predictions for 
hepatic extraction ratio and AUC. are close to the observed values1. V.
but those for AUC were not with both models,p.o.
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Lignocaine was initially synthesized as a potential local 
anaesthetic agent in 1943 by Lofgren in Sweden. It was shown by 
Ehrenberg (1948) to be 3.3 times as active as procaine, the principal 
local anaesthetic used at that time and to have a more rapid onset of 
action. Lignocaine has subsequently become one of the most widely 
used drugs for local anaesthesia in medicine.
The antiarrhythmic properties of lignocaine were first recognised 
when it was used in resuscitating a patient with ventricular fibril­
lation after all other attempts had failed (Southworth, McKusick,
Pierce and Rawson, 1950). Lignocaine was later used in the operating 
theatre by anaesthetists for this purpose, and in due course its action 
of preventing ventricular arrhythmias after acute myocardial infarction 
in animals was recognised (Carden and Steinhaus, 1956; Harris,
Aquirre, Liptak and Brigham, 1955/56). In 1963 Harrison, Sprouse 
and Morrow reported the successful use of lignocaine given intra­
venously for cardiac arrhythmias that occur during and after open 
heart surgery. Lignocaine has subsequently become a drug of first 
choice for the prevention and treatment of ventricular arrhythmias 
especially in patients with acute myocardial infarction (Gianelly, 
von der Groeben, Spivak and Harrison, 1967).
A potential role for lignocaine as an antiarrhythmic drug 
stimulated the first pharmacokinetic studies. The physiological 
disposition of lignocaine compared with procaine in rats was studied 
by Sung and Truant (1954) using a spectrophotoraetric method for the 
determination of lignocaine. They demonstrated that lignocaine given 
intravenously disappeared very rapidly from the blood and found that
the drug was eliminated by metabolism mainly in the liver. Consistent 
with this observation Harrison, Sprouse and Morrow (1963) reported that 
lignocaine had a relatively short duration of antiarrhythmic effect when 
given to man as an intravenous bolus. Continuous intravenous infusion 
of lignocaine was reported to be effective in patients with acute 
myocardial infarction by Gianelly et al (1967). Following the develop­
ment of gas chromatographic techniques which permitted greater sensi­
tivity of measurement (Beckett, Boyes and Parker, 1965; Keenaghan, 1967; 
Rowland, Thomson, Guichard and Melmon, 1971) a more accurate and 
complete understanding of the pharmacokinetics of lignocaine became 
possbile (Boyes, Scott, Jebson, Godman and Julian, 1971; Tucker and 
Boas, 1971; Rowland, Thomson, Guichard and Melmon, 1971) . Various 
workers were able to demonstrate that the dose of lignocaine could be 
related to antiarrhythmic effects (Jewitt, Kishon and Thomas, 1968; 
Gianelly et al, 1967) and a therapeutic concentration range became 
established (Gianelly et al, 1967; Grossman, Cooper and Frieden, 1969). 
These developments enabled successful dosage regimens for the 
attainment and maintenance of therapeutic blood lignocaine concentrations 
to be developed (Harrison and Alderman, 1972; Wagner, 1974; Aps,
Jenkins, Poole-Wilson and Reynolds, 1975; Singh and Kocot, 1976; 
Greenblatt, Bolognini, Koch-Wesser and Harmatz, 1976; Sheridan, Rawlins, 
Crawford and' Julian, 1977) and the drug is now regularly used in most 
coronary care units.
1.1.2 Chemical structure
Lignocaine (2-diethyl araino-2'-6 '-acetoxylidide) is composed of 
three parts :
(i) a hydrophilic amino group (diethylamine);
(ii) a lipophilic aromatic group (2 ',6 * xylidine);
(iii) an intermediate 2 -carbon chain linking (i) and (ii) 
together containing an amide bond.
( / 'V-NH—C—CH—Nv, 2 '
Figure 1.1 Chemical structure of lignocaine 
MW(base) = 234.3 
MW(HCl) = 270.8 
N* is the tertiary amine 
The amide linkage between the aromatic group and its connecting
side chain is protected by two methyl groups attached to the aromatic 
ring in ortho-position. The stability of lignocaine to hydrolysis 
by acid or alkali is due to the presence of these ortho-methyl groups 
(Bullock and Grundy, 1955; Strother, Soong, Dev and Sadri, 1977), 
a general property known as the ortho-effect (Watson, 1949). Notwith­
standing the basic stability o f . the lignocaine molecule, decomposition of 
the drug can occur in solution by hydrolysis of the amide bond 
(Bullock and Grundy, 1955) in the following manner:
/ \ -NHg + (CjHgtN-CHjCOOH
1.1.3 Electrophysiological effects
In common with other drugs which have local anaesthetic action 
lignocaine prevents both the generation and the conduction of the 
impulse in peripheral nerve by blocking the transient increase in 
permeability of the nerve membrane to sodium ions. These effects 
are related to the action of lignocaine on the heart. Many investi­
gators (Davis and Temte, 1969; Singh and Vaughan Williams, 1971; Mandel 
and Bigger, 1971) have attempted to define the electrophysiological 
properties of lignocaine on cardiac muscle and nerve and although 
controversy remains, there are a number of points of general agreement. 
Lignocaine in common with several other local anaesthetic anti­
arrhythmic agents has "membrane stabilising" effects. This results 
in decreased automaticity of pacemaker tissue, and fibrillation 
thresholds for ventricular muscle and Purkinje tissue are elevated in 
normal and in ischaemic hearts. The duration of the action potential in 
Purkinje tissue is decreased in contrast to quinrdine which also has 
"membrane-stabilising" effects, and the effective refactory period (the 
time during which the fibre is unresponsive to stimuli) is shortened 
by lignocaine. In general terms , of the tissues which it effects, 
lignocaine, at therapeutic concentrations, has potent electrophysio­
logical effects on the Purkinje system, less effect on the ventricular 
muscle and very little effect on the sinus and AV nodes and atrial 
muscle. The antiarrhythmic effects of lignocaine are probably due to 
reduced automaticity of pacemaker tissue and to reduced responsiveness 
of cardiac cells to excitation. The effect of lignocaine in shortening 
the action potential duration and the effective refractory period may 
also be beneficial since both become more uniform throughout the 
conducting system.
1.1.4 Haemodynamic effects
There are several reports of the haemodynamic effects of ligno­
caine in large laboratory animals but there is little data on small 
animals,for example the rat> which was used in the present work.
Kao and Jalar (1959) found in the dog that lignocaine in a dose of 
1 to 2 mg/kg body weight increased cardiac output by raising both 
heart rate and stroke volume and suggested that this was due to a 
central action. Constantino, Crockett and Vasko (1967) reported that 
intravenous doses of 2,4 and 8 mg/kg of lignocaine produced temporary 
decreases in cardiac output, systemic arterial pressure and stroke 
volume in anaesthetized dog. The effects in concious dogs were of 
lesser magnitude and of shorter duration. Other studies in dogs 
(Austen and Moran, 1965) showed a dose-dependent decrease in contractile 
force, heart rate and aortic blood pressure. Harrison and Alderman 
(1972) studied haemodynamic effects of lignocaine in dogs with induced 
acute myocardial infarction and found that infusions of lignocaine 
in doses of up to 2 0 0  yg/kg/min produced minimal circulatory change.
On the other hand, bolus injection of 5 mg/kg lignocaine significantly 
decreased heart rate, arterial pressure and cardiac output. Benowitz, 
Forsyth, Melmon and Rowland (1974) studying lignocaine in monkeys 
found a 1 0  mg bolus, followed by an intravenous infusion of 1 0 0  yg 
per kg per minute for 2 or 3 hours caused no significant change in 
any systemic circulatory parameter; during infusion of lignocaine after 
loss of 30% of circulating volume by haemorrage, blood pressure and 
cardiac output remained stable, but heart rate and haematocrit decreased 
and stroke volume increased as intravascular volume expanded. Several 
investigators have reported that in normal humans lignocaine at 
therapeutic doses either by bolus or by intravenous infusion caused 
either no change or only minimal change in heart rate, cardiac output.
stroke volume, mean systemic and pulmonary artery pressure or peri­
pheral arterial resistance and similar absence of haemodynamic upset 
is found in patients with chronic cardiac disease and with acute 
myocardial infarction (Stannard, Sloman, and Sangster, 1968; Jewitt, 
et al, 1968; Schumacher, Lieberson, Childress and Williams, 1968; 
Binnion, Murtagh, Pollock and Fletcher, 1969; Cullhed, 1969;
Grossman et al, 1969). Although there are some reports (Harrision 
et al 1963; Harrison and Alderman, 1972) that lignocaine produces 
a decrease in ventricular contractile force, this depression is mild 
and of short duration. Overdosage of lignocaine can cause hypo­
tension, probably due to a direct depressant effect on myocardial 
contractility, especially in a damaged heart (Harrison et al, 1963; 
Harrison and Alderman, 1972).
1.1.5 Lignocaine and cardiac arrhythmias
The principal use of lignocaine now is in the suppression of 
ventricular arrhythmias especially those complicating myocardial 
infarction. It is widely recognised that in acute cardiac injury due 
to ischaemia, death is often due to ventricular arrhythmia leading to 
ventricular fibrillation and circulatory failure. The importance of 
this field is such that it has been responsible for the establishment 
in most district hospitals of coronary care units which are largely 
geared to the management of cardiac arrhythmias. It says much for the 
efficacy and safety of lignocaine that of the many agents which have 
been used to suppress cardiac irregularity after myocardial infarction, 
it has been for several years and remains, for this condition, a drug 
of first choice (Lown, Fakhro, Hood and Thorn, 1967; Grossman, Lubow, 
Freiden and Rubin, 1968; Harrison and Alderman, 1972). Indeed it has 
been advocated that lignocaine should be used routinely in the
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prophylaxis of myocardial infarction (Sheridan et al, 1977) uncomplicated 
by arrhythmia,although infact this is not a usual practice.
Arrhythmias emanating from atrial or nodal tissue are normally 
less sensitive to lignocaine.
1.1.6 Toxicity
Toxicity data are available for lignocaine in small and in large 
laboratory animals and in man. In mice. Smith and Duce (1971) 
found that large doses caused death with convulsions and calculated 
the to be 292 mg/kg. The same authors found that doses of
lO mg/kg produced emesis in dogs. Boyes, Adam and Duce (1970) also 
found that large doses of lignocaine administered both i.v. and p.o. 
to dogs caused emesis at a time considerably after the maximum blood 
levels of the drug had been attained, an effect possibly due to 
metabolites of lignocaine. The most common side effects of lignocaine 
in man involve the central nervous system (Gianelly et al, 1967).
Milder signs include dizziness, drowsiness, parethesiae, disorientation, 
agitation, twitching, double vision and diminished hearing. Seizures 
and respiratory arrest are among the more severe side effects and are 
encountered at blood lignocaine concentrations in excess of 9 yg/ml.
Two of the major metabolites of lignocaine, monoethylglycylxylidide 
(MEGX) and glycylxylidide (GX) which are capable of inducing convulsions 
in mice and in dogs (Smith and Duce, 1971; Blumer, Strong and 
Atkinson, 1973) and central nervous system toxicity in man during 
conditions of prolonged constant intravenous infusion (Strong, Parker 
and Atkinson, 1973), may also be due to accumulation of these products 
of biotransformation. Adverse electrophysiological effects of 
lignocaine on the heart are uncommon but when present may be serious 
and take the form of sinus arrest, complete A.V. block and atrial or
ventricular dysrhythmias. (Deacock and Simpson, 1964; Pfeifer,
Greenblatt and Koch^Weser, 1976; Benowitz and Meister, 1978). It is 
a general experience that adverse reactions occur more frequently in 
elderly patients and in patients with acute myocardial infarction and 
congestive cardiac failure, that is, in circumstances in which cardiac 
output and in turn liver blood flow are impaired (Zito, Reid and 
Longstreth, 1977).
1.1.7 Protein binding and tissue distribution
Various species differences have been reported in the distribution 
of lignocaine to the different elements of the blood. In rat, ligno­
caine was reported by Katz (1968) to distribute equally to red blood 
cells and to plasma and hence for that animal whole blood and plasma 
concentrations of lignocaine should be equivalent. At therapeutic 
blood concentrations in man (1.2 - 5.0 yg/ml) and in monkey 60-70% 
of lignocaine is bound to plasma proteins (Tucker, Boyes, Bridenbaugh, 
and Moore, 1970; Difazio, 1975; Benowitz, Forsyth, Melmon and Rowland, 
1974a). At high concentrations, binding decreases (Tucker et al, 1970). 
Lignocaine is less well bound to human erythocytes than to plasma protein 
and in consequence for any given blood sample the concentration of ligno­
caine in the plasma is higher than the value in whole blood. Tucker 
et al (1970) found that at a whole blood lignocaine concentration of 0.5 
yg/ml the plasma: blood ratio was 1.5. The initial distribution of
lignocaine after entering the blood stream is highly dependent on
regional blood flow. One minute after intravenous administration of a 
14C labelled bolus dose to rat, the highly perfused tissues, i.e., heart, 
lung, liver, brain, kidney and spleen were found to contain 70% of the 
radioactivity (Katz, 1968). Lignocaine has a pK^ of 7.85 and at pH 7.4, 
the ratio of ionized to unionized drug is 3:1. However, the molecule
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as a whole is highly lipid soluble and the drug partitions extensively 
into body tissues. In rat, 30 min after lignocaine had been adminis­
tered intramuscularly at a dose of 10 mg/kg, Akerman, Astrom, Ross 
and Tele (1966) found high concentrations in kidney, lung, spleen, 
brain, heart and liver. Similar findings have been in dog by 
Ahmad and Medzihradsky (1971) and in rhesus monkey by Benowitz et. al, 
(1974b). During steady state infusion in man Benowitz and Meister 
(1978) estimated that only about 6 % of the amount of lignocaine in 
the body was present in the circulating volume. Although the rate 
of accumulation of lignocaine in various tissues is to a considerable 
extent dependent on the fraction of the cardiac output which is 
received, the well-perfused tissues such as heart, brain, kidney and 
other viscera do not contain the major body load of administered 
lignocaine. Thus muscle and adipose tissue which are less well 
perfused but which are larger in mass, in fact become the major 
storage reservoir of lignocaine.
1.1.8 Pharmacokinetics
The isolated perfused rat liver and the perfused rat liver situ 
have frequently been used to study lignocaine elimination but detailed 
kinetic data for the rat as a whole animal, as used in the present 
study, have not been found in the literature. After intravenous 
injection to the rhesus monkey, Benowitz et al (1974a) found a very 
rapid early exponential decline in blood concentration with a half-life 
(t^) of 1 - 2  min which was followed by a second exponential decline with 
a tĵ of about 15 min, A similar biphasic decline in blood concentration 
after an intravenous bolus dose was found in 1 0  normal volunteers by 
Rowland et al (1971) the initial rapid phase having a mean tĵ  6 . 8  min 
and the subsequent slower elimination phase having a mean t^ of 108 min.
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These and other authors (Boyes et al, 1970) found that the pharma- 
kinetic s of lignocaine could be described adequately by a two-compart­
ment open system. Rowland et al (1971) also noted that the 
volume of distribution of the central compartment which 
describes the initial distribution space and the steady state distrib­
ution volume, which is an indication of the total amount of lignocaine 
in the body as a function of the blood lignocaine concentration during 
constant intravenous infusion of the drug were both in 
excess of the blood volume and of the body water spaces respectively 
which implies considerable extravascular distribution of lignocaine.
The liver is the major site of elimination of lignocaine (Sung 
and Truant, 1954; Hollunger, 1960a and b) and in all species studied 
extensive extraction of the drug has been shown to occur in a single 
passage through the liver. The highest extraction ratio (e ) is found
in rat (0.99) (Pang and Rowland, 1977), other approximate values for
E being: man, 0.7 (Boyes et al, 1970; Perucca and Richens, 1979,
Bennett, Aarons, Bending, Steiner and Rowland, in press); dog, 0.78 
(Branch, Shand, Wlikinson and N'ies, 1973) and monkey, 0.66 (Benowitz et al, 
1974a). By contrast, in cat, Lautt and Skelton (1976) found much 
lower hepatic extraction (E = 0.28). In consequence of its high heptic 
clearance lignocaine is an example of a drug which shows "first pass" 
effect i.e. extensive presystemic elimination. Availability of the drug 
to the systemic circulation by the oral route has been shown to be 
greatly reduced in man (Boyes et al, 1971) and in dog (Boyes, Adams 
and Duce, 1970). A feature of this type of drug, which is discussed 
more fully later, is that the rate of elimination is very dependent 
on the rate of delivery of drug to the liver, that is, on liver blood
flow. Total hepatic blood flow in most species is approximately 25%
of cardiac output and of this about 25-30% is derived from the hepatic 
artery, the remainder being supplied by the portal vein. Thus changes
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in cardiac output or in the regional distribution of the output may 
cause changes in the blood supply to that organ and may thereby be 
expected to affect the elimination of lignocaine. In patients with 
myocardial infarction who had cardiac failure, the terminal half-lives 
of lignocaine were longer than those in myocardial infarction patients 
without cardiac failure (Prescott, Adjepon-Yamoah and Talbot, 1976;
Aps. et al, 1976) a finding which is consistent with the dependence 
of lignocaine blood concentration,on cardiac output and hepatic blood flow. 
Benowitz et al (1974) found reduced clearance and increased half-life 
of Lignocaine in rhesus monkeys subjected to haemorrhage of 30% of 
circulating volume. In the same study the haemodynamic changes 
produced by intravenous infusion of isoprenaline and of noradrenaline 
produced marked alteration in steady state blood lignocaine concentration.
Drugs may affect the pharmacokinetics of lignocaine by other 
mechanisms. Perucca and Richens (1979) found that the systemic 
availability of lignocaine administered to epileptic patients on 
anticonvulsant drugs was much less than that found in normal subjects.
This finding is almost certainly due to induction of hepatic micro­
somal enzymes by anticonvulsant drugs and its implication are 
examined in the later sections of this work.
1.1.9 Metabolism and excretion
Lignocaine is almost entirely metabolised by the liver (Sung and 
Truant, 1954; Hollunger, 1960a and b), and less than 5-10% is excreted 
unchanged in the urine (Eriksson, Granberg and Ortengren, 1966). The 
metabolism of lignocaine vitro was originally established by 
Hollunger (1960a and b) using rabbit liver. He demonstrated that 
lignocaine was metabolised in an hepatic microsomal enzyme system by 
oxidative N-deethylation which required both oxygen and reduced 
NADPH in the reaction.
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Oxidative biotransformation of lignocaine also involves the 
flavoprotein cytochrome c reductase (Williams and Kamin, 1962) and the 
haemoprotein cytochrome P-450 (Omura, Sato, Cooper, Rosenthal and 
Estabrook, 1965), the term P-450 referring to the ability of the reduced 
form of the haemoprotein to react with carbon monoxide to yield a 
complex which has its main absorption peak at 450 nm (Omura and Sato, 
1964). Similar requirements have been shown for the metabolism of 
several other drugs (Brodie, Gillette and La Du, 1958; Gillette, 1963). 
The reactions may be expressed in the following general form:
NADPH
cytochrome c
1. NADPH + A + H'"'— AH^ + NADP"*"
2 . AHg + O^ -------------------- ► "active oxygen complex"
3. "active oxygen complex" + drug substrate ►oxidized drug
+ A + H^O
NADPH + O^+drug substrate + nt-------► NADP^ + Oxidized drug + H^O
where A is the oxidized form and AH^ is the reduced form of cytochrome 
P-450. One molecule of O^ is consumed for each molecule of substrate 
oxidized, one atom of O being introduced into the substrate, the 
other being reduced to form H^O. The metabolising system is thus 
called a mono-oxygenase or mixed function oxidase system. Pretreatment 
with certain drugs, e.g. 3,4-benzpyrene or phenobarbitone, greatly 
increases the metabolising capacity of this enzyme system.
Lignocaine has been found to bind with high affinity to micro­
somal cytochrome P-450 (Moldeus, Grudin, von Bahr and Orrenius, 1973) 
and at high concentration was noted to be unusally rapidly deethylated
by the microsomes with a V of about 15 nmole/mg protein, min and Kmax m
of 250 MM by Nyberg, Karlen, Hedlund, Grudin and von Bahr (1977). They 
proposed that the high affinity of lignocaine for the cytochrome P-450
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system as well as the rapid oxidation of the drug are important 
determinants of the extensive liver extraction and first pass 
elimination of the drug. Von Bahr, Hedlund, Karlen, Backstrom and 
Grasdalen (1977) reported that there are two binding sites for 
lignocaine to microsomal cytochrome P-450, a "low affinity site" 
catalysing dééthylation and a "high affinity site" catalysing 
aromatic hydroxylation. This may explain the larger proportion of 
aromatically hydroxylated as opposed to deethylated metabolite of 
lignocaine which is normally found. Thus Keenaghan and Boyes (1972) 
reported that 65% of an oral dose (25 mg/kg) of lignocaine given to 
female rats, is recovered in urine as 3-hydroxylated metabolites, and 
only 0.7% as MEGX (monoethylglyeinexylidide, a deethylated product).
Hepatic metabolism of lignocaine has been studied extensively in 
animals (Keenaghan and Boyes, 1972; Hollunger, 1960a and B; Akerman, 
et al, 1966; Di Fazio and Brown, 1972) .and man (Beckett, Boyes and 
Appleton, 1966; Mather and Thomas, 1972; Adjepon Yamoah and Prescott, 
1973; Breck and Trager, 1971; Heinonen, Takki and Jarho, 1970;
Stenson, Constantino and Harrison, 1969). Keenaghan and Boyes (1972) 
observed in man that 73% of an administered lignocaine dose (Table 1.1) 
appeared in the urine as 4-hydroxy xylidine, while only minor quantities 
of other metabolites appeared. Urinary excretion in the dog consisted 
mainly of 4-hydroxyxylidine and significant quantities of glycylxylidide 
(GX). In contrast, the rat excreted mainly 3-hydroxy lignocaine and 
3-hydroxy MEGX,. withiless 4-hydroxyxylidine. Figure 1.2 shows the 
structures of lignocaine and its metabolites. The arrows in the 
figure represent the probable major pathways of metabolism. Keenaghan 
and Boyes (1972) compared the metabolic products of lignocaine in 
rat, guinea-pig, dog and man, and the proportion of each metabolite 
excreted by the various species are summarized in Table 1.1. It can
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4-Hydroxy-2,6 -dimethylaniline 2-Amino 3-methyl-
benzoic acid
Figure 1.2 Summary of known pathways of metabolism of lignocaine
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be seen that inter-species variability in the excretion of lignocaine 
metabolites does exist. Nevertheless the species listed all appear 
to produce the same range of metabolic products suggesting that 
differences between species are more those of the proportion of drug 
metabolised by different routes rather than the routes themselves. 
Furthermore it is a feature common to all species studied that hepatic 
extraction and biotransformation of lignocaine is rapidly achieved, 
thus species differences in metabolism are unlikely to be a major, 
obstruction to the extrapolation of animal data, and in the case of 
the present work, rat data, to the findings in man.
Biliary excretion of lignocaine is a minor factor in elimination.
14Katz (1968) found that less than 3% of C-labelled lignocaine dose 
administered to a dog appeared in the bile after five hours. Keenaghan 
and Boyes (1972) reported about 30% recovery of radioactivity in the 
bile collected for 24 hr in rats given lignocaine either p.o. or 
i.v. This radioactivity was exclusively from metabolites, no unchanged 
lignocaine being found in the bile. Metabolism by other tissues is 
minimal.
Lignocaine, a weak base (pK^ 7.85) is reabsorbed from the kidney 
tubules by nonionic diffusion and its renal clearance is affected by 
changes in urinary pH but not significantly by urine flow rate (Eriksson 
and Granberg, 1965). However, excretion of unchanged lignocaine by 
the kidney is a minor route of elimination. About 2.8% of the dose 
administered was reported to be normally excreted unchanged in the 
urine in rats (Keenaghan and Boyes, 1972) and about 3-11% in man 
(Sung and Truant, 1954; Beckett et al, 1966).
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Table 1.1*: Species variation in the metabolism of lignocaine
Compound Percentage of dose recovered in 48hr urir
Rat Guinea-pig Dog Man
Lignocaine 0 . 2 - 0.5 2 . 0 2 . 8
Monoethylglyeinexylidide 0.7 .14.9 2.3 3.7
Glycinexylidide 2 . 1 . .3.3 1 2 . 6 2.3
3-Hydroxylignocaine 31.2 . 0.5 6.7 1 . 1
3-Hydroxymomo nethy1- 
glycinexylidide 36.9 . 2 . 0 3.1 0.3
2,6 -Xylidine 1.5 .16.2 1 . 6 1 . 0
4-Hydroxy-2,6 -di­
methylaniline 12.4 .16.4 35.2 72.6
* from Keenaghan and Boyes (1972)
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1.1.10 Metabolites of lignocaine
The principal metabolites of lignocaine are MEGX and GX. MEGX 
has been noted to cause convulsions in mouse, rat and dog (Smith 
and Duce, 1971; Blumer et al, 1973). The convulsant activity of MEGX 
has been estimated to be equivalent to that of lignocaine (Blumer et al, 
1973). GX may cause death in animals before convulsions are seen and 
it is capable of potentiating the convulsant activities of MEGX and 
lignocaine (Blumer et al, 1973).
Both MEGX and GX may be found in significant concentrations in 
the blood of patients receiving lignocaine therapeutically 
(Adjepon-Yamoah and Prescott, 1973; Collinsworth, Strong, Atkinson, 
Winkle, Perlroth and Harrison, 1975; Halkin, Meffin, Melmon and 
Rowland, 1975; Strong, Mayfield, Atkinson, Burris, Raymon and Webster 
1975; Prescott et al, 1976). Both metabolites have antiarrhythmic 
effects in animal and in man. However, MEGX, the first de-ethylation 
product exhibits 83% of the anti-arrhythmic activity of lignocaine 
(as measured by its ability to suppress digitalis-induced arrhythmias 
in guinea-pig atrium) and it is also a local anaesthetic, whereas 
in common with other primary amines, GX has poor local anaesthetic 
properties and exhibits only about 1 0 % of lignocaine's anti­
arrhythmic effect (Strong et al, 1973; Burney, Di Fazio, Peach, Petrie 
and Silvester, 1974). After oral administration of lignocaine to 
normal volunteers, Bennett et al (in press) found that blood concen­
trations of MEGX and of lignocaine were similar, indicating that the 
oral availability of lignocaine based on anti-arrhythmic activity 
would be greater than the estimate calculated from measurements of 
lignocaine concentration alone. In the study quoted the estimated 
half-lives of MEGX in three normal subjects ranged between 28 and 
94 min which are values comparable to those reported by Adjepon-Yamoah
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and Prescott (1973). Similar estimates of half-life were made in 
three patients who received therapeutic infusions of lignocaine 
intravenously by Halkin et al (1975). It is probable that in some 
patients who receive lignocaine by intravenous infusion, appreciable 
accumulation of MEGX contributes to anti-arrhythmic and possibly also 
to toxic effects (Strong et al, 1973; Halkin et al, 1975; Prescott 
et al, 1976; Nation, Triggs and Selig, 1976).
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1.2 Tocainide
1.2.1 History and chemistry
Tücaihide (2-amino-2',6 ' propionoxylidide HCl), a primary amine 
analogue of lignocaine was synthesised with the object of developing 
an anti-arrhythmic drug that is less rapidlÿ eliminated than lignocaine. 
In common with lignocaine, tocainide has two ortho-methyl groups on 
the benzene ring, which confer considerable stability to the molecule, 
the phenomenon of "ortho-effect".
NH-C-CH-NH
Figure 1.3 Chemical structure of tocainide 
MW (base)= 192.26 
MW (HCl) = 228.72 
N* = the primary nitrogen
In early work tocainide was found to have similar electrophysio­
logical properties to lignocaine and it was shown to be effective in 
suppressing ventricular arrhythmias after experimental myocardial 
infarction in dog (Coltart, Berndt, Kernoff and Harrison, 1974). 
Evidence of its low hepatic extraction in dog (Coltart et al, 1974) 
and in man, together with high bioavailability (Lalka, Melvin,
Meyer, Duce and Elvin, 1976) led to its introduction in to clinical 
use. In 1976 McDevitt, Nies, Wilkinson, Smith, Woosley and Oates 
(1976) reported that oral doses of tocainide given to patients with 




Data in the literature on the electrophysiological effects of 
tocainide are scant and the following account is based on unpublished 
data supplied by Astra Pharmaceutical Products Inc. Tocainide appears 
to resemble lignocaine in several of its effects. When applied to 
desheathed isolated frog sciatic nerve tocainide has a local anaesthetic
acition similar to that of lignocaine. In a voltage-clamped isolated
frog nerve preparation, in which an approximate 80% block of sodium
current is needed to block conduction, tocainide appeared to be about one
third as effective as lignocaine. In the isolated dog Purkinje- 
papillary muscle preparation, tocaininde shortened the effective refrac­
tory period and action potential duration in single Purkinje fibres. 
Tocainide may be classed as an anti-arrhythmic agent with "membrane stab­
ilising" properties and it bears a resemblance to both lignocaine and 
quinidine in its actions. (Investigator's brochure tocainide HCl,
Astra Pharmaceutical Products Inc.).
1.2.3 Haemodynamic effects
Tocainide appears to have little haemodynamic activity. In concious 
dogs, Duce, Smith, Boyes and Byrnes (1973) reported that multiple oral 
dosing with tocainide (25 to 50 mg/kg every 4 hours) did not alter 
systemic arterial pressure or central venous pressure. Coltart et al, 
(1974) failed to find significant circulatory changes in dogs one hour 
after administration of 60 mg/kg orally but when the dose was increased 
to 120 mg/kg a significant decrease in heart rate to 24-32% of control 
value was observed.
Administered to normal volunteers in doses of 10 mg to 1000 mg, 
tocainide caused no significant change in blood pressure, heart rate or 
systolic time intervals. (Investigator's Brochure Tocainide HCL,
Astra Pharmaceutical Ltd., 1977). The electrocardiographic parameters 
of PR interval, QT interval and QRS duration were also unchanged.
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McDevitt et al (1976), in a study of patients with frequent 
premature ventricular contractions (PVCs) gave single oral doses of 
tocainide ranging between 10 mg and 1200 mg in an incremental sequence. 
No significant effects on arterial blood pressure, on heart rate or on 
the electrocardiogram of normally conducted beats were observed. More 
recently, Schwartz, Covino, Duce, Narang, Fiore, Markelis, Rizvi and 
Smith, C1979) reported that following intravenous infusion of tocainide 
to cardiac patients, left ventricular pressure was significantly 
reduced although other parameters of cardiac function (i.e., heart rate, 
cardiac output, cardiac index, stroke volume, syst;emic vascular 
resistance and pulmonary vascular resistance) were unaltered. It was 
suggested that this reflects a direct depressant effect of tocainide 
on myocardial contractility in these patients.
1.2.4 Anti-arrhythmic effects
Tocainide has been found to be an effective anti-arrhythmic drug 
when studied in standard laboratory models of cardiac arrhythmia.
Moore and Spear (1973) reported that chloroform-induced ventricular 
fibrillation in mice was diminshed. They also observed that in dog, 
the threshold for ventricular fibrillation induced by electrical 
impulses was raised by the administration of tocainide. In the same 
study tocainide slowed the rate of discharge of atrial pacemakers in 
dog and completely suppressed ventricular pacemakers with induced 
complete atrio -ventricular block. Similar studies by Duce, Smith,
Boyes and Byrnes (1973) confirmed the effects of tocainide on chloro­
form-induced ventricular fibrillation in mice. These workers also found 
a dose-related suppression of induced ventricular ectopic beats and of 
arrhythmias caused by ouabain in dog. These effects of tocainide 
occurred at plasma concentrations of 15-30 ug/ml in which range no
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change in haemodynamic parameters such as cardiac output, blood 
pressure and heart rate were noted. Coltart et al (1974) confirmed 
that at these concentrations of tocainide, suppression of ventricular 
ectopic beats occurs in dog.
Anti-arrhythmic effects of tocainide have also been demonstrated 
in man. McDevitt et al (1976) in their study of patients with 
frequent PVCs found that oral doses of tocainide in excess of 100 mg 
were associated with a 60% reduction in PVCs in the 5 hours after a 
dose. At oral doses of 400-600 mg. Winkle et al (1976) reported a 
90% reduction in PVCs with tocainide (plasma concentrations of
5-10 yg/ml), Winkle et al (1976) found a 70% reduction in PVCs at 
plasma concentrations of tocainide in excess of 6 yg/ml.
1.2.5 Toxicity and side effects
In animal toxicity testing, deaths in rodents due to tocainide 
were associated with convulsions (Adam, 1972; Smith, 1972) and in dogs 
and monkeys (Duce, 1972) sub-lethal doses of tocainide caused emesis 
and prolonged, severe seizures. Cumulative oral doses of tocainide 
given to dogs with induced ventricular arrhythmias also produced emesis 
and convulsions (Duce, 197 2) but these effects occurred after the 
arrhythmia had been abolished. Subacute toxic effects in animals 
include ataxia and sedation (Duce, 197 2).
The common adverse effects of tocainide in patients are related to 
the gastrointestinal tract (anorexia and nausea) and to the central 
nervous system. Schwartz et al (1979) reported that at blood levels of 
9-29 yg/ml, which are largely but not entirely in excess of the 




After intravenous injection Schwartz et al (1979) noted that'in man, 
blood concentrations of the drug fell rapidly for 15 mins and then 
declined more slowly, that is the disappearance curve of tocainide from 
the blood exhibited a bi-exponential form. Lalka et al (1976) found 
that blood concentration data after intravenous injection of tocainide 
could be fitted satisfactorily to a two-compartment open pharmacokinetic 
model. However, the initial exponential decline is of short duration, 
that is the ratio A/a is very small compared to the ratio B/3 (see 
Chapter 1.3.; Basic Pharmacokinetics) and for many purposes the 
pharmacokinetics of tocainide may be described adequately by a one 
compartment open model. Most available kinetic data refer to man. The 
average disposition half-life (tĵ  3 ) for this drug in man was found by 
Lalka et al (1976) to be 11.3 hr. In four normal males the mean initial 
dilution space, (0.91 L/kg) and the volume of distribution at steady
state, Vj , (1.44 L/kg) were reported to be greater than the human
blood volume and body water spaces respectively implying that there is 
extravascular concentration of tocainide in a manner similar to that of 
lignocaine. Clearance of tocainide from the blood is reported in man 
to be 62% hepatic and 38% renal. Little comparable data exists in 
other species.
Binding' of tocainide to plasma protein was studied by Lalka 
et al (1976) who found that in the clinically effective range of 
2f-13 yg/ml approximately 50% of the drug is bound, that is the plasma; 
blood ratio is approximately unity. These workers also reported that 
there are two classes of binding site of tocainide to human plasma, 
one with low capacity and high affinity and another with low affinity 
and high capacity.
25
After oral administration to laboratory animals and to man, 
tocainide is well absorbed from the gastrointestinal tract (Duce et al, 
1973; McDevitt et al, 1976) and peak blood concentration occurs 
approximately 60 min after dosing. Lalka et al (1976) found that the 
rate of absorption of tocainide was so rapid that it was not possible 
to assign an order to the process. Bioavailability of tocainide has 
been found to approach 1 0 0 % whether calculated by excretion of parent 
drug and metabolites in urine (Lalka and Feldman, 1974) or by direct 
comparison of areas under blood concentration-time curves following 
intravenous and oral dosing (Lalka et al, 1976). It has also been 
recorded that the presence of food in the stomach may reduce peak 
blood concentrations by up to one third but bioavailability is not 
altered by food (Lalka et al, 1976).
1.2.7 Metabolism and excretion
The complete bio transformation pathways and individual metabolic 
products of tocainide in various species have yet to be elucidated.
In microsomal incubation experiments (Nyberg et al, 1977) tocainide, in 
contrast to lignocaine, was found to have a very low affinity for liver 
microsomal cytochrome P-450.. The primary amine structure of tocainide 
which resists rapid N-deethylation together with its low affinity for 
the principal drug metabolising enzyme system are compatible with the 
slower rate Of hepatic metabolism of tocainide as compared with 
lignocaine.
The principal metabolites of tocainide which has been proposed
(Investigator's Brochure Tocainide HCl, Astra Pharmaceutical Ltd., 1977; 
Elvin, Keenaghan, Byrnes, Tenthorey, McMaster, Takman, Lalka, Maninon, 
Baer, Wolshin, Meyer and Ronfeld, 1980) are shown in Figure 1.4.
26



















CH3 ' " 3y
NH-C-C=0
Figure 1.4 Tocainide and known or suspected products of elimination
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About 25% of the dose is accounted for by the Compound III which 
is believed to be a metabonate, that is, a substance formed after 
excretion from the body. Compound III is believed to derive from 
the substance labelled II which is an hypothesised metabolite in which 
a carbonyl group has been added between the tocainide and the glucuronic 
acid molecules. Only small amounts of metabolites IV and V are present 
in urine and about 30% of an administered dose has yet to be accounted 
for.
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1.3 Basic pharmacokinetic concepts
Dynamic processes feature in almost all facets of pharmacology. 
Pharmacokinetics has been defined by Notari (1975) as that branch of 
pharmacology which is concerned with "the study of the kinetics of 
absorption, distribution, metabolism and excretion of drugs and their 
pharmacologic, therapeutic or toxic responses in animals and man".
The objectives of pharmacokinetics include the derivation of mathe­
matical expressions and the determination of constants which can be 
used to depict and to predict the time-course of drug concentration 
and effect in the body. The temporal relationships of drug effect 
depend on the dosage regimen used and on the absorption, disposition 
and elimination processes which in turn affect drug concentration at 
its site of action. A problem in defining accurate dosage regimens or 
in acheiving a meaningful understanding of biological responses is that 
drug at its site of action is usually inaccessible to measurement. In 
practice, most often drug measurements are made in blood or plasma 
and expressed graphically in the form of a concentration-time profile 
which can be analysed mathematically.
1.3.1 Compartmental analysis
The most common approach to the pharmacokinetic characterization 
of a drug is to express the body as a system of compartments, even 
though these compartments may not specifically correspond to well- 
defined anatomical or physiological spaces or volumes. Rather compart­
ments are mathenatical concepts postulated to explain observed drug 
concentrations on the basis of the amount of the drug in the body.
In particular circumstances a compartment may represent a specific 
anatomical entity (e.g. G.I. tractor liver), a specific physiological 
entity (e.g. blood or urine) or a non-specific collection of entities
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(e.g. poorly or well-perfused tissues) . Drug transfer from one 
compartment to another is usually assumed to be a first order process, 
that is, the rate of exit of drug from a given space is proportional 
to the concentration of drug within it. In the presence of capacity 
limited elimination or of saturation of a transport system, the 
processes become zero order. Appropriate rate constants are thus 
assigned to different processes.
The one-compartment open model
If after intravenous injection, a drug distributes instantaneously 
and homogenously to the tissues and fluids of the body, and if drug 
elimination from the body is a first order process then the relationship 
between the logarithm of the concentration of drug in the blood and 









Figure 1.5 Schematic graph of drug concentration in the blood plotted
on a logarithmic scale against time after a single intravenous 
bolus of a drug when the body is depicted as an open one
compartment linear system
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The half-life (t^) of the drug in the blood is the time for any given 
concentration to decrease by one half. In the case of a drug which is 
eliminated in a manner characterised by first order kinetics, t^ is 
independent of dose. It follows that if a series of different doses 
of a drug are given to the same individual, a plot of blood concentration/ 
dose with respect to time will give a line which is independent of dose. 
This is known as the principle of superposition. Lengthening of half- 
life with increase of dose is an indication that elimination is no 
longer first order, that is that saturation of the elimination process 
is occurring.
A drug which distributes rapidly and is eliminated by first order 
kinetics such that its blood concentration-time profile is monophasic 
as in Figure 1.5 can be regarded as one which treats the body as a 
one-compartment open system. This is depicted in Figure 1.6
Dose
Figure 1.6 One-compartment open model
where V is the apparent volume of distribution of the drug in the body
(V ) and k is the first order rate constant for overall elimination of d e
drug from the body. It follows that for such a system there is a
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proportionality between the concentration of drug in the compart­
ment and the rate of elimination, that is
rate a concentration eq. (1 )
Expressed in differential form
= —k C eq. (2)dt e
where
e is drug concentration 
t is time
and k is the first order rate constant for the elimination er
-1process with units of reciprocal time (t ) .
If instantaneous input and distribution of drug are assumed, then 
the relationship between blood concentration in the system and time 
can be found by integration of eq. (2) to give
C ̂  "ket eq. (3 )
where c^ is the drug-concentration at time t and Cq is the drug 
concentration at zero time, obtained by extrapolation of the log^^QC 
versus t plot, and e is the base of the natural logarithm (In). It 
follows that
In C = (In Cg)-k^t eq. (4)
and from the relationship
2.303 log^^C = InC eq. (5)
Since eq. 6 is a simple linear equation the rate constant, k^ may be 
obtained from the slope of the line. It may also be derived from 
according to the relationship
eq. (7)
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The two-compartment open model
In practice whether or not blood concentrations of a drug 
demonstrate one-compartment characteristics often depends on how soon 
the first blood samples are taken. In a survey of the pharmacokinetic 
characteristics of 38 drugs Dvorchik and Vessel (1978) found that 
considerable errors were associated with calculation of clearance on 
the basis of a one-compartment model if drug disposition followed" 
multi-compartment kinetics, and that the magnitude of the error was 
related to the initial distribution of the particular drug. Generally 
after single intravenous injection blood concentrations of most drugs 
decrease in an initial rapid phase, after which there is a phase or 
phases of slower decline in blood concentration. A plot of the 
logarithm of blood concentration against time can often be resolved 
into two linear components. The method of residuals may be used to 
achieve this graphically, a process also called "feathering" in 
which differences in concentration between the extrapolation of the 
slower phase of the logarithm of concentration-time curve to zero 
time (B) and the observed blood concentration-time curve at various 
times are used to construct the initial linear component (Notari,













Figure 1.7 Semilogarithmic plot of blood drug concentration versus time 
after a single intravenous bolus of a drug when the body is 
*^®pi-Cted as an f̂ r’̂'n twc*- rar^menf 1 i c r 1-.
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If the slopes of the rapid and slow exponential phases are 
designated -a/2,303 and -3/2.303, respectively, where a and 3 are 
apparent first order rate constants, and the intercepts on the con­
centration axis are A and B, then the entire blood concentration-time 
curve may be described by the following bi-exponential equation:
eq. (8 )
when decline in drug concentration in the blood is biexponential, 
it is justifible to depict the body as an open two-compartment system. 
The commonest model of this type conceives of a small volume central 
compartment and a large volume peripheral compartment. Drug is 
administered to and is elimination from the central compartment as is 
shown in Figure 1.8
DOSE
Figure 1.8 Two-compartment open model
''l 1̂2
Cl 2̂1
andg represent drug concentration in the central and peripheral 
compartment respectively. Similarly and indicate the volumes of 
these compartment, and k^^ are the first order rate constants of
drug transport between the central and peripheral compartments and k^ 
is the first order rate constant for elimination of drug from the 
central compartment. Although these compartments are theoretical.
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for many drugs,the blood and highly perfused tissues such as liver, 
kidneys, heart and lungs are probably representative of the central 
compartment.. It is for this reason that elimination is depicted as 
occurring from that compartment.
Mayersohn and Gibaldi (1971) provided a mathematical solution to 
the two-compartment open model enabling the rate constants k^gf 
and k^ to be determined in terms of a, 3, A and B as follows:
k_ = a3 + Bg eq. (9)
A + B
k = a 3 eq. (lO)
" >'21
k^ 2  = Ot + 3 - kg^- eq. (11)
1.3.2. Apparent volume of distribution
Although in compartmental analysis the body is conceived of as 
consisting of one or more homogeneous spaces, it is obvious that in 
fact this not so. Drug concentrations may well be different in tissues such 
as muscle, liver, adipose tissue and blood. However, for many drugs 
the ratio of drug in the blood to that in the remainder of the body 
is reasonably constant. Thus it is possible to derive a 
proportionality constant which relates the blood concentration of 
drug (C) to the total amount of drug in the body (A);
A = Vd C
This proportionality constant is known as the apparent volume of 
distribution (Vd) and it can be derived in various ways.(Riegelman,
Loo and Rowland, 1968; Benet and Ronfeld, 1969;
Gibaldi, Nagashima and Levy, 1969; Perrier and Gibaldi, 1973).
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Distribution volume by extrapolation
If the body is regarded as a single compartment then Vd can be 
derived from the intravenous dose which represents the amount of drug 
in the body at zero time and the blood concentration at that time, Co 
found by the extrapolation of the plot of logarithm of blood concentration 
with respect to time;
Vd = i.v. dose
Co
eq. (1 2 )
However, the kinetic characteristics of many drugs are compatible 
with a two-compartment open system and with such a model the extra­
polated value for B is given by 
B = dose (k2i~3)
V^ (a-3) eq. (13)
Where V^ is the volume of the central compartment. This enables
calculation of Vd by extrapolation (Vd^^^^^^) 
V^ extrap = i.v. dose = V]̂  (a-3 )
^ 2 1  ^
eq. (14)
Distribution volume by area
The concept of a distribution volume implies an equilibrium state 
and this is a condition not met by extrapolation methods of calculation. 
Nagashima, Levy and O'Reilly (1968) drew attention to the fact that 
after bolus administration of a drug a "pseudo-distribution" equili­
brium exists when the terminal phase of a logarithm of concentration 
versus time plot becomes linear. In other words the observed blood 
concentrations may be related to the total amount of drug in the body 
at all times after distribution equilibrium has been attained. For a 
drug which displays the characteristics of removal from the blood 
described by eq.(8 ),in time, the first exponential term becomes
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negligible i.e. the equation becomes monoexponential and accordingly 
= Be eq. (15)
Integration of eq. (8 ) between zero and infinity gives a value for 
the area under the coneentrâtion-time curve:
= j;area = Cdt = A + B̂0 a 3 eq. (16)
Correspondingly eq. (15) becomes 
area = ^
3




Accordingly in terms of the one compartment model a distribution 
volume may be derived from area measurements and 3 thus:
Vd = Dose
3 .area
For a drug which obeys the two-compartment open model the
corresponding relationship is:
Vd, . = Dose (area)
eq. (19)
3 (A + B) eq. {20h
(a 3)
Disbribution volume at steady state
An alternative method of expressing distribution volume in a form 
which takes account of an equilibrium between drug in the blood and 
drug in the. body as a whole is the distribution volume at steady state 
(Vdgg). In the two compartment system this presents a difficulty 
because as distribution is occurring into the peripheral compartment 
drug is also lost by elimination from the central compartment. A steady 
state of equilibrium can only be said to exist when there is no nett 
transfer of drug between the two compartments. This occurs at only one 
instant following an intravenous bolus. Nevertheless assuming that nett 
transfer of drug between the two compartments is zero, Vd^^ may be estimated
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from the rate constanst as follows: (Riggs, 1963, quoted by
Riegelman et al, 1968)
Vd ss
^ 2 1
eq. (2 1 )
Although the constraint of no nett transfer of drug between
compartments is a theoretical limitation to the use of Vd afterss
single intravenous bolus injections, under conditions of constant rate
intravenous infusions when equilibrium has been reached, the Vd^^
correctly relates the steady state blood concentration to the amounts
of drug in the body.
Reigelman et al (1968) pointed out that distribution volumes
calculated by the extrapolation and by the area methods are influenced
by the elimination processes but it is apparent from eq. 2 1 that
Vd is no affected by elimination. Hence factors which alter ss
elimination (other drugs, disease) may influence Vd ^ and Vdextrap area
but not Vdgg and in this respect the latter is more acceptable as a 
constant.
Much of the work to be described is concerned with altering
conditions of elimination of drugs which were administered in single
doses and all three methods were used to express distribution volume
Vd , Vd and Vdextrap area ss
1.3.3 Clearance
The notion of clearance (CL) was originally developed to describe 
the elimination of urea by the kidney (Holler, McIntosh and Van Slyke, 
1929). Clearance has subsequently been widely adopted in pharmaco­
kinetic work to quantify removal of drug by liver, kidney and other 
organs and hence to provide an essential parameter for the construction 
of dosage regimens. In terms of an eliminating organ clearance is 
defined as the volume of perfusing medium which is effectively
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cleared of drug by the organ in unit time; clearance thus has the 
dimensions of volume and time. Total body clearance is the sum of the 
clearances. :of the constituent tissues and organs of the body.
If a drug equilibrates rapidly between blood and tissues after 
intravenous injection and if after oral administration it is not 
metabolised before entering the systemic circulation, then its kinetics 
can often be described by the one-compartment open model with elimination 
as a first-order process as shown in Figure 1.6. Since the present 
work is mainly concerned with hepatic eliminatin k^ can here be 
considered the first-order rate constant for removal of drug by the 
liver.
In such a system clearance is related to k^ and V, the apparent 
volume of distribution of the drug as follows:
CL = Vkg eq. (22)
The relationship of half-life (t^) to k^ in the model depited 
in Figure 1.6 is in Figure 1.6 is
S  = ^  eq. (7)
e
It is thus apparent that in the one compartment model, clearance 
and half-life are directly related to drug elimination as expressed 
in eq. (22)and eq.(7)and both parameters.thus characterise elimination
of drugs which are distributed according to this system.
Many drugs, however, display in the body the distribution 
characteristics of a two-compartment open system with elimination from 
the central compartment as shown in Figure 1.8. For drugs which are 
eliminated only by the liver, k^ in this scheme must also be the 
first-order rate constant for hepatic elimination.
3S
The general relationship between the dose of drug administered 
and clearance (Perrier and Gibaldi, 1974) is given by 
CL = dose eq. (23)
where A U C , . is the area under the blood concentration-time(o-»<%)
curve from zero time to infinity. Thus for the one-compartment model, 
AUC = dose
V.kg eq. (24)
In the case of the two-compartment system with elimination only 
from the central compartment (V^)
eq. (25)
Hence for this system also
CL = V,k eq. (26)
1 e
indicating that there is a direct relationship between clearance 
and hepatic drug elimination.
By contrast, however, in multi-compartment systems, half-life is 
not only a function of the activity of the eliminating organ but it 
is also influenced by drug distribution. For the two-compartment 
open system Perrier and Gibaldi (1974) related half-life and the 
individual rate constants as follows:
t^ = 0.693/ - A .................2
eq. (27)
It is clear that in such a complex relationship there would not 
be a proportionality between change in hepatic elimination and change 
in half-life. Hence in multi-compartment systems clearance (eq. (26)) 
can be expected to give a more realistic insight into the elimination 
characteristics of drugs which are removed by the liver.
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1.3.4. Absorption kinetics
The rate at which a drug is absorbed from its point of administ­
ration can be determined from the blood concentration-time profile 
(Nelson, 1961; Loo and Riegelman, 1968). When a drug is taken orally 
its absorption can usually be described by first-order kinetics, 
sometimes proceeded by an apparent lag phase. Drug absorption and 
elimination can thus be depicted as two consecutive apparent first 
order processes thus:
drug at kab drug in - metabolised and
absorption site body excreted drug
If k̂ ĵ  exceeds k^ then the slope of the plot of logarithm of
blood concentration against time will eventually be equal to that
found after intravenous administration, that is, - k^ . However,
2.303
if the absorption process is slow and k,j exceeds k ^ ,  then the slope 
of the logarithm of concentration against time plot will be less 
steep than that obtained after intravenous administration. In the 
present work, the influence on rate of disappearance from the blood 
of one drug which is rapidly absorbed from the gut (lignocaine) may 
be contrasted with one which is slowly absorbed (tocainide).
Determination of the first order absorption rate constant (Notari, 
1975; Gibaldi and Perrier, 1975) may be achieved by the method 
of residuals, by back-extrapolation of the plot of the logarithm of 
blood concentration versus time to zero time as depicted in Figure 1.9. 
The differences between the extrapolated line and the observed drug
concentration points with respect to time have a slope of -k 
from which the absorption rate constant may be calculated.










Figure 1.9 Estimation of by the method of residuals (see text)
1.3.5 Systemic availability
Drug availability can be defined as the extent to which a drug, 
after administration, reaches the point of measurement. The concept 
of the two-compartment open model commonly proposes that the central 
compartment comprises the blood and highly perfused tissues including 
the elminatlng organs, the kidneys and liver.and it is often assumed 
that drug is administered into the central compartment. However, it has 
become clear that the route by which drug reaches the systemic 
circulation may have an important influence on its kinetics. Drugs 
such as lignocaine (Boyes, Adams and Duce, 1970); propranolol (Shand, 
Nicholls and Oates, 1970); propoxyphene (Perrier and Gibaldi, 1972) 
and nortrypline (von Bahr, Borga, Fellinius and Rowland, 1973), which 
undergo high hepatic elimination are subject to extensive biotrans­
formation during the initial pass through the liver when they are
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administered by the oral route. This phenomenon has been termed the 
"first-pass" effect. It follows that drugs subject to this effect 
have a smaller AUC after oral than after intravenous administration of 
an equivalent dose indicating reduced systemic availability despite 
complete absorption by the oral route. Thus for such drugs, avail­
ability and by implication, pharmacological effect, are influenced 
by the route of administration (Gibaldi and Perrier, 1974; Shand, 
Kornhauser and Wilkinson, 1975).
Presystemic elimination raises considerable implications for 
therapeutics for not only does dosing by the oral route recjuire to be 
greater than that for intravenous administration to achieve the same 
effect but the extent of first pass varies between individuals as was 
shown by Evans and Shand (1973) for propranolol in single and in 
repetitive dosing. Liver disease which is often associated with 
reduced first-pass elimination of highly hepatically cleared drugs may 
further complicate dosing (Wilkinson and Schenker, 1975; Wilkinson 
and Schenker, 1976).
While the first-pass effect is most often thought of in terms of 
hepatic elimination, the cells of the gut wall are undoubtedly capable 
of metabolising certain drugs including isoprenaline (Conway, 1968); 
chlorpromazine (Curry, D'Mello and Mould, 1971) and salicylamide 
(George, Blackwell and Davies, 1974). Such drugs also exhibit reduced 
availability by the oral route despite complete absorption from the 
gut. In laboratory animals comparison of AUC after drug administration 
by the oral and intraperitoneal routes can signify significant gut wall 
metabolism since drug in the peritoneal cavity mainly enters the 
hepatoportal system but avoids first-pass through gut cells.
1.3.6 Presystemic drug elimination - a compartmental model
A pharmacokinetic approach to the issue of first-pass or pre­
systemic elimination was adopted by Gibaldi, Boyes and Feldman (1971) 
using a compartmental scheme. These workers proposed the addition 
to the two-compartment model of a third hepa to-portal compartment which 





Figure 1.10 First-pass pharmacokinetic model (three-compartment 
open model)
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When drug is administered into compartment 1, equivalent to an
intravenous.dose, the following relationship was derived:
AUC. = D(k_, + k )/(V, k, k ) eq. (28)I.v. 21 e 1 1 2  e
Where AUC, is the area under the blood concentration-timei.v.
curve after intravenous administration.
Administration of drug into compartment 2, comparable to the oral
route and assuming negligible loss in the gut wall, or to delivery into
the hepatic portal vein gives rise to the following relationship:
AUC = D(k. )/(V^ k._ k ) eq. (29)p.o. 21 1 1 2 e
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where AUC is the area under the blood concentration-timep.o.
curve after oral administration.
As previously indicated, the significant feature of drugs which 
undergo presystemic elimination is that the AUC differs with route 
of administration. Comparison of AUC by the oral and by the intra­
venous routes provides a measure of the fraction of drug in the 
hepatoportal compartment which reaches the central compartment, that 
is, systemic availability (F) which is derived as follows:
'îA




If it is assumed that:
a) clearance between compartments is equal in both directions 
(Perrier and Gibaldi, 1974), i.e. k^^ and
b) transfer between compartments 1 , and 2 is blood flow limited 
(Bischoff and Dedrick, 1968) i.ê. k^^ = Q where Q is hepatic blood 
flow, then the following general relationship can be derived from
eq.(31).
' ■ ÔT^TT
This compartmental model can be used to estimate systemic 
availability . V 2 kg represents clearance of drug from the 
hepatoportal compartment and since k^^ = k^, from eq. (29)
p.o.
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Hence from eq. (3 2)
F = ________Q_______
Q + (D/AUC ) p . o .
eq. (34)
assuming that the dose D is completely absorbed from the gut.
Perrier and Gibaldi (1974) defined V_ k as the "intrinsic2 e
clearance" (CL^^^^) of drug from the hepatoportal compartment in that 
it describes "the inherent ability or capacity of the liver to meta­
bolize a drug assuming the drug is not limited in its access to 
hepatic cells by distributional factors". It is evident from eq. (33) 
that with this compartmental model, is dependent only on dose
and AUC and hencep.o.
^ % . o .  " — ^  eq. (35)
^^int
Substituting eq. (35) into (eq. (28) permits a definition of 
availability as 
F = Q eq. (36)
Furthermore from the general formula for clearance eq..(23) and 
the AUC^ ^ given by eq. (28), clearance for this model may be defined 
as
int
It will be shown that equivalent relationships for availability 
and clearance may be derived from the "well-stirred" perfusion model 
(3.1.7).
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1.3.7 Hepatic drug clearance - perfusion models
The essential value of pharmacokinetic models should lie in their 
ability to predict changes in drug disposition when the determining 
conditions change. Compartmental models, while they can be descrip­
tively accurate, are limited in the extent to which they can be 
manipulated to express changes in drug disposition induced by altered 
physiological or pathological conditions. Rowland, Benet and Graham 
(1973) for example have pointed out that the influence of blood flow 
on steady state clearance cannot be predicted by the compartmental 
model.
The value of clearance as a parameter by which drug elimination 
may be expressed has already been referred to and in recent years this 
approach has been used increasingly by investigators (Rowland et al,
1973; Perrier and Gibaldi, 1974a; Wilkinson and Shand, 1975). In respect 
of a particular organ, clearance may be defined as that volume of 
blood from which drug is completely removed in unit time and it is 
equal to the product of blood flow through the organ (Q) and the 
extraction ratio (E), hence:
CL = QE eq. (38)
Clearance Is a parameter of the efficiency with which drug is 
removed from the blood irrespective of the extent to which drug 
distributes* to other tissues and is thus independent of whichever model 
may be selected to describe its pharmacokinetics. In the instance in 
which a drug is eliminated exclusively by a single organ, the charac­
teristics of drug elimination by the body as a whole are expressed by 
the clearance of drug by that organ. Thus for a drug which is eliminated 
solely by the liver, body clearance is equivalent to hepatic clearance.
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The fundamental biological determinants of drug elimination by 
the liver are:
a) hepatic blood flow;
b) the inherent ability of the liver to remove drug from the blood 
(hepatic metabolic and transport processes).
c) drug binding to plasma proteins and cellular constitutents of 
the blood ..
The "well stirred" model
With the objective of incorporating such variables into a 
predictive scheme, Rowland (1972a) and Rowland et al (1973) proposed 





Figure 1.11 Perfusion limited model
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In this model, blood perfuses an eliminating organ, which in the 
present context may be taken to represent the liver, and is then 
returned to a reservoir which represents the rest of the body.
Q is the blood flow entering and leaving the organ. It is assumed 
that:
1 . that complete mixing takes place between the hepatic arterial 
and the hepatic portal supplies before blood enters the hepatic 
sinuoids. There is evidence that this is so (Greenway and Stark, 1971).
2 . that the liver is a single well-stirred compartment.
3. that blood entering and leaving the liver contains drug in the
unbound state and drug bound to plasma proteins and blood cells.
4. that drug distribution in the liver is rapid, such that drug
in the emergent venous blood is in equilibrium with that in the liver.
5. that only drug in the unbound state can cross cell membranes.
6 . that there is no barrier to diffusion between drug in the blood
and the enzymes within the liver cells i.e. that distribution is 
limited only by perfusion.
7. that the drug elimination rate is a function of the unbound 
drug concentration in the fluid surrounding the enzymes.
8 . that the concentration of drug in the blood entering the liver 
is equal to that in the reservoir.
9. that the concentration of drug in the blood leaving the liver 
is equal to that entering the reservoir.
Various relationships may be derived on the basis of this model. 
Consider drug at a steady state concentration in the blood entering 
the liver; the quantity of drug which is eliminated from the blood in 
unit time is given by:
= ''max "b =hv
K - 4' a  ^9- <39)m B hv
where: CL^ is hepatic drug clearance from the blood.
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is the concentration of drug in the blood entering the liver 
(systemic)
is the concentration of drug in the emergent venous blood 
(hepatic vein)
f is the unbound fraction of drug in the blood B
V and K are the Michaelis constants for the removal process,max m
In most circumstances the concentration of unbound drug in the
liver (f_ C, ) is much less than K and since drug elimination is B hv m
assumed to be a first order process eq. (39) reduces to
CL^ C = V .. f^ Ch s max ,B ,_hv gg. (4 0 )
’'m
The constants V and K may be combined into a single clearance max m
term which is a measure of intrinsic hepatocellular enzyme activity
independent of blood flow and binding. This is the "intrinsic free
drug clearance" CL. ^ . and it relates the rate of hepaticint(free)
elimination to the concentration of drug surrounding the hepatic 
enzymes. It is thus defined as the volume of liver water which is 
effectively cleared of drug in unit time (Shand et al, 1975). Eq. (40) 
may then be rearranged:
■ ‘3^int(free) ' eq. (41)
Data relating organ clearance of drug to organ blood flow often
involve measurements in whole blood, whereas intrinsic clearance as
defined above refers only to unbound drug. It was therefore proposed
by Kornhauser, Wood, Vestal, Wilkinson, Branch and Shand (1978) that
intrinsic clearance calculated on the basis of free drug be called
intrinsic free drug clearance CL. , and that intrinsicint(free)
clearance on the basis of total drug concentration be termed total
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intrinsic clearance CL. , , . The relationship betweenint (tot)
^ int (free) ^ \ n t  (tot)
^^int(tot) " ^^int(free) *
The term C^^ represents that fraction of drug in the blood
c T
which is not removed by the liver i.e. which becomes available to the 
systemic circulation, that is F. By definition, the value F must 
equal 1-E where E is the hepatic extraction of the drug. Thus by 
substitution in eq. (38) and (41)
OE = ^hnt(free) ' '^-E) eq. (43)
hence
E = f_ CL.AviStir
and
CL^ = QE = Q f  C TB int(free)
G ^ ^B ^^int(free)
eq. (45)
It is apparent that this perfusion model permits an analysis of 
clearance of drug from the blood in a relationship which includes three 
of the fundamental biological variables of hepatic drug elimination 
namely
a) blood flow;
b) the intrinsic ability of the liver to remove drug from the blood
and
c) binding of drug within the blood.
The general equation (45) allows an assessment of the influences
of blood flow, drug metabolism and drug binding on AUC for different
modes of administration.
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1 , intravenous bolus dose
Estimation of CL^ across the liver according to eq. (38) presents 
technical difficulties vivo but when a drug is cleared exclusively 
by the liver, the total body clearance (CL^) may be determined from an 
intravenous dose according to the general relationship eq. (23), thus:
^^t ^i.v. eq. (46)
where D. is the intravenous dose and AUC. is the area underI.v. I.v.
the blood concentration time curve after intravenous administration, 
extrapolated to infinity.
Then substituting eq (45) into eq (46) and rearranging
AUC. -I.v, CT fint(free).. B
^ ^^int(free) . ^B
eq. (47)
In the case of a highly cleared drug, when Q «  f CL, .B int(free)
eq. (47) may be reduced to:
AUC. = D .
eq. (48)
Thus for this category of drug AUC is influenced by alteration in
liver blood flow but effects of alteration in hepatic metabolism on
AUC are minimal.
By contrast for a drug which is poorly cleared, that is when
Q »  f„ CL. . .  eq. (47) may be reduced to B int(free)
AUC, = D,
  eq. (49)
B int(free)
Hence for this category of drug, AUC is influenced only by changes 
in the intrinsic metabolic clearance of the drug.
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2 . constant intravenous infusion
At steady state after a consistant rate intravenous infusion (R°)
C _ = R °  = .SS CLt CL fint(free) . B
^ ^^int(free) . ^B
eq. (50)
Where C is the total blood concentration at steady state, ss
Since eq. (50) is similar to that for AUC after an intravenous
bolus it is apparent that the same conclusions may be drawn.
3. single oral dose
When a drug is absorbed from the gut it is carried in the portal
system to the liver where a fraction of the dose is eliminated (E) and
the remainder (1-E) becomes available to the systemic circulation.
For a drug which is removed totally by hepatic metabolism the fraction
1-E is then cleared from the blood at a rate equal to total systemic
clearance eq. (23). Consequently:
AUC = D . (1-E)
Që  eq. (51)
where: AUC is the area under the blood concentration-timep.o.
curve after oral administration, extrapolated to infinity and
D is the oral dosep.o.
Hence clearance by the oral route is given by:
CL = D = QEftgc°' 3-E eq. (52)
p.o.
Substituting for E in the general relationship eq. (45) thus 
gives;
= \ .o. = “ int(free) ' "9- (53)
thus
DAUC =  P.O.
“ int(free) ‘ ^B '94)
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4. repeated oral dosing
If an oral dose of a drug is given repeatedly at intervals of time 
T, the mean blood concentration at steady state (C_^ is given by:
= D (1-E)
"9- (99)
where T is the dosing interval.
Assuming all the drug is absorbed from the gut, that there is no
loss of drug prior to reaching the liver and that the liver alone is
responsible for drug elimination i.e., that CL^ = QE
C—  = D (1-E)ss p.o.
QE . T (96)
Rearrangement of the general relationship in eq. (43) yields
^^int(free) eq. (57)
Substitution of eq (56) into (57) gives
ss P'O'
“ int(free) ' ^ (58)
Hence for both highly cleared and poorly cleared drugs, the steady 
state blood concentration is dependent on intrinsic clearance and is 
independent of flow.
The "well stirred" model has been considered in some detail here 
because it has been most widely examined. There is, however, another 
less frequently studied model which also relate?? blood flow, drug 
binding and metabolism to hepatic drug extraction, namely the 
"parallel tube" model.
The "parallel tube" model
The "parallel tube" model was proposed by Winkler, Keiding and 
Tygstrup (1973) and Winkler, Bass, Keiding and Tygstrup (1974).
The assumptions and predictions of this model have been examined in 
detail by Pang and Rowland (1977a). The "parallel tube" model describes
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the sinusoids of the liver as a series of identical and parallel 
cyclinders in which the enzymes are distributed evenly in the hepatic 
cells surrounding the cylinders. Blood flows along the cylinders 
only in one direction and at any point in the cylinder, drug in the 
blood is in equilibrium with that at the site of enzyme action. Hence 
the concentration of unbound drug declines within the cylinder along 
the direction of flow as depicted in Figure 1.12
QC,in
Elimination
^ o u t
Figure 1.12 Diagrammatic represenation of hepatic elimination in the 
"parallel tube" model
It is assumed that the total metabolising ability of the liver is 
the sum of the metabolising capacity of individual cylinders. The parallel 
tube model shares a number of assumptions with the well-stirred model 
namely:-
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1 . that complete mixing of blood takes place between the hepatic
arterial and the hepatic portal supplies before blood enters 
the sinusoids;
2 . that blood entering and leaving the liver contains drug in the
unbound state and drug bound to plasma proteins and blood cells;
3. that there is no barrier to diffusion between drug in the blood
and the enzymes within the liver cells, i.e. that distribution 
is limited only by perfusion;
4. that only drug in the unbound state can cross cell membranes,
i.e. that the drug elimination rate is a function of the unbound
drug concentration in the fluid surrounding the enzymes.
The assumptions in the parallel tube model of progressive 
decline of unbound drug concentration with blood flow along each 
eyeUnder is in distinct contrast with the well-stirred model concept 
of the liver as a homogeneous entity in which unbound drug concentration 
is equal throughout. Accordingly differences may be anticipated in the 
predictions made by each model when the major physiological determinants 
alter.
In a theoretical analysis of the well stirred model (Model I) and the 
parallel tube model (Model II), Pang and Rowland (1977a) derived 
relationships for pharmacokinetic parameters (hepatic extraction and 
clearance, availability, AUC after single doses and steady state blood 
concentration after both intravenous and oral dosing), for both models 
in terms of blood flow, intrinsic clearance and drug binding, and 
compared the predictions of the models when these determinants were 
altered. (Table 1.2). For change in blood flow no marked difference was 
found in the predictions of these two models in respect of extraction 
ratio, clearance, AUC following a single intravenous dose and steady 
state drug concentation following a constant intravenous infusion.
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However, a significant difference between the models lies in their
predictions for AUC following a single oral dose of a highly cleared
drug. In terms of Model I AUC^ ^ is dependent only on dose and
intrinsic clearance and no change in area occurs with alteration in
blood flow whereas by Model II, AUC is affected by change in bloodp.o.
flow. Most available experimental data have been related to the 
predictions of Model I. Using the isolated perfused rat liver prep­
aration, Branch et al (1973) showed that propranolol clearance was 
dependent on hepatic blood flow as predicted by Model I but this evidence 
does not favour one or other model since hepatic clearance is a poor 
discriminator between the models. However, using the same preparation 
Shand et al (1975) provided evidence that the steady state blood 
concentration of lignocaine after oral administration was independent of 
flow compatible with the predictions of Model I. In a direct comparison 
of the predications of both models using the perfused rat liver situ 
preparation Pang and Rowland (1977b) found that their data with ligno­
caine supported the assumption of Model I rather than Model II. In 
contrast Bennett, Bending, Steiner and Rowland (1978) studying ligno­
caine in man when hepatic blood flow was altered by change of posture, 
found that AUC after oral administration did change with alteration in 
blood flow as predicted by Model II.
The present work which examines the influence of alteration in blood 
flow and metabolism on drug kinetics offersa further opportunity to 
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Blood binding and hepatic extraction
The relationship between drug binding and hepatic extraction with 
perfusion models has been discussed in detail by (Wilkinson and Shand 
(1975) and by Pang and Rowland (1977). In respect of elimination of 
unbound drug two types of hepatic extraction may be considered:
a) restrictive in which elimination is limited to the circulating
free drug and hence E<fg
and
b) non-restrictive in which extraction is sufficiently avid to 
remove bound as well as unbound drug, hence E>fg.
The present study is concerned with one drug in which extraction 
would be expected to be restrictive (tocainide, f^-O.S, E-0.06) and 
one in which extraction would be expected to be non-restrictive ! 
(lignocaine, f^-0.7, E-0.98). In the present work drug binding to cells 
or plasma proteins was not measured and the implication of these 
observations are considered in the section on Discussion (Chapter VI).
Blood versus plasma measurements
Since CL is an index of the efficiency of drug removal from blood
by the eliminating organ, e.g. liver rather than from plasma or liver
water, in this work measurements of total drug in blood were used 
(Rowland, 1972b).
1.3.8 Hepatic blood flow 
Measurement of liver blood flow
Many techniques have been used to estimate liver blood flow; the 
number of methods which has been developed reflect the fact that no 
single technique is widely accepted as satisfactory. Ideally the 
measurement of liver blood flow should be non-invasive and the estimation 
should be carried out under normal physiological conditions. Techniques 
for measuring liver blood flow have recently been reviewed (Ohnhaus, 1979) 
and include:
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a) the electromagnetic flowmeter
This method is based on the induction of an electrical potential 
by a conducting substance moving at right angles to the lines of force 
of a magnetic field. The conductor is the stream of blood passing 
between the poles of a magnet and the induced current is led off by 
electrodes placed across the stream; the current generated is proport­
ional to the velocity of the stream. Hepatic artery and portal flow 
can be estimated separately but it is an invasive method.
b) the heat exchange method
A thermocouple heated by a constant current is implanted into the 
liver and is cooled by the flow of blood; change in blood flow is 
reflected in change in the current. The method is only semiquantitative 
and only change in liver blood blow can be measured but it can be used 
in long term experiments in animals (Ohnhaus, Emons and Breckenridge, 
1970).
c) inert gas technique
Inert gases such as (Tobias, Jones, Lawrence and Hamilton,
1331949) or Xe (Conn, 1955) can be given by injection into the hepatic 
artery or portal vein or by inhalation from a spirometer in a closed 
system. A recording is made of the wash-out over the liver by external 
counting using a scintillation detector or gamma camera. The inhalation 
technique is non-invasive and is applicable several times to the same 
individual.
d) labelled colloid uptake
A rapid single injection of a radioactively-labelled colloid is 
given e.g. labelled chromic phosphate, ^^^AU or human serum albumin
labelled with ^^^I (Dobson and Jones, 1952; Caesar, Shaldon, Chiandussi, 
Guevara and Sherlock, 1961). These substances are taken up by the 
Kupffer-cellsof the liver and the disappearance rate, which can be 
obtained from blood sampling from a peripheral vein or by external
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counting using a gamma counter or scintillation collimeter, is used 
to estimate hepatic blood flow. The necessity of using radio-active 
substances is a disadvantage when the technique is used in man.
e) dye clearance methods
An indicator dye is infused continuously into a peripheral vein 
and liver blood flow can be measured from the formula:
Q = e
C -C, a hv
where Q is hepatic blood flow, e the elimination rate of the
indicator, C the hepatic areterial concentration and C the hepatic a hv
venous concentration. At equilibrium and assuming no extrahepatic
elimination e is equal to the infusion rate (I), then 
IQ =
Bromsulfphthalein, rose bengal and rndocyanine green which are dyes 
eliminated exclusively by the liver have been used (Simpson, Erzow 
and Sapirstein, 1954; Ketterer, Weigland and Rappaport, 1960). The 
method is invasive requiring catheterisation of a peripheral artery 
and the hepatic vein.
Methods used for calculation of liver blood flow in present study
f) lignocaine clearance
If a drug is completely absorbed from the gut and is cleared only
by the liver, then total body clearance equals hepatic clearance.
Thus from the general relationships in eq. (23) and eq. (38)
CL = CL, = Dose. = QE t h 1 .V.
and F = AUC
P'O'
AUC.1. V.
but substitution and rearrangement
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Q =  ______Dose_____
AUC. -AUC eq. (60)i.v, p.o.
Lignocaine satisfies the above criteria and has been found after 
intravenous and oral administration to man to give values comparable 
to  those obtained with other techniques (Bennett et al, in press;
Perucca and Richens, 1979). In the present work this method has been 
used to estimate liver blood flow in the intact rat, an approach which 
has not previously been used in this animal,
g) radioactively labelled microspheres
With this method; i) the cardiac output;
ii) the distribution of regional blood flow 
and iii) the fractional shunting of blood through
arteriovenous anastomoses can be determined. 
The origin of the method was the intravenous injection of radioactive 
substances which are homogenously distributed in the body and taken up 
by the organs during its first transit. Organ blood flow is deter­
mined from the distribution of these substances within the organs. 
Earlier work by Sapirstein (1956) used radioactive meterial such as 
^^KCl, ^^Rb Cl or ^^^I-antipyrene. However, after radioactive micro­
spheres labelled with different isotopes such as ^^Cr, ^^^Ce, ^^Sr and 
125I were introduced by Rudolf and Heymann (1967) as the indicator 
substances, many experiments have been performed in small laboratory 
animals using this method (Neutze, Wyler and Rudolph, 1968; Mendell and 
Hollenberg, 1971; Sasaki and Wagner, 1971; Bartrum, Berkowitz and 
Hollenberg, 1974 and McDevitt and Nies, 1976; Yates, Hiley and Back, 
1979). The microspheres are of such a size (9-50 y) that after 
injection they are distributed according to blood flow but are trapped 
in capillaries of the perfused tissue. The number of particles entering 
each organ during the first transit is proportional to the blood flow
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to that organ. The distribution of radioactivity in the excised tissues 
is determined using a radiation detector such as a gamma-counter.
Cardiac output and regional blood flow can then be determined (see 
Chapter 2.11). This method is based on the assumptions (Wagner, Rhodes, 
Sasaki and Ryan, 1969) that: i) microspheres must be well mixed with
blood; therefore they are usually 
injected through a catheter placed in 
the left ventricle;
ii) the circulation should not be dis­
turbed by the administration of 
microspheres and;
iii) the microspheres should all be trapped 
in the capillaries during the first 
circulation.
If the blood flowing through the liver is completely cleared of 
the radioactive micorspheres during a single passage, the equation for 
conservation of mass under the assumptions of steady flow and complete 
mixing of indicator is (Archie, Fixler, Ullyot, Hoffman, Utley and 
Carlson, 1973)
flow = I/( C(t)dt
where I is the quantity of spheres, C(t) is the concentration of 
indicator at any time, and t is time. Microspheres are injected directly 
to the heart, an arterial sample is collected at a known constant rate 
(Qar^ and the sample radioactivity (I^^) is counted. Then, if the amount 
of radioactivity injected (I^^^^ and the radioactivity in the liver 
dhepî are known, the cardiac output (CO) and liver blood flow (Q) are 
determined as follows:
= "tot 





Lignocaine hydrochloride 2-diethylamino-N-(2,6 -diinethylphenyl ) 
acetamide hydrochloride j , tocainide hydrochloride 2-amino-N-(2, 6 -
dimethylphenyl) propanamide hydrochloride j* , 2-methylethylamino-N- 
(2,6 -dimethylphenyl) acetamide hydrochloride, W36149 hydrochloride
2-amino-N(2,6 -dierathylphenyl) butanamide hydrochloride j were 
generous gifts from Astra Chemicals Ltd., Watford, sotaloi hydrochloride 
was supplied by the Bristol-Myers Company Ltd., Windsor, and polystyrene 
microspheres, 14.8 ± 1.1 ym diameter (^^Sr labelled) were purchased 
from 3M Co., St. Paul, MN, U.S.A.
In addition, phenobarbitone sodium (The British Drug Houses Ltd., 
Poole), benzo (a) pyrene (3,4-benzpyrene, Sigma Chemical Company,
London), pentobarbitone sodium (Sagatal, May and Baker, Dagenham) and
corn oil (Mazola brand. Best Foods) were used.
Chemicals and reagents used throughout, whenever possible, were 
of Analar grade. They were obtained from commercial sources and 
purified before use where appropiate.
2.2 Animals
Male albino rats of the CFY strain (Anglia Laboratory Animals, 
Huntingdon) weighing between 350-500 g were used throughout. Rats were 
housed in controlled photoperiod conditions (14 hour light, 10 hour 
dark) at a temperature of 21°C with food (Oxoid diet 4IB) and water 
available ad libitum until the experimental conditions below were 
impo sed.
2.3 Dosage and administration of compounds
For all experiments dosing was on a weight related basis and the
stated weights of lignocaine and tocainide refer to the base form.
6 h
although the drugs were administered as the hydrochloride. Drugs 
were dissolved in physiological saline for intravenous and intraperi- 
toneal injection and were dissolved in distilled water for oral 
administration. 3,4-Benzpyrene was dissolved in corn oil by heating 
at 50°C for 1 hour.
Single dose studies
-1Animals dosed orally were given either lignocaine (50-90 mg.kg )
-1or tocainide (50-400 mg.kg ) by direct oesophageal intubation of 
the manually-restrained animal, using an adapted, blunt, stainless 
steel needle fitted to the appropriate size of syringe. These rats 
were starved overnight (approximately 2 0  hours) prior to drug 
administration and the fast was continued for a further 4 hours after 
which they were allowed access to food. Free access to water was
permitted at all times. Rats which received lignocaine (2.5-10.0
-1 -1 mg.kg ) or tocainide by the i.v. route (5.0-50.0 mg.kg ) received
a bolus injection via a tail vein, the duration of the injection
being one minute. These animals were allowed free access to food
and water throughout the experiments.
Multiple dose studies
For the multiple i.v. dosing experiments, rats were given 
-1tocainide ( 2 0 mg.kg ) every 8 hours for seven doses and free access
to food and water was permitted throughout. When tocainide was
-1given in multiple oral doses ( 2 0 0 mg.kg , every 1 2  hours) the rats 
were fasted for 16 hours before the first dose of tocainide was 
given and for the first 4 hours after each subsequent dose, following
which 5 g of food was given to each animal and the excess if any was
taken away after 2 hours so allowing a fast of 6 hours before the 
next dose.
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Enzyme induction and liver blood flow studies
Phenobarbitone was dissolved in isotonic saline to give a solution
-1 -1 of lOO mg.ml and rats received lOO mg.kg daily for 4 days by
intraperitoneal injection. 3,4-benzpyrene was dissolved in corn oil
-1to give a solution containing 8 rag*ml and rats received a dose of
80 mg.kg by a single intraperitoneal injection. Sotalol hydro­
chloride was dissolved in isotonic saline to give a solution containing
-1 -1100 mg.ml and rats received doses of lOO mg.kg by intraperitoneal
as described in Chapter 5. Two control groups were.used; one group
-1received isotonic saline (1 ml.kg daily for 4 days) and the other
-1group received corn oil ( 1 0 ml.kg ) in both instances by intra­
peritoneal injection. Rats were then allocated to pharmacokinetics 
studies of lignocaine and tocainide, blood flow studies, biochemical 
investigation or determination of pentobarbitone sleeping time.
2.4 Collection of rat urine
Following dosing, animals were housed singly in metabolism cages 
(7.5" diameter) fitted with a 0.5" mesh floor, placed over a 8 " diameter 
polyethylene funnel designed so that urine could be collected separately 
from faeces. Urine was collected at Gr6 , 6-12 and 12-24 hr after 
dosing. At the end of each collection period the funnel was throughly 
rinsed with distilled water and the washings were added to the 
collected urine.
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2.5 Collection of blood samples
Throughout the studies 0.3-0.5 ml samples of whole blood were
taken from the tip of the tail of each animal at specified times.
Animals were placed in all metal restraining cages that allowed
minimal movement and free access to the tail. The tip of the tail
was removed with a scalpel blade and blood was collected into
polyethylene tubes containing approximately 10 yl of heparin (5000 
-1units ml ) . Drainage of blood into the collecting vessel was aided 
by gentle stroking of the tail with the fingers in a base-to^tip 
direction. Blood was collected during a period of 4 5 to 60 seconds 
for each sample.
2.6 Storage of biological samples
Blood samples were stored in heparinized polyethylene tubes 
(Sarstedt, Leicester) at -20°C. An aliquot of the measured volume 
of urine (+ washings) and homogenized tissues were stored in 6 ml. 
polyethylene pill tubes (Ventura Plastic Ltd., Chessington) at -20°C 
without pH adjustment prior to analysis.
2.7 GLC analysis
2.7.1 Gas-liquid chromatography
A PYE Unicam 104 chromatograph equipped with a flame ionization 
detector was used. The chromatographic column was of glass, 4 mm in 
inner diameter and 1 . 6  m in length.
Lignocaine
Column packing ; 5% KOH + 0.75% Carbowax 20 M coated on 
Chromosorb G AW-DMCS (85-100 mesh)
Operating conditions: Oven temperature ?= 180°C
Injector port = 210°C
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Tocainide
Column packing: 3% OV-17 coated on Chromosorb W-HP
(80-100 mesh)
Operating conditions: Oven temperature = 195°C
Injector port = 275°C
Conditioning of columns
The packed columns were conditioned prior to use as follows:
after initial heating at 50°C for 60 min the oven temperature was
raised by 1°C min ^ to 100°C and maintained at that temperature for
60 min, then increased by 1°C min ^ to 200°C (lignocaine) or 250°C
(tocainide) for 24 hr. Throughout conditioning the columns were
-1perfused with argon at a flow rate of 15 ml.min . The detector 
temperature was that of the oven. The columns were silanized situ 
with Silyl- 8 (Pierce) . Hydrogen and air were adjusted to give
optimum recorder response and in these analyses the flow rate was for
-1 -1 H^ ,50 ml min and for air, 400 ml min . Argon was used as the carrier
-1gas at a flow rate of 40 ml min
Under these conditions the retention times were 6 min 10 sec 
(lignocaine), 4 min 30 sec [ 2-methylethyl-amino-N-(2,6 -dimethyl phenyl) 
acetamide j, 3 min 30 sec (tocainide) and 4 min 15 sec (W 36149).
2.7.2. Estimation of lignocaine by gas-liqUid chromatography
Lignocaine in blood and urine was assayed by GLC according to the 
method of Mather and Tucker (1974).
0.05 to 0.5 ml of biological material (whole blood or urine) in 
a 15 ml stoppered round-bottomed glass tubes was mixed with 2-methyl- 
ethyl-amino-N^ (2,6 -dimethyl phenyl) acetamide HCl as the internal 
standard (1 yg, 50 yl of a 20 yg/ml solution), made alkaline with 
1 M NaOH (100 yl), extracted with ether (3 ml) by stirring on a vortex
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mixer for 30 sec and then centrifuged. The upper organic phase was
transferred in a pasteur pipette to a 1 0  ml glass stoppered centrifuge
tube containing 1 M hydrochloric acid (200 yl) and the phases were
mixed and separated as before.
The organic phase was discarded and the aqueous phase was heated
to about 60°C by placing the test-tube in a water bath for several
minutes in order to allow residual ether to evaporate. After it had
cooled, 2 M NaOH (200 yl) was added and lignocaine was extracted with
redistilled methylene chloride (25 yl). The phases were separated
by centrifugation. Aliquots (1-2 yl) of the organic phase were
withdrawn with a microsyringe and taken for GLC analysis.
Lignocaine concentrations in biological fluids were measured
using a previously established calibration curve constructed by
analyses of known amounts of lignocaine added to normal blood or urine
and plotting the peak height ratio (lignocaine : internal standard)
versus the lignocaine concentration (see Figure 2.1). The standard
- 1curve was linear over a range of 0.05 to 8.00 yg of lignocaine ml 
The coefficients of variation of the assay were as follows;
0.05 yg ml“^ (8.29%), 0.50 yg ml“^ (3.59%), 0.75 yg ml"^:(3.22%),
-1 -11 . 0 0  yg ml (2.12%) and 2.00 yg.ml (2.89%) with h = 5 for each
concentration.
During determination of lignocaine in biological samples in no 
case was a peak observed at the retention time of lignocaine or of 
the internal standard in blank samples and identical linear calibration 
curves were acheived whether lignocaine was placed in blood, in plasma 












1 62 73 84 5
Blood lignocaine (yg.ml 
Figure 2.1 Standard calibration curve for lignocaine in whole blood
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2.7.3 Estimation of tocainide by gas-liquid chromatography
Whole blood or urine (0.05-0.5 ml) was placed in a 15 ml stoppered
round bottomed-glass tube, and an aqueous solution of 5 yg W36149 as
-1the internal standard, (50 yl of a 100 yg.ml solution) and 1 ml of 
1 M NaOH were added, together with distilled water to make a total 
volume of 5 ml. The tube was vortex-mixed for 10 sec and methylene 
chloride (5 ml) was added. The tube was capped with a teflon stopper, 
shaken mechanically for 10 min, and centrifuged for 20 min. The 
aqueous layer was removed by aspiration and the organic phase was 
transferred to a clean 10 ml glass stoppered centrifuge tube. The 
organic phase was then evaporated to dryness in a water bath of 50°C 
and the residue was dissolved in 20 yl of HFBI heptafluorobutyrlimi- 
dazole. Pierce) in redistilled methylene chloride (HFBI: methylene
chloride, 1:10) using a vortex-mixer. A 1-3 yl sample was taken for 
GLC analysis.
Tocainide concentrations in biological fluids were measured
using a previously established calibration curve constructed by
analysis of known amounts of tocainide added to normal blood or urine
and plotting the peak height ratio (tocainide: internal standard)
versus the tocainide concentration (see Figure 2.2). The coefficients
-1of variation of the assay were as follows: 0.1 yg.ml (6.05%),
0.5 yg.ml ^ (3.78%) 1.0 yg.ml ^ (2.94%), 2.5 yg.ml ^ (4.46%) and 
-15.0 yg.ml (3.12%) with n = 5 for each concentration. During deter-
was
mination of tocainide in biological samples in no casera peak observed 







- 1Blood tocainide (pg.inl )
Figure 2.2 Standard calibration curve for tocainide in whole blood
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2.8 Enzyme Induction parameters
Following the administration of the two enzyme inducing agents, 
phenobarbitone and 3,4-benzpyrene (see dosage and administration of 
compounds, 2.3) the following parameters of hepatic microsomal 
enzyme activity were measured: 
i) Microsomal protein; 
ii) Cytochrome P-450;
iii) p-nitroanisole 0 -demethylase activity;
iv) Pentobarbitone sleeping time.
2.8.1 Preparation of microsomes for enzyme assay
Twenty four hours after the last injection of phenobarbitone and 
48 hours after 3,4-benzpyrene injection, rats which had been starved 
overnight were Icilled by exanguination from the carotid artery under 
ether anaesthesia. Each liver was immediately removed, rinsed in 
ice-cold phosphate buffer (pH7.25, see Appendix 22), blotted dry and 
weighed. Five to 10 g of liver was homogenised in ice-cold phosphate 
buffer (pH7.25) in a glass homogeniser with a motor driven teflon 
pestle. Homogenates were centrifuged at 10,000 g for 15 min at 4°C 
in a M.S.E. Superspeed 65. The resulting supernatant was decanted 
without disturbing the pellet and centrifuged at 105,000g for 60 min 
at 4°C. After discarding the supernatant and rinsing the microsomal 
pellet with glycerol phosphate buffer (pH7.25, see Appendix 23), lipid 
adhering to the walls of the centrifuge tubes was wiped off with tissue 
paper. The microsomal pellet was resuspended in glycerol phosphate 
buffer (pH7.25, 2 ml of buffer for each gram of liver) with the aid of
a teflon pestle. The microsomal suspension (approximately 10 mg protein
— 1 oml ) was then stored at -20 C pending analysis.
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2.8.2 Microsomal Protein Measurements
Microsomal protein concentration was determined in the SP 500
spectrophotometer by the method of Lowry et al (1951) using bovine
serum albumin as standard. Figure 2.3 shows the standard curve for
bovine serum albumin that was obtained using this method in the 
- 1range 1 - 2 0  mg.ml
2.8.3 Cytochrome P-450 Assay
The content of cytochrome P-450 was determined by the method of
Omura and Sato (1964).
Liver microsomes were diluted with glycerol phosphate buffer
(pH7.25) such that 1 ml of the suspension contained 2-3 mg protein.
- 1ml , then delivered to cuvettes of 1 cm light path, and lO mg of 
sodium hydrosulfite (dithionite) were added to IxDth sample and 
reference cuvettes. Carbon monoxide (Air Products Ltd., Surrey) was 
bubbled through the suspension in the sample cuvette for 30 sec. The 
difference in absorbance at 450 and 490 my (AE 450-490 my) was deter­
mined in a Unicam SP 1800 spectophotometer using a molar extinction coefficient 
-1 -1of 91 cm mM . Figure 2.4 shows carbon monoxide difference spectra 
of reduced microsomes for control and for 3,4-benzpyrene treated rats.
2.8.4 Para-nitroanisole 0-demethylase assay
The microsomal 0-demethylation of p-nitroanisole was determined 
by measuring the amount of formaldehyde which was produced during the 
déméthylation of the substrate, p-nitroanisole to p-nitrophenol.
To 0.9 ml of incubation mixture (0.2 M Tris pH 7.2, 0.1 M MgCl^) 
NADH and NADPH, see Appendix 24), 0.1 ml of microsomal suspension
-3(approximately 10 mg. protein per ml) and 40 yl 1x10 M p-nitroanisole, 
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Protein concentration (mg.ml“l)
Figure 2.3 Standard curve for bovine sérum albumin as used in the
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Figure 2.4 Carbon monoxide difference spectra of hepatic microsomes 
of control and treated rats.
77
Gallenkamp shaking water bath for 20 min. The reaction was stopped by 
the addition of 1 ml ice-cold 0.5 M citrate buffer (pH5.6, see 
Appendix 25) . One ml of distilled water was added and the solution was 
transferred to a 15 ml stoppered glass tube and extracted three times 
with 5 ml of chloroform shaking for 60 sec per extraction. The organic 
phases were discarded and the aqueous phase was centrifuged at 1500 rpm 
for 15 min to precipitate protein. Two ml aliquots of the supernatant 
were assayed spectrophotometerically for the amount of formed formal­
dehyde according to the method of Nash (1953).
A standard curve for optical density plotted against formaldehyde 
concentration was constructed and is shown in Figure 2.5.
2.8.5 V m a x  and determination
The maximum velocity (V ) and Michaelis-Menten constant (K )max m
values of p-nitroanisole in control and in induced microsomes were
-3 -3determined by using substrate concentrations of 0.25x10 M, 0.50x10 ,
-3 -31.00x10 M and 1.50x10 M in the incubation mixture. The assay of
p-nitroanisole 0 -demethylase activity was carried out as described above
except that the reaction was stopped after 3,6,9,12 and 15 min.
V and K were obtained by plotting —  against —  (v = ymoles of max m v s
formaldehyde formed per unit time and s = molar concentration of p-nitro­
anisole) and —  were taken to be the x and y axis intercepts respectively,
km ^max
2.8.6 Measurement of pentobarbitone sleeping time
Rats were given enzyme inducing agents as described above. Twenty-
four hours after the last dose of phenobarbitone and 48 hours after
- 13,4-benzpyrene injection, pentobarbitone (40 mg.kg ) was given by i.p. 
injection. Sleeping time was defined as the time between loss and 
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yg of formaldehyde
Figure 2.5 Standard curve for formaldehyde determination in the 
estimation of p-nitroanisole-O-demethylase.
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2.9 Measurement of hepatic and organ blood flow
Hepatic and organ blood flow were determined by the method of
McDevitt and Nies (1976) using radioactive microspheres. With this
method the total cardiac output, its fractional distribution, and
organ blood flow can be measured simultaneously in the same animal.
- 1Rats were anaesthetized with sodium pentobarbitone (50 mg.kg ,
i.p., Sagatal, May & Baker). The right carotid and right femoral
arteries were cannulated with intravenous cannulae (outer diameter
1.02 mm and 0.75 mm respectively, Portex, Kent) and blood pressure
was monitored from the left femoral artery using a Bell and Howell
pressure transducer (type 4 - 4220001) connected to a two channel
recorder (Devices M2). The arterial blood sample from the right
- 1femoral artery was withdrawn at a constant rate (0 . 6  ml min ) by
a Perfusor IV pump (Braun, Melsungen, Germany). A third cannula was
passed through the right carotid artery into the left ventricle, the
placement being considered satisfactory only when a typical left
ventricular pressure pulse tracing had been obtained from the
pressure monitor (see Figure 2.6) .
A vial containing 60-80,000 polystyrene microspheres (diameter - 
8515 ym), labelled with Sr, in 0.6 ml 0.9% NaCl containing 0.02%
Tween 80 at 37°C was placed in an ultrasonicator for at least 2 min 
to break down any aggregates of micro spheres that may have formed.
The solution thus mixed was drawn into a 1 ml syringe. After expulsion 
of air, the syringe was connected to the left ventricular cannula and 
the microspheres were injected over a 2 0 sec period and the cannula 
was rinsed with saline. For 70 sec after the injection of micro­
spheres, arterial blood was withdrawn from the femoral artery at a 
rate of 0.6 ml min . Systemic blood pressure was monitored during 
the microsphere injection to ensure that no alteration occurred
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during this period. No change in pressure was noted in any animal 
used in this work. The rat was then killed with an overdose of sodium 
pentobarbitone and the placement of ventricular cannula was checked by 
visual examination of the opened thorax. Heart, lungs, liver, spleen, 
kidneys, gastrointestinal tract and pancreas were then excised and 
weighed.




10 20 30 40
Seconds
Figure 2.6 Change in arterial pressure in anaesthetized rat when
a cannula was manipulated into the left ventricle through 
the carotid artery.
The excised organs were dissolved in warm concentrated nitric acid 
(30 ml for liver and gastrointestinal tract and 7 ml for the other organs) 
and adjusted to a volume of 100 ml (liver and GI tracts) or 25 ml (other 
organs) with 1% Tween 80 in H^O.
Radioactivity in aliquots (4 ml) of these suspensions and in blood 
samples were measured in a Nal (Tl) Well-type Scintillation Counter 
(V.P. Engineering, Reading).
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Cardiac output and organ blood flow were determined from the 
following formulae:
cardiac output =
(total counts injected)x(blood sample withdrawal rate)
(counts in blood sample)
and organ blood flow =
(counts in organ)x(blood sample withdrawal rate)
(counts in blood sample)
Because of its particular anatomical position the liver receives 
both hepatic arterial and portal venous blood. Hepatic arterial flow 
was determined from the microspheres trapped in the liver and portal 
venous return was obtained from microspheres trapped in spleen, 
pancreas and gastrointestinal tract (Nies et al, 1976). Liver blood 
flow, in this study, refers to the sum of hepatic arterial and portal 
venous flow.
2.10 Presentation of figures
For linear plots of drug concentration against time, a line was 
drawn to connect adjacent points.
For logarithmic plots of drug administered intravnously an 
arbitrary decision was made defining the initial rapid and the sub­
sequent slow phase of decline of drug concentration. Lines were drawn 
to connect adjacent points in the rapid phase and the line was 
connected to the linear least square regression line for the points 
on the slow phase.
For logarithm plots of drug administered p.o. an arbitrary 
decision was made defining the absorption and the disposition phases 
of drug concentrations. Lines were drawn to connect adjacent con­
centration points in the absorption phase and the line was connected 




Pharmacokinetics of lignocaine and tocainide
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3.1 Single intravenous doses of liqnocaine
Twenty rats with body weights ranging between 370 g and 480 g were
given lignocaine by intravenous bolus injection. Six rats received
-1 -12.5 mg.kg , 8 rats received 5.0 mg.kg and 6 rats received 10.0
mg.kg , Blood samples were taken before and after dosing at appropriate
intervals and assayed for lignocaine. The blood coneentrâtion-time
values for individual rats and the group means are given in Appendix 1
and the mean data are shown graphically on linear and on logarithmic
scales plotted against time in Figure 3.1 and 3.2 respectively.
The mean concentrations of lignocaine in blood ranged from 0.19 to
-13.16, 0.55 to 7.32 and 0.76 to 13.66 pg.ml following 2.5, 5.0 and 
- 110.0 mg.kg respectively. AUC of lignocaine increased with the dose
given. Concentration of lignocaine in blood declined in a biphasic
manner with an initial rapid and a subsequent slow phase which was
linear when logarithm of concentration is plotted against time (Figure
- 13.2). One rat, following a 2.5 mg.kg i.v. dose of lignocaine,
exhibited a blood concentration-time curve with too short an a phase to
permit estimation of A, a and t, . The kinetic parameters of this rattzcx
were included in the mean data.
The kinetic parameters A, B, a, B, t^^, t^g, the rates constants
(%1 2 ' ^21 kg)' the volume constant Vp, Vd^^^^,vd^j,g^,Vdgg,AUC and
the mean systemic clearance of lignocaine (total body clearance) were
obtained from the blood concentration-time data for each animal using
the non-linear least squares regression analysis programme NONLIN
(Metzer, 1969) as described in Appendix 21..
Table 3.1 shows the mean data after single i.v. doses of lignocaine
at three different doses. Using parametric (t) and non-parametric
(Wilcoxon) statistical tests no significant differences in a, $, Vp,
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Figure 3.2 Mean blood concentrations of lignocaine with respect to time
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The mean values of AUC of lignocaine are given in Table 3.2. 
Figure 3.3 shows the relationship between AUC and dose, over the dose 
range used. The areas under the blood concentration time curves of 
lignocaine after intravenous administration are linearly related to 
dose (r = 0.883, p<0.001) and the 95% confidence interval for the 
slope of the regression line includes the origin of the plot of AUC 
against dose.
Table 3.2. Mean (± SEM) values for area under blood-concentration­
time curves of lignocaine after intravenous administration
- 1at doses of 2.5, 5.0 and 10.0 mg.kg
Dose
(mg.kg'l) 2.5 5.0 1 0 . 0
AUC 188.03 444.72 774.32
(yg.ml“^.min) ±25.01 ±48.19 ±64.05
n 6 8 6
Figure 3.4 shows dose-normalised blood-concentration time curves 
for lignocaine over the range studied and indicates that the curves may 
be superimposed.
The constancy of the above pharmacokinetic parameters with 
changing dose of lignocaine indicates that for the rat in the dose­
ra nge studied the kinetics are dose-independent. Accordingly when
alteration in the physiological determinants of lignocaine disposition
- 1were studied (Chapter 4,5) the middle dose (5.0 mg,kg ) was selected.
- 1Recovery of lignocaine in the urine after a dose of 2.5 mg.kg , 
i.v., was estimated in two rats and found to be less than 3% of the 
administered dose. No sign of toxicity was observed in the rats over 
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Figure 3.4 Superposition plot of mean blood lignocaine concentrations 
with respect to time following intravenous doses of 2.5,
- 15.0 and 10 mg.kg *2
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3.2 Single oral doses of lignocaine
Twenty-four rats with body weights ranging between 355 g to 475 g
- 1were given lignocaine by mouth. Eight rats received 50 mg.kg , eight
-1 -1 received 70 mg.kg and eight received 90 mg.kg . Blood samples were
taken before and after dosing and assayed for lignocaine. The blood
concentration-time data for individual rats and the group means appear
in Appendix 3. The mean blood concentrations ranged from 0.13 to 0.60,
-1 -1 0.13 to 0 . 8 8  and 0.29 to 1.29 yg.ml at the 50, 70 and 90 mg.kg dose
levels respectively. Lignocaine was detected in the blood within 10 min 
and the maximum concentration occurred 30-45 min after drug administ­
ration.
Figures 3.5 and 3.6 show plots of mean blood concentration of
lignocaine on a linear and on a logarithmic scale respectively against
time. It is apparent that after single oral administration the AUC
increases with the dose given and that the terminal phase of the plot
of logarithm of drug concentration with respect to time is linear.
The kinetic parameters k^^^ k^, t^, AUC and oral clearance were
obtained from the blood concentration-time data for each animal as
demonstrated in Appendix 20 and the mean data appear in Table 3.3.
There was no significant difference in k^ and consequently t^ did not
change with dose.
Table 3.4 presents the mean values for the AUC and these values
are also plotted against dose in Figure 3.7. This shows that AUC is
linearly related to dose over the range studied (r = 0.872, p<0.001).
It is noted that the regression line does not pass through the origin,
- 1rather it crosses the x-axis at a dose equivalent to 23 mg.kg 
However, the 95% confidence interval for the slope of the regression 
line does include the origin of the plot of AUC against dose.
9 1
1—(
1 CO 00 CO
tr> II II IIM c a c
cn
























Uo go O '













uo(D C8 1-41CnTOo Ô*0 a
rHA oO cnTJ2 GGW Ow4-1o
CM G(0 S
0) iw2 0




- 1Dose (mg.kg ) 
• = 50 (n=8 )
A  = 70 (n=8 )








T3OOrH 0 « 2m
0,1
0,05
1802 0 60 1 0 0 140
Minutes
Figure 3.6 Mean blood concentrations of lignocaine with respect to
time following oral doses of 50, 70 and 90 mg.kg - 1
Table 3.3 Kinetic parameters of lignocaine HCl following oral
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Figure 3.7 Relationship between AUC and dose for lignocaine following 
oral administration (Means ± S.E.M.)
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Table 3.4 Mean (±SEM) values for area under the blood concentration- 
time curves after oral administration of lignocaine at
doses of 50, 70 and 90 , — 1 mg.kg
Dose 50.0 70.0 90.0
(mg^kg”l)
AUC 6 6 . 6 8 103.10 160.72
(yg.ml“^.min) ±7.78 ±9.48 ±5.96
n 8 8 8
Figure 3.8 shows dose normalised blood concentration-time curves 
for lignocaine for the doses studied and indicates that the curves are 
superposable. Apparent clearance of lignocaine after oral administration 
fell with increasing dose but the differences were not significant.
Systemic availability of orally administered lignocaine, calculated 
as the ratio of the dose normalised AUC at each oral dose to the mean 
of all dose normalised AUC's obtained after i.v. administration, is 
shown in Table 3.5. No statistically significant differences were 
found indicating the dose-independency of orally administered ligno­
caine within the range studied.
After oral administration, the amount of drug recovered as
unchanged lignocaine in urine was found to be less than 1%. Rats
- 1receiving lignocaine at a dose of 90 mg.kg exhibited reduced activity
but no other adverse effect of lignocaine were noted.
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Figure 3.8 Superposition plot of mean blood lignocaine concentrations
with respect to time following oral administration of 50, 
- 170 and 90 mg.kg
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Table 3.5 Systemic availability of lignocaine following oral









50 6 6 . 6 8 4026.50 0.0166
70 103.10 5637.10 0.0183
90 160.70 7247.70 0 . 0 2 2 2
Mean 0.019010.0016
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3.3 Single Intravenous doses of tocainide
The duration of restraint in metabolic cages necessiated by this 
study was longer than that required for the experiments on lignocaine 
and attempts to collect both blood and urine simultaneously after 
dosing with tocainide were unsuccessful. The experiments were therefore 
designed in such a way that each animal received two doses of tocainide 
on separate occasions; after one dose urine only was collected and 
after the other dose blood only was collected.
Tocainide was given by i.v. bolus injection to rats in doses of 
- 15, 20, 35 and 50 mg.kg . Five rats were studied at each dose making 
a total of 20 rats (body weight 465-575 g) . The rats were kejit in 
metabolic cages and all urine passed in the 24 hr after dosing was 
collected. One week later each animal again received the same dose 
of tocainide by i.v. bolus injection and blood was taken at appropriate 
times and assayed for tocainide.
The blood tocainide concentration-time data for individual 
animals and the group means are given in Appendix 5. The mean blood 
concentrations of tocainide plotted against time at the four doses 
are shown graphically on a linear scale in Figure 3.9 and on a 
logarithmic scale in Figure 3.10.
The mean concentrations of tocainide ranged between 0.21 and 10.21,
- 10.29 and 27.45, 0.54 and 30.61 and 0.93 and 49.49 yg.ml after doses
- 1of 5f 20, 35 and 50 mg.kg , respectively. After intravenous injection 
the concentration of tocainide in the blood declined in biphasic 
manner with an initial rapid and a subsequent slow phase which was 
linear when the logarithm of concentration was plotted against time 
(Figure 3.10). Kinetic parameters were obtained from the blood 
concentration-time data for each animal using the non-linear least 
squares regression analysis programme NONLIN as described in Appendix 
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Figure 3.10 Mean blood concentration of tocainide with respect to time
following intravenous administration of doses of 5, 20, 35 
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The data for AUC following different intravenous doses of 
tocainide appear in Table 3.7.
Table 3.7 Values for areas under blood concentration-time curves 
of tocainide following single intravenous injection at 
four dosés to rat.
(Mean ± SEM)
Dose 5 2 0 35 50
(mg.kg)
AUC 570.83 2293.38 4001.46 5901.95
(yg.ml“^.min) ±28.48 ±116.69 ±196.85 ±168.74
n 5 5 5 5
Dose independent kinetics are indicated by the linear increase 
in AUC with dose (Figure 3.11). Dose normalized blood concentration­
time curves for the doses studied are shown in Figure 3.12 and are
super imposable a finding indicative of dose-independent kinetics.
-1Accordingly a dose of 35 mg.kg , which was in the middle of the
range studied, was selected for the multiple dose study (3.7) and also
the studies in which blood flow and drug metabolism were altered
(Chapter 4, 5). Total body clearance and renal clearance of tocainide
following intravenous dosing were calculated for each rat as indicated
in Appendix 20 and the mean values are listed in Table 3.8. No
significant difference in total body clearance was found for the four
-1 -1doses studied (range of means 8,50-8.85 ml.min ,kg ), The percentage
of total body clearance accounted for by non-renal clearance was also
constant within the dose range studied (77.6-82,1%),
Symptoms of toxicity did not appear in rats receiving i.v. tocainide
-1in the range of 5 to 35 mg.kg . Sedation occurred in four out of five
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r = 0.989, p<0.001
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Figure 3.11 Relationship between AUC and dose following intravenous 




















D = 5 (n=5)
■ = 20 (n=5)
A. = 35 (n=5)






Figure 3.12 Superposition plot of the means of blood tocainide concentration
-1(yg.ml ) following four intravenous doses
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3.4 Single oral doses of tocainide
Twenty-two rats with body weights ranging between 450 and 575 g
were given tocainide by mouth in doses of 50,,100, 200, 300 and 400 
.-1mg.kg . Blood samples were taken at appropriate times and assayed for
tocainide. The individual blood concentration-time data and the mean
for each dose group appear in Appendix 7. Tocainide mean blood
-1concentrations at each dose ranged as follows; 0.21-7.15 yg.ml
(50 mg.kg ^), 0.89-12.16 yg.ml  ̂ (100 mg.kg ^), 2.09-15.85 yg.ml ^
(200 mg.kg ^), 183-28.05 yg.ml ^ (300 mg.kg and 2.08-54.59 yg.ml ^
-1(400 mg.kg ). Maximum blood concentrations were reached between 2.5
and 4 hours after dosing. The mean blood concentration data are plotted
in Figure 3.13 on a linear scale and in Figure 3.14 on a logarithmic
scale with respect to time. It is apparent that the plot of logarithm
of drug concentrations with respect to time is linear and that AUC
increased with the dose given (Table 3.9).
The kinetic parameters kgĵ , k^, t^ and CL were calculated and the
-1mean values appear in Table 3.9. At the 50 mg.kg dose, t^ was 
significantly shorter by student's 't' test (p<0 .0 0 1 ) than the t^ at 
all other doses. The relationship between t. and dose is depicted 
graphically in Figure 3.15. It is also noted that the t^ of tocainide 
after oral administration is substantially longer (4.6-11.7 hr) than 
that obtained after the drug was given intravenously (113.4-130.5 min).
Within the range studied dose increased linearly with AUC 
(r = 0.976, p<0.001) and the 95% confidence interval for the slope of 
the regression line includes the origin of the plot of AUC against 
dose (Figure 3.16). Dose-normalized blood concentration-time curves 
for the doses studied are shown in Figures 3.17. Between doses of 100 
to 400 mg.kg ^ the plots are superimposable.
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Figure 3.14 Mean blood concentrations of tocainide with respect to time 
after oral administration
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Figure 3.15 with respect to dose of tocainide following oral 
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Figure 3.16 Relationship between AUC and dose following oral 
administration of tocainide. (Mean ± S.E.M.)
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Figure 3.17 Superposition plot of the means of blood tocainide 
following four oral doses
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Table 3.. 10 Systemic availability of tocainide following oral doses










50 4303.01 5803.46 0.7414
lOO 11043.49 11606.93 0.9514
2 0 0 18530.37 23213.85 0.7982
300 32675.03 34820.78 0.9384
400 50007.51 46427.71 1.0771 
Mean+SEM 0.941210.0570
Systemic availability (F) of orally administered tocainide was 
calculated as the ratio of the AUC at each oral dose to the mean of 
all AUC's obtained after intravenous administration normalised for
dose. A mean figure of (94.1 ± 5.7%) was obtained from the lOO, 200,
-1 -1 300 and 400 mg.kg doses. The data for the 50 mg.kg dose were
excluded from this analysis because t^ was significantly shorter and 
the dose normalized blood concentration-time plot was not super­
imposable with those obtained from other doses. Since tocainide is 
completely absorped from the gut (3.6), not metabolised within the 
gut wall (3.5) and since renal clearance can be assumed to be equal 
for intravenous and for oral dosing a value for hepatic extraction 
(E) of tocainide and be obtained (E=l -F) and is equal to 0.06.
Apart from slight sedation no other clinical signs of toxicity 
were evident in animals recieving 50, 100, 200 and 300 mg.kg”^ orally. 
Four out of five rats in the 400 mg.kg ^ dose group developed seizures 
within one hour of dosing, one rat died in the fourth hour after 
dosing and the rest survived.
1 1 4
3,5 Single intraperitoneal dose of tocainide
- 1Tocainide in 100 mg.ml saline was given by intraperitoneal
- 1injection to six rats (body weight 455-500 g) in a dose of 50 mg.kg
Blood samples were taken at appropriate time intervals before and after
administration and were assayed for tocainide. The individual blood
concentration-time data are given in Appendix 8 together with the
means for the group. Mean blood concentration of tocainide ranged
- 1between 1.51 and 11.05 yg.ml and the maximum concentrations were
reached between 1 and 2.5 hours. The mean blood concentration-time data
are plotted in Figure 3.18 on a linear scale and in Figure 3.18 on a
logarithmic scale with respect to time. The latter figure shows that
the logarithm of the terminal phase of decline in drug concentration
with time is linear. The kinetic parameters k^, t, and AUC wered ^ o ^
calculated for each animal as described in Appendix 20 and the mean
data are given in Table 3.11. This table also shows kineitc parameters 
calculated for the same dose of tocainide administered to six rats by 
the oral route (3.4). The terminal blood t^ of tocainide was less 
after intraperitoneal than after oral administration (p<0 . 0 0 1  by 
Student's 't' test) but A U C ^ ^  showed no statistically significant 
differences when the two routes of administration were compared 
indicating that after oral administration of tocainide there is no 
loss of drug prior to its reaching the liver.








































( iui*5rl) apTUTBooq. poo%g T“
C M(O C O









































Table 3.11 Comparison of the kinetic parameters of tocainide








i»p» 483.33 6 0.0034 203.2** 4489.08
±6.91 ±0 . 0 0 0 1 ±6.9 ±203.21
p.o. 524.17 6 0.0026 276.6 4303.01
±14.17 ±0 . 0 0 0 2 ±19.7 ±544.32
** p<O.OOl
3.6 Completeness of absorption of orally administered tocainide
Tocainide was given by mouth to three rats (body weights 450,
- 1460 and 465 g) in a dose of 200 mg.kg . All faeces passed after 
dosing were collected and 48 hours after dosing the animals were 
killed by cervical dislocation. The entire alimentary tract of each 
animal was then removed and washed through with isotonic saline 
until the washings were clear. Faeces and washings from each animal 
were then combined and assayed for tocainide. The mean percentage 
recovery of unchanged drug was 0.025 ± 0.006% indicating essentially 
complete absorption of tocainide from the alimentary tract.
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3.7 Multiple intravenous administration of tocainide
Tocainide was given by i.v. bolus injection to six rats (body
- 1weights 450-570'kg) in a dose of 20 mg.kg every 8 hours for seven
doses. Blood samples were taken prior to and after the first dose,
after the sixth dose and before and after the seventh doses, at
appropriate time intervals. Because the total procedure involved
more blood samples than were taken in the single i.v. dose study, the
number of blood samples taken to describe the first and the seventh
doses had to be reduced for reasons associated with the method of
sampling (cutting off the tip of the rat tail). Consequently it was
not possible to define the rapid (a) phase of drug distribution
adequately. The individual and the mean blood concentration-time
data appear in Appendix 10.
Table 3.12 shows the individual and mean values for k^, t^ AUC,
Vd ^ and total body clearance for the first and for the seventh extrap
doses of tocainide. This table also gives the mean blood concentration 
at steady state (C^^) which was calculated from the seventh dose by 
the relationship:
Cgs =
When the kinetic data for the first and for the seventh dose 
were compared no significant statistical differences were found by 
Student's 't' test and by the Wilcoxon signed rank test. The mean 
blood concentration-time curves are shown graphically in Figure 3.15. 
The difference in mean t^ (145,8 min for the first dose and 203.8 min 
for the seventh dose) was almost entirely due to rat 3 in which the 
individual t^ increased over threefold. It was also noted that this 
rat convulsed immediately after administration of the sixth and of
118
the seventh doses, the duration of convulsions being about 30 mins 
on each occasion. The other five rats exhibited less than normal 
activity after the sixth and seventh doses.
Thus in five of the six rats studied under the stated conditions 




■ first dose (n=6 )








Figure 3.20 Means ± S.E.M. of blood tocainide concentration following 
the first and the seventh dose of tocainide 50 mg.kg 
intravenously every 8 hours.
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3.8 Multiple oral dosés of tocainide
Tocainide was given by mouth to five rats (body weights 470-495 g)
- 1in a dose of 200 mg.kg every 12 hours for ten doses. Blood samples 
were taken at appropriate time intervals before and after the first 
dose, at six and nine hours after the first , and fifth doses and before 
and after the tenth dose. The individual blood coneentrâtion-time data 
and the mean data for the group are given in Appendix 11. Table 3.12 
shows the individual and mean values for k^, t^, AUC and total body 
clearance for the first and for the seventh dose of tocainide. The 
table also gives the mean blood concentration of tocainide at steady 
state (C^) which was calculated from the tenth dose by the relationship:
^ss " ^^^0 + 1 2  hr 
T
where T is the dose interval.
The mean blood concentration-time curves are also shown on a linear 
scale in Figure 3.21 and on a logarithm scale in Figure 3.22. The 
limitations imposed by the necessarily reduced freqency of blood 
sampling in this experiment resulted in there being fewer concentration 
points on which to base the estimation of t̂ .̂ For the first dose t^ 
was based on the 6 , 9 and 12 hour samples and for the tenth dose t^ was 
estimated from samples obtained between one hour after the peak 
concentration and the 12 hour sample. In rats 3 and 5, t, increased 
substantially after the tenth dose and both these rats showed clinical 
signs of toxicity after the tenth dose had been given. No change in 
tĵ  and no signs of toxicity were noted in the other animals. When the 
group means are compared no statistically significant difference were 
found in t^ when the first and tenth doses are compared.
1 2 2
AUC for the first dose was compared with AUC , « , (Wagner et al 
0 ->a 0 > 1 2  hr
1965 ) for the tenth dose and no significant difference was found
for the group of rats as a whole, although it was noted that in rat 3
AUC had almost doubled after the tenth dose.
It is appreciated that the reduced frequency of blood sampling
in this study has meant that the estimation of t^ for the first dose
and therefore AUC: is less secure than would ideally be the case.o-»a
Nevertheless, it would appear that in the stated condition of multiple 










6 1 0 1 24 820
Hours
Figure 3.21 Mean ± S.E.M. of blood tocainide concentration following
the first and the tenth dose of multiple oral administration
- 1of a 2 0 0  mg.kg dose every 1 2  hours
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50 Dose
■ = first dose (n=5) 










Figure 3.22 Mean of blood tocainide concentration following the 
first and the tenth dose of tocainide 2 0 0  mg.kg 
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CHAPTER IV
Effects of enzyme inducing agents on pharmacokinetics 
of lignocaine and tocainide in rats
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4»1 Effects of 3,4 benzpyrene and of phenobarbitone on hepatic
microsomal enzyme activity
Thirty-one rats, 300-350 g body weight, were given either sodium
-1 -1phenobarbitone (100 mg.kg in 1 ml.kg saline, daily for 4 days) by
-1 -1intraperitoneal injection or 3,4 benzpyrene (80 mg.kg in 10 ml.kg 
corn oil) by single intraperitoneal administration as described in 
Chapter 2. Thirty-two control rats received equivalents volumes of 
saline or of corn oil only by intraperitoneal injection. Twenty four 
hours after the last injection of phenobarbitone and 48 hours after
3,4-benzpyrene, the difference in hepatic enzyme activity between the 
two groups of rats was determined using the following indices of drug 
metabolism; (1 ) pentobarbitone sleeping time;
(2 ) liver weight;
(3) hepatic microsomal protein;
(4) cytochrome P-450 content
and (5) p-nitroanisole 0-demethylase activity.
1. Pentobarbitone sleeping time
Groups of rats which had received either phenobarbitone, or 3,4-
benzpyrene, or saline or corn oil as described above were given sodium
-1pentobarbitone 40 mg.kg in a single intraperitoneal injection. After 
injection each animal was observed and tested for the presence of the 
righting reflex. Sleeping time was taken as the time from the loss of 
the righting reflex. The mean data are given in Figure 4.1. After 
phenobarbitone and after 3,4 benzpyrene, the mean pentobarbitone 
sleeping times were decreased by 82,9% (p<0 .0 1 ) and by 35,0% (p<0.01) 
respectively.
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Figure 4.1 Effects of phenobarbitone (PB) and of 3,4 benzpyrene
(3,4 BP) on pentobarbitone sleeping time in rats (MeaniS.E.M.)
Saline Phenobarbitone Corn Oil 3,4- benzpyrene
Sleeping 104.2±3.5 17.8±4.3 106.2±5.5 69.1±3.5
time









Saline PB Corn oil 3,4 BP
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2, Liver weight
Groups of rats which had received either phenobarbitone, or
3,4-benzpyrene or saline or corn oil as described above were killed by 
cervical dislocation. Livers were immediately removed and weighed.
The mean values are shown in Table 4.1. There was no significant 
difference in liver weight between the two control groups but in the 
group which received phenobarbitone liver weight was on average 26.0% 
greater than in the group which received saline. Liver weight in the 
group which received 3,4 benzpyrene was not significantly different 
from that in the group which received corn oil.
Table 4.1 Effects of phenobarbitone and of 3,4 benzpyrene on liver 
weight in rats. (Mean ± SEM)
Treatment No of rats g.liver. loo  g of 
body weight"!
Control 1 0 3.48 ± 0.13
Phenobarbitone 7 4.39 ± 0.32*
Corn Oil 4 3.43 ± 0.12
3,4 benzpyrene 6 3.67 ± 0.27
* p<0 . 0 0 2
3. Hepatodyte mixed function oxidase activity
a) Stimulation of microsomal protein and cytochrome P-450 
formation
Cytochrome P-450 is an important constituent of the mixed function 
oxygenase system in the liver, and an increase in the concentration of 
cytochrome P-450 is taken to indicate an increase in hepatic metabolising 
capacity, i.e. enzyme induction.
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-1Groups of rats received either phenobarbitone (100 mg.kg , i.p.,
-1daily for 4 days) (4 rats) or 3,4 benzpyrene (80 mg.kg , i.p. on one 
occassion) ( 4 rats) as described in Chapter 2. Twenty four hours 
after phenobarbitone and 48 hours after 3,4 benzpyrene the rats were 
killed and microsomes were prepared from each liver and assayed for 
protein concentration and cytochrome P-450 content according to the 
methods of Lowry (1951) and Omura and Sato (1964) respectively.
The mean microsomal protein concentration and the mean cytochrome 
P-450 content in the above groups of rats are present in Table 4.2.
A significant increase in liver microsomal protein and in cytochrome 
P-450 content was found in phenobarbitone and in 3,4 benzpyrene treated 
rats when compared with saline and corn oil respectively. The results 
in both treated groups were similar and no significant difference 
between these groups was noted when the results are expressed as "per 
g liver". However, in the phenobarbitone animals there was a 
significant increase in liver weight which was not observed for the
3,4 benzpyrene rats. Therefore, the total increase in microsomal 
protein and in cytochrome P-450 content was greater after administration 
of phenobarbitone.
b) Stimulation of p-nitroanisole-O-demethylase
Change in the activity of microsomal 0-demethylation of p-nitro­
anisole was used as an indication of alteration in overall liver micro­
somal drug metabolising ability, although this particular enzyme plays 
no part in the metabolism of lignocaine or of tocainide. Specific 
activity was observed by determining the amount of formaldehyde formed 
during incubation of substrate (p-nitroanisole) at different concent­
rations with hepatic microsomes from sixteen rats pretreated with
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-1 -1 4 days), corn oil (10 ml.kg ) or 3,4 benzpyrene (80 mg.kg in corn
oil) i.e. four groups with four rats in each group. The mèthod used
is described in Chapter 2. The mean data for each group appear in
Table 4,3. This shows that p-nitroanisole-O-demethylase activity
increased in the phenobarbitone group almost three-fold and in the
3,4 benzpyrene group almost two and a half-fold when compared with the
controls.
The kinetic behavior of normal and of stimulated enzymes was 
studied by determining the Michaelis-Menten constant (K^) of p-nitro­
anisole. The data, plotted according to the method of Lineweaver and 
Burk (1934) were analysed statistically by least square linear 
regression in order to facilitate drawing the line of best fit. The 
results are shown in Figure 4.2. Phenobarbitone and 3,4 benzpyrene
treatment resulted in an increased maximum velocity (V ) of 0-demethy-max
lase, whereas was unchanged, showing that an increase in enzyme 
activity was obtained without alteration in substrate affinity.
4.2 Effects of phenobarbitone, 3,4 benzpyrene, lignocaine and 
tocainide on haemodynamic parameters in the rat 
In this section the effects of the individual drugs used in this
chapter on various haemodynamic parameters are reported.
-1 -1 Rats received either phenobarbitone (100 mg.kg , I.p. in 1 ml.kg
-1 -1saline, daily for 4 days) or 3,4 benzpyrene (80 mg.kg in 10 ml.kg ,
corn oil, i.p., as a single dose) and were sttidied 24 hours or 48 hours
after the last dose of phenobarbitone or 3,4 benzpyrene respectively.
.-1Other rats received lignocaine 5 mg.kg in saline or tocainide 35 
mg.kg ^ in saline as an i.v. bolus and were studied 30 minutes after 
injection of either lignocaine or tocainide. Control rats received
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by intraperitoneal injection,. The timing of haemodynamic studies after 
drug administration was arranged to coincide as a) with known times of 
significant enzyme induction for phenobarbitone and 3,4 benzpyrene from 
section 4.1 and from previously published work (Ohnhaus et al, 1971; 
Nies et al, 1976) and b) in the case of lignocaine and tocainide with 
known times of high blood concentration when it was assumed that any 
haemodynamic effects would be maximal.
Mean arterial blood pressure, cardiac output and organ blood flow 
were measured as described in Chapter 2.
4.2.1 Effect on mean arterial pressure and on cardiac output
The data for arterial pressure and cardiac output for individual 
rats appear in Appendix 12—19 and the mean values are given in Table 4.4.
It is appreciated that a total analysis would have included the 
effect of combinations of the drugs as used in this work on these 
parameters but this was not undertaken. Rather the effect of only one 
combination namely phenobarbitone followed by tocainide (as in 
Chapter 4,5) was studied and the data for this are also given in Table 
4.4.
Analysis of the data by student's 't' test and by the Wilcoxon 
signed rank test indicates that administration of phenobarbitone, 
lignocaine, tocainide or phenobarbitone followed by tocainide as stated 
caused no significant change in mean arterial pressure or in cardiac 
output when compared with the effect of administration of saline. By 
the same statistical tests, treatment with 3,4 benzpyrene producted no 
significant change in these parameters when compared with the group of 
rats which received corn oil.
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Table 4,4 Influence of phenobarbitone, 3,4 benzpyrene, lignocaine, 
tocainide and phenobarbitone followed by tocainide on 
haemodynamic parameters in rat (Mean ± SEM)






saline 1 0 ; ii6,5 + 3.1 87.1 + 9.3 192.4 + 13.4
phenobarbitone 7 128.9 ± 3.0 107.5 + 15.1 213.5 + 25.6
corn oil 4 118.0 + 3.2 94.5 + 16.3 223.2 + ’32.2
3,4 benzpyrene 6 113.3 + 3.5 82.0 + 3.9 188.4 + 1 2 . 2
lignocaine 4 113.1 + 4.0 121.7 + 2 0 . 8 212.9 + 15.1
tocainide 4 1 2 0 . 6 + 6.9 109.1 + 19.4 2 1 1 . 0 + 29.0
phenobarbitone 
+ tocainide 4 121.9 + 5.2 78.7 + 7.8 204.6 + 1 1 . 0
4.2.2 Effect on liver blood flow and on liver weight
The data for liver blood flow and liver weight for indivdual animals 
are given in Appendix 12-19 and the mean values appear in Table 4.5. There 
were no significant differences by student's 't ' test or by the Wilcoxon 
signed rank test in hepatosplanchnic flow (total liver blood flow) or 
liver weight between rats receiving saline and those receiving corn oil. 
Likewise, there were no significant differences in these paramenters when 
treatment with 3,4 benzpyrene was compared with treatment with corn oil 
alone or when treatment with lignocaine or tocainide was compared with 
treatment with saline alone.
Treatment with phenobarbitone however, was associated with a 39% 
increase in hepatosplanchnic flow (total liver blood flow) per 1 0 0  g 
body weight and a 26% increase in liver weight per lOO g body weight.





































































































1—1 CN 'd* m 'd ’ CD CJl O CN CD o
1—1 CD O CD r—1 in O 1-4 O O 1—1
o O O O O O o o O O o
4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1m r-' O in CN 00 CD CN ro CD CDifi CN œ m ■cj* a\ O CN ro [ " •
O m iH O i-H O O iH
f" O CN CN CT> en - ( f o ro CD 00
m ro O CN O CN CN fH O O ro
O O O O O O O o O O O
4-1 4-1 -H 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1
rH i n CD O 00 r " CDr- 1—1 iH O CN 1—1 O in i—1 ro
CN n o r-4 ro iH O O
CD
O CN
o r 4 ro rH G\ ro Q 'd* ro
CN m o 'd* 1—1 rH O O O TT
O O o O o O O O O O O
4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1in n (T> CN 0 0 CO rH fH O
m CD iH O 1—1 0 0 rH <N TT iH




















r- ifl 1—i Tf CD r- o TT m m •nj*CN CN O ro O ro 1—1 iH O O CN
o o O O o O o O O O O4-1 4-1 4-1 4-14-1 4-14-1 4-14-1 4-14-1r- rH CD CD in ro 'd' CD 00 CO CDCD O rH rH I—1 00 CD CD CN ro CN








~ >  tr> -H
tn
tr>
M  O'ü —' C4 en c/l
. g
C 4  i - H  I— I I— I
01 4 4  I I 
O G G 
P  fO  -H  -H(d O a a
A  O • •








p i —I r—) I—I
Ü P  I I 
fd G G 
M T3 -iH -HP O a a o • •
I—I <—I 1-4 I—Iu X» a a
-  p
en (U





(T> m  
O  ifi
O O
4-1 4-1 4-1 -H 4-1 4-1 4-1 4-1 4-1 4-1 4-1 5ro m 00 O r~- CN CD CD 00 CD O
iH rH o rH CD 00 CD CN rH
U-lro ro O ■njr i—1 CN o O O O CN y
* •H
* * G
-te 4e 4e rG
CN CD 1—1 CD r- 1—1 1-4 CN m CD oro CN o m rH CN rH U1 1-4 O CN SfdO O o o O O o o o O O 1-4
4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 eu
CD CN CD r-' CN CD CD CD enro CD 1—1 CD ro CD ro CD ro ro O 0
p
CN O ir> 1—1 ro I—i 1-4 O O CN fdS*. Xi
ro •nj* rH ro rH O in o m ro m II
rH CN O f—1 ro r—1 CN O O CN
uO O o O o O O O O O o +
4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 4-1 rQ
0 0 CD O CD O m O CN 4 -









0  I H  
1-4 >  I
4 4  n  P
I. 0)
88B
1-4 r 4  CT* 
P3 • •
U  P  I I 
•H G G 
P  no "P 'Hfd O a aC4 o • •
(U I— I 1-4 r-4a P  a a
G G 
0) -H<u a a






in CN O O
9 9eu eu 
** *
g
~  ü 
B &







+  Il 
fd P
138
increase (p<0.05) in portal venous flow, that is, flow from the gastro­
intestinal (GI) tract and pancreas. Splenic blood flow and hepatic 
arterial flow to the liver did not increase significantly after pheno­
barbitone. Neither spleen weight nor the combined weight of the GI 
tract and pancreas were found to be affected by phenobarbitone. Since 
both hepatosplanchnic flow and liver weight were increased by pheno­
barbitone, liver blood flow when expressed as "per g of liver" was 
unchanged by phenobarbitone.
Administration of phenobarbitone followed by tocainide was 
associated with similar changes in liver weight and hepatosplanchnic 
flow to those found with phenobarbitone alone. The data are represented 
graphically in Figure 4.4
4.2.3 Effects on blood flow to other organs and on regiodal distrib­
ution of cardiac output
The data for blood flow to and weight of heart, lungs and kidneys 
for individual animals appear in Appendix 12-L9 and the mean values are 
given in Table 4.6. No significant differences were found after any 
drug treatment. The individual values for the percentage of cardiac 
output received by the major organs are given in Appendix 12-19 and the 
mean values appear in Table 4.7. A significant increase in distribution 
to GI tract and pancreas was observed after treatment with phenobarbi­
tone followed by tocainide (p<0.05) but not by treatment with 
phenobarbitone alone. Other treatments did not produce significant 













Figure 4.4 Effects of phenobarbitone (PB), 3,4 benzpyrene (3,4 BP),
lignocaine, tocainide, and phenobarbitone followed by tocainide
-1 -1on liver blood flow (ml.min .100 g, bw ) in rat. Hepatic 
arterial flow is represented by cross-hatched bars and portal 
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4.3 Pharmacokinetics of lignocaine given in a single intravenous dose
in 3,4 benzpyrene and in phenobarbitone ptqtreated rats.
-13,4 benzpyrene (80 mg.kg ) was administered by a single i.p.
injection to six rats weighing 435 to 480 g, and phenobarbitone (lOO 
- 1mg.kg ) was administered, i.p. daily for 4 days to nine rats weighing
-1375 to 425 g. Lignocaine (5.0 mg.kg ) was administered to all rats 
in each group by single i.v. injection via the tail vein 48 hours after
3.4 benzpyrene and 24 hours after the last dose of phenobarbitone.
Blood samples were taken at intervals and assayed for lignocaine. The
data for individual rats and also the group means appear in Appendix 2.
-1The group of ëight rats which also received lignocaine 5 mg.kg
intravenously but without prior administration of 3,4 benzpyrene or
phenobarbitone in the earlier dose-ranging study (Chapter 3.1) served as
a control group in this study. Mean blood lignocaine concentrations in
control and in enzyme induced rats have been plotted on a linear scale
(Figure 4.5) and on a logarithmic scale (Figure 4.6) against time.
Kinetic parameters for each animal (except for one rat in the
phenobarbitone treated group) were derived using the non-linear least
sc[uares regression analysis programme NONLIN as described in Appendix 21.
The blood concentration data in one animal in the phenobarbitone group
exhibited a mono-exponential decline with time but are included in the
analysis where appropriate. The mean values appear in Table 4.8.
When the data for the inital distribution space, Vp, are compared
by student's *t' test, there was no difference between control and
treated groups and there was no significant difference between both
treated groups, Vd , Vd and Vd were all significantlyextrap' area ss ^ ^
increased in the phenobarbitone treated group as compared with controls 
but these parameters were not increased in rats treated with 3,4 
benzpyrene. It is noted that in 3,4 benzpyrene group, k^ is signifcantly
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increased but no significant changes occurred in ^21’ There
were no difference in terminal half-life (t^^) of lignocaine between 
control and enzyme induced rats and between the two treated groups.
In the phenobarbi to ne-treated group the AUC for lignocaine was 
significantly decreased but this was not so far the group treated with
3,4 benzpyrene. Consequently total systemic clearance of lignocaine 
was signficantly increased by phenobarbitone treatment but not by 













































































































































8.0 • = control (n=8 )
A  = phenobarbitone (n=9) 
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Figure 4.6 Mean blood concentration-time graphs of lignocaine following
- 1Smg.kg intravenous injection in control, phenobarbitone and 
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4.4 Pharmacokinetics of lignocaine given in a single oral dose in
3.4 benzpyrene and in phenobarbitone pretreated: rats
- 13.4 benzpyrene (80 mg.kg ) was administered by a single i.p.
injection to six rats weighing 430 t6  475 g and phenobarbitone (100
mg.kg"^) was administered i.p. daily for 4 days to six rats weighing 350
- 1to 455 g. Lignocaine (70 mg.kg ) was administered to all rats in
each group in a single oral dose 48 hours after 3,4 benzpyrene and
24 hours after the last dose of phenobarbitone. Blood samples were
taken at intervals and assayed for lignocaine. The blood concentration
time data for individual rats and the means for each group are presented
in Appendix 4. The group of eight rats which also received lignocaine 
- 170 mg.kg by single oral dose but without prior administration of
3.4 benzpyrene or phenobarbitone in the earlier dose-ranging study 
(Chapter 3.2) served as a control group in this study. The mean blood 
lignocaine concentrations in control and in enzymes induced rats have 
been plotted on a linear scale (Figure 4.7) and on a logarithmic scale 
(Figure 4.8) against time. The kinetic parameters for each group were 
derived as described in Appendix 20 and the mean data are listed in 
Table 4.9. This shows that there was no change in the rate constant 
for absorption (k^) and for disposition (k^) between control and 
enzyme-induced rats. Consequently blood of lignocaine was unchanged. 
However, the AUC after oral administration of lignocaine in both groups 
of enzyme-induced rats was singificantly less than in the control 
groups, the decrease in AUC being more marked in the phenobarbitone- 
treated group. Consequently apparent clearance of lignocaine by the 
oral route was significantly increased in the enzyme-induced rats, the 
increase being more marked in the phenobarbitone treated group. Change 
in t^, AUC and in apparent oral clearance in control and in enzyme- 















































































































1.0 • = control (n=8 )
A =  phenobarbitone (n=6 ) 
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Figure 4.8 Mean blood concentration-time graphs of oral lignocaine
- 1(70 mg.kg ) in control, phenobarbitone and 3,4 benzpyrene 
treated rats
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Table 4.9 Pharmacokinetic parameters of lignocaine following a
- 1single oral dose (70 mg.kg ) in control, 3,4 benzpyrene 
and phenobarbitone pretreated rats
Control 3,4 benzpyrene Phenobarbitone
n 8 6 6
Body weight 417.5 452.5 430.0
(g) ±13.2 ±6.7 ±16.6
^a 0.1044 0.1135 0.0846
(min ) ±0.0174 ±0.0269 ±0 . 0 2 0 0
kd _i 0 . 0 1 2 1 0.0129 0.0116
(min ) ±0.0009 ±0.0007 ±0 . 0 0 1 1
59.2 54.5 62.0
(min) ±4.6 ±3.4 ±5.6
AUCpo _i 103.10 65.74* 33.14**
(yg.ml .min) ±9.48 ±7.63 ±7.94
CL 73.0 113.9* 254.9**
(ml.min .lOOg,bw ) ±8 . 0 ±13.0 ±13.9
* p<0 . 0 2
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Figure 4.9 Effects of enzyme inducers on half-life, apparent oral
clearance and area under blood concentration-time curves 
of lignocaine following 70 mg.kg  ̂ by single oral administration
* p<O.OOl
** p<0 . 0 2
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4., 5 Pharmacokinetics of tocainide given in a single intravenous
dose in 3,4 benzpyrene and in phenobarbitone pretreated rats
- 13,4 benzpyrene (80 mg.kg ) was administered by a single i.p.
injection to six rats weighing 400 to 460 g and phenobarbitone 
- 1(loo mg,kg ) was administered i.p. daily for 4 days to six rats
weighing 470 to 525 g. Tocainide (35 mg.kg was administered to
all rats in each group by a single i.v. infection via the tail vein
48 hours after 3,4 benzpyrene and 24 hours after the last dose of
phenobarbitone. Blood samples were taken at intervals and assayed
for tocainide. The data for individual rats and also the group means
appear in Appendix 6 . The group of five rats which also received
- 1tocainide 35 mg.kg. i.v. but without prior administration of 3,4- 
benzpyrene or phenobarbitone in the earlier dose-ranging study 
(Chapter 3.3) served as a control group for this study. Mean blood 
concentrations in control and in enzyme-induced rats have been plotted 
on a linear scale (Figure 4.10) and on a logarithmic scale (Figure 4.11) 
aginst time.
Kinetic parameters for each animal were derived using the nonlinear
least squares regression analysis programme NONLIN as described in
Appendix 21 and the mean values appear in Table 4.10.
When the data for the volume constants Vp, Vd , Vd andextrap area
Vd^^ are compared, there was no significant difference between the 
control and the treated groups by student's 't' test. However, in both 
enzyme-induced groups of rats, there was a significant increase in the 
rate constant k^ but no change was noted in the rate constants k^^ and 
^21' There was no change in t^g in the group which received 3,4 benz­
pyrene but pretreatment with phenobarbitone was associated with an 
approximate halving of t^g (p<0 .0 2 ) cœipared with the control group.
AUC in both the enzyme-induced groups of rats was significantly
153
decreased as compared with controls, the decrease being greater after 
phenobarbitone treatment. Consequently total body clearance was 
increased in both enzyme-induced groups, the increase being greater 
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Figure 4.11 Mean blood concentration-time profiles of tocainide following 
35 mg.kg single intravenous administration in control, 
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4,6 Pharmacokinetics of tocainide given in a single oral dose in
3 , 4  benzpyrine and in phenobarbitone pretreated rats
3 , 4  benzpyrene (80 mg,kg was administered by single i.p. 
injection to six rats weighing 400 to 480 g and phenobarbitone was
administered i.p. daily for 4 days in six rats weighing 460.to 490 g.
- 1Tocainide (50 mg.kg ) was administered to all rats in each group in
a single dose 48 hours after 3,4 benzpyrene and 24 hours after the
last dose of phenobarbitone. Blood samples were taken at intervals
and assayed for tocainide.
The concentration-time data for individual animals and the means
for each gorup are presented in Appendix 9. The group of six rats
- 1which also received tocainide 50 mg.kg by single oral dose but 
without prior administration of 3,4 benzpyrene or phenobarbitone in 
the earlier dose-ranging study (Chapter 3, 4) served as a control group 
in this study. The mean blood concentrations in control and in enzyme-
induced rats have been plotted on a linear scale (Figure 4.12) and on
a logarithmic scale (Figure 4.13) aginst time. The kinetic parameters 
of each group were derived as described in Appendix 20 and the mean 
data are listed in Table 4.11. The groups were compared by student's
*t* test and by Wilcoxon signed rank test. No difference was found
in the rate constants for drug absorption (k^) but pretreatment with 
both 3,4 benzpyrene and with phenobarbitone was associated with an 
increase in the disposition rate constant k^. Consequently t^ was 
reduced in both enzyme-induced groups. The AUC^ ̂  was also considerably
reduced by pretreatment with both 3,4 benzpyrene (49.1%) and with
phenobarbitone (57,5%), Consequently the oral clearance of tocainide 
was significantly increased (p<0 .0 1 ) in both groups of rats which had
received enzyme-inducing drugs. Change in tĵ , AUC and oral clearance
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Figure 4.13 Mean blood concentration-time profiles of tocainide (SOmg.kg -I) 
following single oral administration in phenobarbitone and 
3,4 benzpyrene treated rats.
160
Table 4.11 Pharmacokinetic parameters of tocainide following a single
-1oral dose (50 mg.kg ) in control, 3,4 benzpyrene and 
phenobarbitone treated rats
control 3,4 benzpyrene phenobarbitone

























. T - 1(ml.min
1 0 0 g,bw~l
1.3±0.2 2.410.2** 2.910.32**
t p<0.05
* p<0 . 0 2
** p<0 . 0 1




















CL AUCnn CL AUC__ t, CL AUCpo
control Phenobarbitone 3,4 benzpyrene
Figure 4.12' Effects of enzyme inducing drugs on half-life, clearance
and area under blood concentration-time curve of tocainide
-1following a single oral dose (50 mg.kg )
* p<0 . 0 2
** p<0 . 0 0 2
*** p<0 .0 l
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CHAPTER V
Effects of alteration in liver blood flow by sotalol on the 
pharmacokinetics of lignocaine and of tocainide in rat
163
In this Chapter the effects on the pharmacokinetics of lignocaine 
and of tocainide brought about by alteration in blood flow by the 
beta-adrenoceptor antagonist,sotalol are presented.
5.1 Effects of sotalol on mean arterial pressure and on cardiac 
.output
Preliminary dose ranging expreiments with sotalol were undertaken. 
Blood pressure and heart rate were recorded in pentobarbitone anaesthe-
-1tized rats which had received sotalol in doses varying between 1 0  mg.kg
and 300 mg.kg The objective of these experiments was to find a
dosing regime which would acheive a significant and stable reduction
in LBF sufficient to study the kinetics of single doses of lignocaine
and tocainide under conditions of reduced blood flow. No significant
difference in either blood pressure or in heart rate in rats were
-1noted with doses of sotalol from 10 to 50 mg.kg , i.p., Table 5.1
shows the effect of sotalol at higher dosage levels on mean arterial
pressure, heart rate and cardiac output in anaesthetized rats. A dose 
-1of loo mg.kg , i.p. was noted to being about a satisfactory fall in
heart rate and arterial pressure for 3 hours. At doses in excess of
this, rats died after 2 hours. The following dosing regimen was
-1therefore adopted; sotalol lOO mg.kg , i.p., was administered at 
“24 hours, at-18 hours, at-12 hours before either lignocaine and 
tocainide, then at O hours followed by either lignocaine 15 minutes 
later or tocainide 3o minutes later. In experiments involving ligno­
caine no further sotalol was given but in experiments involving
-1tocainide, sotalol (100 mg.kg ) was given again at+4 hours, at+ 8 hours 
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Table 5,2 gives mean data for arterial pressure and cardiac 
output in rats 30 minutes after the fourth (i.e. O hour) dose of 
sotalol.
Table 5.2 Effects of sotalol on mean arterial pressure and on
cardiac output in rats (for details of dosing see text; 
mean ± SEM)
Control Sotalol
n 1 0 7
mean arterial pressure 
(mm.Hg)








50.5 ± 3.6** 
142.2 ± 10.7***
* p<0 . 0 0 1
** p<0 . 0 1
*** p<0 . 0 2
5.2 Effects of sotalol on liver blood flow and on liver weight
-1Sotalol (100 mg.kg ) was given by intraperitoneal injection, as 
described in 5.1 at -24 hours, -18 hours, -12 hours and O hours to 
seven rats weighing 245 to 415 g. Thirty minutes after the fourth 
dose liver blood flow was measured as described in Chapter 2. The 
individual values appear in Appendix 16 and the mean data are shown 
in Table 5,3, Ten rats weighing 300 to 595 g and which received no 
sotalol (Chapter 4.2) served as a control group, Hepatosplanchnic 
flow decreased by 29,1% after sotalol when flow is expressed "per g 
of liver" and 22,7% when flow is expressed per lOO g body weight. The 
reduction in hepatosplanchnic flow was principally accounted for by 
a reduction in hepatic arterial flow (p<0.05). Flow to GI tract and 
pancreas and splenic blood flow were also reduced but these differences
were not significant.
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Table 5.3 Effects of sotalol on liver weight and liver blood
flow in pentobarbitone anaesthetized rats. (Mean ± SEM)
Salihe Sotalol
No of rats 1 0 7
Liver weights
(g/lOO g b.w.) 3.48 ± 0.13 3.73 + 0.19
Hepato splanchnic
blood flow1 —1 ml.min ^ g liver 1.17 ± 0 . 1 1 0.83 ■+ 0.09* (t=2.214)
ml.min .1 0 0 g,bw-l 4.06 ± 0.43 3.14 + 0.34
GI tract and pancreas
blood flow#
weight (g) 13.5 ± 1 . 1 12.4 ± 0 . 8
ml.min"! g tissue"! 1.05 ± 0.15 0.67 + 0 . 0 8
ml.min .1 0 0 g,bw“! 2.70 ± 0.30 2.33 + 0.33
Hepatic arterial
flowb ^ 1
ml.min ^,g liver ^ 0.30 ± 0.05 0.14 + 0.02* (t=2.390)
ml.min ,1 0 0 g,bw 1.04 ± 0 . 2 0 0.51 + 0 .0 8 * (t=2.142)
Spleen blood flow
weight (g) ^ 0.9 ± 0.04 0 . 8 + 0.05
ml.min"!,g tissue^ 1.87 ± 0.25 1.13 + 0.26
ml.min .lOOg,bw 0.32 ± 0.03 0.26 + 0 . 0 6
NB t = 2il31, df = 15, p<0.05 
a = portal flow 
b = hepatic artery flow 
a+b = hepatosplanchnic flow
1 6 7
Table 5.4 Effect of sotalol on blood flow to heart, lungs and 
kidneys in rat. (Mean ± SEM)
Saline Sotalol
n 1 0 7
Heart
weight (g) 1 . 6 8 ± 0 . 1 2 1.30 ± 0.09
blood flow ^ 
ml.min"!.g tissue 2.24 + 0.46 2.03 ± 0.26
ml.min“!.1 0 0 g,b.w.“! 0.82 + 0.13 0.73 ± 0 . 1 0
Lungs
weight (g) 1.92 + 0 . 1 2 2.36 ± 0.27
blood flow
ml.min"!.g tissue"^^ 












weight (g) 3.74 + 0.15 3.07 ±0.16
blood flow, ,
, . — 1 . . —1 ml.min_^.g tissue ^










No change in the weight of liver, spleen or in the combined 
weight of pancreas plus GI tract was noted after administration of 
sotalol,
5.3 Effects of sotalol on blood flow to heart, lungs and kidneys 
and percentage of cardiac output received by major organs 
The individual values for blood flow to heart, lungs and kidneys 
and for fractional distribution of cardiac output appear in 
Appendix 16. Blood flow to heart and kidneys was slightly reduced 
after administration of sotalol but these changes were not significant. 
No change was noted in the weights of these organs (Table 5.4). 
Percentage of cardiac output received by major organs in control and 
sotalol treated animals are listed in Table 5.5. There were no sign­
ificant changes in the proportion of the cardiac output distributed to 
these organs.
Table 5.5 Effect of sotalol on percentage of cardiac output received 
by major organs in rats. (Mean ± S.E.M.)
Saline Sotalol
n
Hepatosplanchnic 24,0 ± 1,5 20.7 + 0.7
GI tract and pancreas 15.9 + 1,3 15,5 + 1 . 1
Liver 6 . 2 ± 1 , 0 3.6 + 0 , 6
Spleen 1,9 ± 0 . 1 1.7 ± 0.3
Lungs 1.4 ± 0.3 1 . 8 ± 0.9
Kidneys 18.9 + 2 , 1 18.8 + 1,4
Heart 4.8 + 0 . 6 4.8 + 0.3
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5,4 Pharmacokinetics of lignocaine following a single'intravenous
dose in rats pretreated with ' sotalol
Sotalol (100 mg,kg , i,p.) was administered to six rats weighing
360 to 410 g, as described in 5.1 at -24 hours, -18 hours, -12 hours
and O hours-. Fifteen minutes after the fourth dose of sotalol, ligno- 
-1caine (5 mg.kg ) was administered by intravenous injection into the 
tail^ of each rat. Blood samples were taken at appropriate times 
and assayed for lignocaine.
The blood concentration-time data for each rat and the means for 
the group are given in Appendix 2. The mean blood cone entrât ion-time 
data are plotted on a linear scale (Figure 5.1) and on a logarithmic 
scale (Figure 5.2) against time. Kinetic parameters were obtained 
from the blood cone entrât ion-time data for each animal using the non­
linear least squares regression analysis programme NOMLIN as described 
in Appendix 21 and the mean values appear in Table 5.6. The data in
the treated group are compared with those in eight rats which also
-1received lignocaine 5 mg.kg , i.v., as part of the earlier dose 
ranging, study (Chapter 3.1). These rats had not been pretreated with 
sotalol and therefore served as a control group. Table 5.6 shows 
that the rate constants for the slow (3 ) phase of decline in blood 
lignocaine concentration with time was significantly decreased (p<0.05 
by 't' test) in the sotalol treated group; consequently t^g was 
significantly prolonged in this group (78.5 min) as compared with 
the control (48.1 min). Table 5.6 also shows that sotalol pretreat­
ment was associated with an approximate doubling of AUC, consequently 
systemic clearance of lignocaine was approxiraatley halved in the 
sotalol pretreated group. No statistically significant changes were 







































O  = control (n=8 )
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Figure 5.2 Mean blood concentration-time graphs following lignocaine
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5,5 Pharmacokinetics of lignooaine following a single oral dose in
sotalol pretreatcd rats 
-1Sotalol (loo mg.kg ) was administered to six rats, weighing
355 to 425 g, by intraperitoneal injection as described in 5.1 at
-24 hours, -18 hours, -12 hours and at O hours. Fifteen minutes after
-1the fourth dose of sotalol, lignocaine (70 mg.kg ) was administered 
by mouth to each rat. Blood samples were taken at appropriate times 
and assayed for lignocaine.
The blood concentration-time data for each rat and the means 
for the group are given in Appendix 4. The mean blood concentration­
time data are plotted on a linear scale (Figure 5.3) and on logarithmic 
scale (Figure 5.4) against-time. Kinetic parameters were derived 
from the blood concentration-time data for each rat as described in 
Appendix 20 and the mean values are given in Table 5.7. The data was
compared with those in eight rats which had also received lignocaine 
-170 mg.kg by mouth as part of the earlier dose ranging study (Chapter
3.2). These rats had not been pretreated with sotalol and therefore 
served as a control group. Table 5.7 shows that after sotalol there 
was no significant change in the rate constant for absorption (k^) but 
that there was a significant decrease (p<O.OOl by student's 't' test) 
in the disposition rate constant (k^) . Consequently t^ was lengthened 
significantly in the sotalol treated group. Furthermore AUC was 
approximately doubled by sotalol pretreatment (p<0 .0 1 ) and in consequence 
the apparent oral clearance of lignocaine was almost half of the value 
for the control rats.
Changes in t^, CL and AUC for control and for sotalol pretreated 


















































O = control (n = 8 ) 












Figure 5.4 Mean blood concentration-time graphs following lignocaine 
(70 mg.kg-1 by mouth) in control and in sotalol treated rats
Table 5.7 Pharmacokinetic parameters of lignocaine following 
70 mg.kg"^ by mouth)in control and in sotalol treated 






417.5 ± 13.2 396.7 ± 9.5
(min ) 0.1044 ± 0.0174 0.1027 ± 0.0242
kd _i(min ) 0 . 0 1 2 1  ± 0.0009 0.0054 ± 0.0005**
(min) 59.2 ± 4.6 135.4 ± 16.1**
AUCp.o
(yg.ml .min) 103.10 ± 9 .48 205.80 ± 27.78*
CL
(ml.min .lOOg,bw ) 72.97 ± 7.98 36.74 ± 4.10*
* p<0 . 0 1






uD-p u < 80
40
I
T: CL AUC,T> CL AUCp.o
Control (n=8 ) Sotalol (n=6 )
Figure 5.5 Effects of sotalol on half-life, apparent oral clearance 
and area under blood coneentrâtion-time curve of ligno­
caine (70 mg.kg"^) by mouth 
* p<O.Ol 
** p<0 .0 0 l
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5,6 Pharmacokinetics of tocainide following a single intravenous
dose in rats pretreated with sotalol 
- 1Sotalol (loo mg.kg ) was administered to six rats, weighing 350
to 490 g, i.p. at -24 hours, -18 hours, -12 hours and O hours.as
described in 5.1. Thirty minutes after the fourth dose of sotalol,
-1tocainide (35 mg.kg ) was administered by intravenous injection into
-1the tail vein of each rat. Sotalol (lOO mg.kg , i.p.) was also given 
+4 hours, + 8  hours and +12 hours. Blood samples were taken at 
appropriate times and assayed for tocainide.
The blood concentration-time data for each rat and the means for 
the group are given in Appendix 6 . The mean blood concentration-time • 
data are plotted on a linear scale (Figure 5.6) and on a logarithmic 
scale (Figure 5.7) against time. Kinetic parameters were obtained 
from the blood concentration-time data for each animal using the non­
linear least squares, regression analysis programme NONLIN as described 
in Appendix 21 and the mean values appear in Table 5.8. The treated
group are compared with the data in five rats which also received
-1tocainide 35 mg.kg , i.v., as part of the earlier dose ranging study 
(Chapter 3.3). These rats had not been pretreated with sotalol and 
therefore serve as a control group. Table 5.8 shows that sotalol 
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Figure 5.7 Blood concentration-time graphs following tocainide
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5.7 Pharmacokinetics of tocainide following a single oral dose in
sotalol pretreated rats 
-1Sotalol (100 mg.kg ) was administered to six rats weighing 380
to 480 g, i.p./ as described in 5.1 at -24 hours, -18 hours, -12 hours
and O hour. Thirty minutes after the fourth dose of sotalol, tocainide 
- 1(50 mg.kg ) was administered by mouth to each rat. Sotalol (100 
mg.kg i.p.) was also given at +4 hours, + 8  hours and +12 hours.
Blood samples were taken at appropriate times and assayed for 
tocainide.
The blood cone entrât ion-time data for each rat and the means for
the group are given in Appendix 4. The mean blood concentration-time
data are plotted on a linear scale (Figure 5.8) and on logarithmic
scale (figure 5.9) against time. Kinetic parameters were derived from
the blood concentration-time data for each rat as described in
Appendix 20 and the mean values are given in Table 5.9. The data are
compared with those in six rats which had also received tocainide 
-150 mg.kg by mouth as part of the earlier dose ranging study
(Chapter 3.4). These rats had not been pretreated with sotalol and
therefore served as a control group. Table 5.9 shows that after
sotalol there was an increase in the rate constant for absorption (k )a
which just achieved statistical significance (p<0.05) but no signifi­





























































□ = control (n=6 ) 











Figure 5.13 Blood concentration-time graphs of tocainide following 
50 mg,kg by mouth in control and sotalol treated rats
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Figure 5.14 Effects of sotalol on half-life, apparent oral clearance
and area under blood concentration-time curve of tocainide 
following SOmg.kg~^ single oral administration
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Table 5.9 Pharmacokinetic parameters of tocainide following
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6. DISCUSSION
6.1 INTRODUCTION
Lignocaine and tocainide are both used for the treatment of cardiac 
dysrhythmias in man. There are however, a number of important differences 
between the two drugs. Although they are structurally similar, ligno­
caine is a tertiary amine with strong local anaesthetic activity and 
tocainide is a primary amine which lacks local anaesthetic properties. 
Lignocaine is totally eliminated by the liver whereas to some extent 
tocainide is dependent on the kidney for elimination (McDevitt et al,
1976; Winkle et al, 1976). The kinetic properties of the two drugs also 
differ; lignocaine is highly hepatically cleared (Sung and Traunt, 1954; 
Hollunger, 1960a) shows low systemic availability by the oral route and 
has a short half life; tocainide is cleared more slowly, has high 
systemic availability by the oral route and has a long half life (Lalka 
et al, 1976). These properties are reflected in the ways the drug are 
used clinically, lignocaine by continous intravenous infusion (Harrison 
and Alderman, 1972) and tocainide by the oral route (Graffner, Conradson, 
Hofvendahl and Ryden, 1979). A further contrast is that lignocaine is
a well established drug which has been used for 20 years and has been
a
extensively studied whereas tocainide is^relatively new drug about which 
much less is known.
In recent years the major factors which determine drug elimination 
by the liver have been increasingly understood. They are liver blood 
flow, liver metabolism, drug binding and probably intrahepatic shunting. 
The present work has been concerned with the effects of two of these 
variables, namely blood flow and drug metabolism on the kinetics of 
lignocaine and tocainide. Most drugs which are eliminated by the liver 
may be separated into those in which blood flow and those for which 
metabolism is the ma]or determinant of elimination. It is therefore to 
be antic ip,3 ted thut ihese variables would hav- different effects
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on the kinetics of lignocaine (flow dependent) and tocainide (metabolism 
dependent). Furthermore these physiological varabiles were altered in 
a manner which could be clinically relevant, blood flow being reduced 
by $-adrenoceptor blockade and metabolism being increased by enzyme 
induction.
In the first instance therefore the work was undertaken to observe 
the changes which would be encountered in the kinetics of these two 
antiarrhythmic drugs when liver blood flow and liver metabolism were 
altered. However, in recent years two mathematical models have been 
developed in attmepts to predict drug kinetics on the basis of the 
major variables flow, metabolism and binding. The data in this thesis 
therefore, also provide an opportunity to test in part the capacity of 
these models to predict the kinetics of a blood-flow dependent and of 
a metabolism-dependent drug when factors governing elimination are 
altered.
6 .2 Basic kinetics of lignocaine in the rat
The gas liquid chrmoatographic technique for measuring lignocaine
has proved to be both accurate and sensitive at blood concentrations 
-1of 0.05 yg.ml (Chapter 2.7.3) which was adequate for the purposes of 
the present study. Furthermore, these estimations could be performed 
on small quantities of blood (-0.3 5 ml). Lignocaine in blood and in 
urine could be stored for longer than three months prior to analysis 
with no measurable loss of drug. In addition the method of collecting 
blood, i.e. cutting off the rat tail tip proved to be sufficient for the 
repeated blood sampling demanded by this study.
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Kinetics of lignocaine have been studied in monkey (Benowitz et al, 
1974 a and b), dog (Boyes et al, 1970) and man (Boyes et al, 1971;
Rowland et al, 1971; Tucker and Boas, 1971; Thomson et al, 1973; Nation 
et al, 1977; Perucca and Richens, 1979). The rat has also been used 
but as the perfused rat liver situ (Pang and Rowland, 1977b) or as 
the isolated perfused rat liver (Shand, Kornhauser and Wilkinson, 1975). 
The present work is believed to be the first systematic attempt to 
investigate the basic kinetics of lignocaine in the intact rat.
The blood concentration of lignocaine in rat following 
intravenous injection was found to decline in a biexponential manner 
and may be fitted to the two compartment open model (Mayersohn and 
Gibaldi, 1971; Greenblatt and Koch-Weser, 1975) using graphic techniques. 
However, this is a tedious approach and depends on the subjective judge­
ment of the experimenter. Therefore, the lignocaine concentration-time 
data were fitted to prescribed functions using the non-linear least 
squares regression analysis programme NONLIN (Metzler, 1969). It was 
found that the blood lignocaine following an intravenous dose could be 
adequately fitted by the sum of two exponentials and from the coefficients 
and exponents of the biexponential equation the volume constants and 
rate constants for intercompartmental transfer of drug in the two 
compartmental open model were derived. Table 6.1 compares the means 
of intravenous calculated by the computer programme "NONLIN" and
by trapezoidal rule indicating there were no significant differences 
between the means of AUC obtained by these two methods.Q-H»
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Table 5.1 Comparison of the means of intravenous AUC calculated
^  0 - X »
by computer programme "NONLIN" and by trapezoidal rule.
Dose AUCq <̂x) (yg.ml 1 .min)
(mg. kg ) "NONLIN" Trapezoidal rule
Lignocaine 2. 5 188.0 174.8
5.0 444.7 441.8
1 0 . 0 758.4 753.8
Tocainide 5.0 571.8 565.2
2 0 . 0 2293.4 2290.0
35.0 4001.5 3987.9
50.0 5901.9 5896.1
A bi-exponential decline in blood lignocaine concentration after 
intravenous administration has also been found in monkey (Benowitz et al, 
1974 a and b) and man (Boyes et ai, 1971; Rowland et al, 1971; Thomson 
et al, 1973; Perucca and Richens; 1979). The initial (a) exponential 
decay phase in rat, with an average half-life of 6.5 minutes, is similar 
to that of 5 to 10 minutes reported in man by Boyes et al (1971);
Rowland et al (1971); Perucca and Richens (1979) and to that of 1.5 
minutes described in monkey by Benowitz et al (1974a). The t^ of the 
3 phase of decline in blood concentration in rat (52 minutes) is com­
parable to that found in dog (40 minutes) reported by Boyes et al (1970),
monkey (15 minutes) and man (80 to 108 minutes). The Vp (approximately
-1 -1 0.56 l.kg ) and Vd^^ (0.93 l.kg ) were similar to those found in dog,
monkey and man.
Rapid equilibration of intravenously administered lignocaine between 
blood and highly perfused organs is also indicated by other techniques. 
Katz (1968) and Keenaghan and Boyes (1972) using radioactive labelled 
lignocaine found that immediately after injection 70% of the activity
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was found in vessel-rich tissues (heart, lung, liver, brain, kidney
and spleen). The rapid distribution of lignocaine was also reported
in monkey by Benowitz et al (1974a) using a perfusion model. They
estimated that within 0.5 minute after injection, 70% of drug had left
the blood pool and had entered lung, viscera, and muscle. It is also
noticeable that the peak concentrations of lignocaine after intravenous
injection depend on the speed of administration. In the present
experiments when injection time was reduced to less than 30 sec, rats
-1which received the highest dose of lignocaine ( 1 0 mg.kg ) died within
seconds of injection presumably because of high concentration in essential
organs. Significantly the most common cause for toxicity of lignocaine
in patients was reported by Collinsworth (1976) to be excessivley
rapid administration of the drug. Akerman et al (1966) found that the
concentration of lignocaine in numerous organs of rat (brain, liver,
lung, kidney, heart and spleen) to be higher than those in blood 2 hours
-1after intramuscular injection at the dose of 1 0  mg.kg indicating 
considerable localisation of the drug in tissues.
Blood concentration data for lignocaine following oral administration 
in man have been analysed by computer fitting by Boyes et al, (1971), 
using Vp, k^^, k^^ and k^ calculated from the intravenous data and 
allowing k^^ to vary. In the present work, this technique was not used. 
The blood concentration data of lignocaine after single oral adminis­
tration, therefore, were fitted by least squares linear regression 
analysis. The t^ of lignocaine after oral administration was similar 
to that found after the drug had been given intravenously and peak 
concentrations were acheived within 30-4 5 minutes after drug adminis­
tration, The findings are compatible with rapid absorption of ligno­
caine as has been found in man (Boyes et al, 1971; Perucca and Richens, 
1979) and in dog (Boyes et al, 1970).
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The AUC for lignocaine after oral administration, however, was 
considerably less than the AUC after intravenous administration when 
comparable doses are considered indicating extensive presystemic 
elimination of the drug. Indeed the area ratio gave a mean value for 
availability (F) of 0.019, that is an hepatic extraction (E) of 0.981.
The value for hepatic extraction in the present study agrees well with 
those of Pang and Rowland (1977b) who used the perfused rat liver in 
situ and obtained a value for E of 0.99. Indeed hepâtic extraction 
of lignocaine in rat is highest of all species studied^values for E 
in other animals being dog 0.78 (Branch et al, 1973), man 0.7 (Boyes 
et al, 1970; Perucca and Richens, 1979; Bennett et al in press), 
monkey 0.66 (Benowitz et al, 1974 a) and cat 0.28 (Lautt and Skelton,
1976).
In rat and in dog recovery of radioactively labelled drug and 
metabolites in urine after oral and intravenous administration of ligno­
caine are similar (Keenaghan and Boyes, 1971), indicating that 
absorption of lignocaine from the gut is complete as well as rapid. 
Pre-systemic elimination of an orally administered drug may be due to 
metabolism either in the gut wall, in the liver or in the lung. There 
is considerable evidence that the major site of elimination of ligno­
caine is the liver (Sung and Traunt, 1954; Beckett et al, 1966; Boyes 
et al, 1971). In most species studied the hepatic clearance of ligno-
caine is high for example in monkey (269 ml.min ; Benowitz et al, 1974a);
-1 -1 dog (433 ml.min ; Branch et al, 1973) and man (0.54-1.54 1 .min ;
Stenson et al, 1971). The values approximate to 1 ml.min ^.gm of liver
that is, a figure approaching that for liver blood flow. The present
findings in rat are well in agreement with those for other animals. Thus
although there are differences in the pattern of metabolites (Keenaghan
and Boyes, 1972).the rat appears io be comparable to the other species
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studied in that it is capable of extensive extraction of lignocaine 
by the liver from the blood. Thus as in other species lignocaine may be 
be regarded in the rat as a blood flow dependent drug and changes in 
hepatic blood flow will be reflected in changes‘in the elimination of 
lignocaine.
In the pvesent work the kinetics of lignocaine after intravenous 
administration did not change with dose, the blood coneentrâtion-time 
curves were superimposable and AUC increased linearly with dose, the 
regression line of the plot of AUC against dose passing through the 
origin. There is strong evidence therefore, that the kinetics of 
lignocaine are linear over the dose range tested, i.e. the metabolic 
and disposition processes were not saturated. Studies of this type 
in the literature are scarce. Bennett et al (in press) studying 
lignocaine kinetics in man found that in 3 normal volunteers AUC 
increased linearly with doses of 50 and 100 mg, i.v. However, Lalka 
et al (1976a) who gave constant rate intravenous infusions of lignocaine 
(40, 80, 120 mg) found that clearance decreased with increase in dose in man 
suggesting that the kinetics were dose-dependent under these conditions.
Furthermore, in a study by Bennett et al (in press) following multiple
oral dosing with lignocaine 300 mg eight hourly for 7 doses, one subject 
appeared to show saturable kinetics whereas no evidence of saturation 
was found in .two other subjects. The issue of time-dependency was 
not explored in the present work with lignocaine because it was
planned only to use single doses in later work.
After oral administration no change was found in the absorption 
rate constant (k^)or in the disposition rate constant (k^) with change 
in dose. AUC increased linearly with dose in the range 50-400 mg.kg 
but it was noted that the regression line relating AUC to dose did not 
pass through the origin, rather it crossed the dose axis at a point
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-1equivalent to a dose of 23 mg.kg . In an attempt to define the
-1 -1relationship at lower levels doses of 10 mg.kg and 30 mg.kg were 
given orally to rats but the blood lignocaine concentrations acheived 
in these experiments were too often below the acceptable limit of 
sensitivity of the assay and the AUC could not adequately be defined.
Shand and Rangno (1972) made a similar finding in human subjects who 
took propranolol by mouth in that the line relating AUC to dose crossed 
the dose axis at a dose of 30 mg. They proposed a separate extraction 
process for propranolol which at low doses avidly extracts the drug 
from plasma. It is possible that a similar process may operate for 
lignocaine in the rat but this was not studied further in the present 
work. Furthermore, since the point at which the trend line crosses 
the dose axis is included in the 95% confidence interval for the line 
it may not even be necessary to evoke a separate mechanism for the 
elimination of lignocaine at low doses.
Systemic availability of orally administered lignocaine did not 
change within the dose range studied (Table 3.5) and similar conclusions 
were made by Bennett et al (in press). Earlier studies by Boyes et al, 
(1971) have suggested that in some subjects oral availability of ligno­
caine may increase with dose.
The present studies in summary have shown that in the rat there is 
a dose range over which the kinetics of lignocaine are clearly linear 
and it is therefore possible to select a dose for further studies in 
which factors influencing the elimination of lignocaine may be conducted. 
Furthermore, as in other species, lignocaine is obviously a drug which 
is highly cleared by the liver and it can thus be regarded as blood flow 
dependent for its elimination. Thus the rat has been shown in the present 
work to be a suitable experimental animal in which to conduct studies of 
lignocaine kinetics and the data obtained are comparable to those 
previously established for other species such as dog, rncaikey and man.
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6.3 Basic kinetics of tocainide in the rat
Tocainide is a structural anaogue of lignocaine and appears to 
possess many of the pharmacodynamic properties of the parent drug 
(Winkle et al, 1978). In contrast the pharmacokinetic properties of 
tocainide are very different from those of lignocaine.
In the present study the GLC technique for assaying tocainide in
the rat was sufficient to provide accurate estimations to concentrations 
-1of 0 . 1  yg.ml which was sufficinet to define the blood concentration­
time curves within the dose-range selected. No apparent loss occurred 
in storage of the samples at -20°C for up to 3 months.
Most available kinetic data on tocainide have been obtained in man. 
and the present work is believed to be the first full analysis of the 
kinetic properties of the drug in an animal species. The blood concen- 
tration-time data after intravenous administration were analysed by the 
non-linear least squares regression analysis programme NONLIN.(Metzler, 
1969). It was observed that after intravenous administration of 
tocainide to rats the blood concentration-time curve exhibited a biexpon­
ential form with a relatively short initial phase (average half-life of
9.2 minutes) and a much longer secondary phase (average half-life of
127.7 minutes). As for lignocaine, the data could be adequately 
described by a two-compartment open system. The t^ of the 3~phase of 
elimination of tocainide from the blood is substantially longer than 
that of lignocaine (t^ ^ - 52 minutes). A similar difference is also 
found in man which t^ ^ for tocainide is 11 hours (Lalka et al, 1976) 
in contrast to that of lignocaine (100 minutes). The more gradual 
elimination of tocainide than lignocaine from the blood is one reason 
why it has become used for the long term management of arrhythmias 
in man.
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The volume distribution constants (Vd) were all of the order of 
.-1
1 - 2  l.kg implying that tocainide like lignocaine undergoes consider­
able extravascular distribution. These data are similar to the findings 
in man (Lalka et al, 1976; Gmffner et al, 1979) .
After oral administration peak blood concentration of tocainide 
were acheived within 2-4 hours. The logarithm of blood concentration
during the disposition phase was linearly related to time and t^ at
-1doses of 100, 200, 300 and 500 mg.kg ranged between 8.3-11.7 hours
but are not significantly different from each other. However, t^ of
-1the lowest dose (50 mg.kg ) was significantly shorter at 4.6 hours than
-1that for the other doses. Doses below 50 mg.kg were not explored
because blood concentration attained could not be measured with sufficient
accuracy to define the concentration-time curves. The significant
feature when comparing t^ after i.v. and after p.o. administration of
tocainide was the much longer t^ by the latter route. Absence of drug
from faeces and gut contents after a single oral dose of tocainide to
rate (3.6) suggest complete absorption of the drug from the alimentary
tract, as does the similarity of AUC obtained after p.o. and i.p.
-1administration of 50 mg.kg (Table 3.11). The longer t^ of tocainide 
after oral administration thus suggests that although a substantial 
amount of the drug may be absorbed rapidly to give the early peak con­
centrations absorption, thereafter continues for several hours. Because 
both absoprtion and disposition are first order processes the logarithm
of drug concentrationin the disposition phase is still linearly related
-1to time. The half-life of tocainide (50 mg.kg ) after i.p. injection 
was significantly shorter than that after p.o. administration (p<0 .0 0 1 ) 
but significantly longer than, that after i.v. injection (p<0.001). This 
suggests that although diffusion of tocainide from the peritoneal cavity 
is more rapid than absorption from the gut, even from the peritoneal
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cavity there exists a significant barrier to diffusion. Although there
are no human studies in which t. of tocainide was measured after i.v.
'2
and p.o. administration to the same subjects Lalka et al (1976), found 
that t^ after intravenous infusions was 11 hours whereas McDevitt 
et al (1976) found that the value after p.o. administration was 14 
hours, suggesting that in man slow absorption from the gut may also 
contribute to the finding of a longer t^ when the drug is given by 
the oral route. On the other hand these differences in man could
simply be due to sampling error and a proper comparison of t^ after
i.v. and p.o. administration.is needed to clarify the issue.
Renal clearance of tocainide was on average 20.5% and remained
relatively constant when dose was changed (range 17.9-22.4%). These
values are approximately half those found in man by Lalka et al (1976) .
In the latter study it was found that urinary clearance of tocainide
could be reduced by alkalinisation but urine pH was not controlled in
the present work. It has been assumed that renal clearance of tocainide
is the same irrespective of the route of administration. Thus estimates
of AUC still give a value for availability. Calculation of F for doses
- 1of 100, 200, 300 and 400 mg.kg in relation to the mean of all intra­
venous doses gave an average value for availability of 0.94 that is an 
hepatic extraction (E) of 0.06.
The constancy of the kinetic parameters after intravenous and after
-1oral dosing in the range 100-400 mg.kg , the superimposibility of 
dose-normalised blood concentration-time curves and the linear 
relationship between AUC and dose provide good evidence for regarding 
the kinetics as showing dose-independency over the range studied.
Because tocainide is a relatively new drug and is proposed for 
long term use in man the studies of tocainide were extended to include 
multiple doses. At a dose selected from the middle of the linear
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-1range for single intravenous dose studies ( 2 0 mg.kg ), five of six 
rats showed no change in t^ or AUC after 7 doses when it was assumed 
that steady state would have been attaned (4 x t^) indicating that the
kinetics were substantially time-independent under these conditions.
-1For multiple oral dosing a dose of which was higher (200 mg.kg ) but 
which was still within the linear range for the single oral dose 
studies was selected. The quality of the data was less satisfactory but 
three out of five animals showed no change in t^ or AUC after 12 doses 
whereas two rats showed altered kinetics (t^ or AUC) and evidently 
suffered from drug toxicity. On a weight related basis these oral doses 
are substantially in excess of the dosing regimens used in man.
The kinetics of tocainide in rat thus shows dose-independence and 
in a proportion of animals time-independence under the stated conditions. 
Although a detailed exploration of the kinetics of tocainide has not 
been conducted in another species, Lalka et al (1976) in man found that 
for oral doses between 50 mg and 850 mg, AUC increased linearly with 
dose indicating stable kinetics for this dose range.
Hence, tocainide, a drug structurally and pharmacodynamically 
similar to lignocaine has been shown in the rat to be pharmacokinetically 
very different from lignocaine. Although lignocaine relies almost 
exclusively (99%) and tocainide very largely (80%) on the liver for 
elimination, .the hepatic extraction of tocainide (0.06) contrasts sharply 
with that for lignocaine (0.99). Consequently alteration in liver blood 
flow would be anticipated to have little influence on the elimination of 
tocainide but changes in drug metabolism would be expected to alter the 
kinetics of tocainide significantly. The rat has therefore been shown 
to be a satisfactory experimental animal in which to examine the 
influence of such variables on the elimination of tocainide.
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6.4 Effect of enzyme induction on the kinetics of lignocaine and of 
tocaihide in rat
6.4.1 Enzyme Induction
The duration and intensity of action of many drugs are largely 
determined by the speed with which they are metabolised by enzymes in 
liver microsomes. The activités of drug metabolising enzymes in liver 
microsomes can be markedly increased when animals are treated with 
various hormones, drugs, insecticides or carcinogens. This increase 
in activity appears to represent an increased concentration of enzyme 
protein and is referred to as "enzyme induction" (Conney, Davison,
Gastel and Burns, 1960; Conney, 1967; Remner, 1972). The induction of 
liver microsomal enzymes is important pharmacologically, for it leads 
to an accelerated biotransformation of drugs and so alters duration 
and intensity of drug action. It is evident that enzyme induction 
is likely to have most effect on the kinetics of drugs which exhibit 
low hepatic clearance i.e. drugs for which the rate of metabolism 
governs elimination. Kinetics of flow-dependent drugs might be expected 
to be less affected. However, the picture is further complicated by 
the fact that some enzyme inducing drugs also alter blood flow. This 
section of the work is concerned with the effect of altering meta­
bolism by enzyme induction on the kinetics of lignocaine (blood flow 
dependent) and of tocainide (metabolism dependent). There is a particular 
practical relevence to understanding the effect of enzyme induction on 
the kinetics of tocainide, since the latter drug is proposed for long 
term oral use in patients for whom maintenance of therapeutic blood 
concentrations is important. Because of the variable effects on blood 
flow of known enzyme inducers two agents were selected; 3,4 benzpyrene 
which is a potent enzyme inducer without effect on liver blood flow
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and phenobarbitone which has been shown in rat to induce hepatic 
enzymes and to increase liver blood flow.(Ohnhaus et al, 1971;Ohnhaus, 
et al, 1975), Phenobarbitone is known to stimulate various drug meta­
bolic reactions including oxidation, reduction, de-esterification and 
glucuronide formation. In contrast 3,4 benzpyrene induces a more limited 
group of reactions (Conney, Davison, Gastel . and Burns, 1960; Conney, 
Gillette, Inscoe, Trams and Posner, 1963; Conney, 1967). The time 
course by which enzyme induction is increased has been well studied and 
is different for the two drugs. After daily administration of phenol 
barbitone to rats the maximal increase of enzyme activity is acheived 
after least 3 days (Conney et al, I960; Ohnhaus et al, 1971) whereas 
after a single intraperitoneal injection of 3,4 benzpyrene enzyme 
activity more than doubles within 3-6 hours, the maximal increase is 
observed within 24 hours and the effect lasts for many days (Conney 
et al, 1957; Ohnhaus et al, 1971). Because these time relationships 
have been well studied in the past, they were not repeated in the 
present work. However, the essential changes brought about by the 
administration of 3,4 benzpyrene and of phenobarbitone are given (Chapter 
4.1): These showed that pentobarbitone sleeping time was reduced
(Table 4.1) indicating increased metabolism and reduced biological 
effect of that drug. An enzyme inducing dose of 3,4 benzpyrene had 
no effect on liver weight but administration of phenobarbitone caused a 
26% increase in liver weight (Table 4.2) and this finding has also been 
made by other workers (Ohnhaus et al, 1971; Ohnhaus and Locher, 1975;
Nies et al, 1976). Both enzyme inducers caused an increase in micro­
somal protein and in cytochrome content (Table 4.3) confirming well
established previous work (Orrenius and Ernster, 1964; Ohnhaus et al, 
1971; Remmer, 1972). It was noted that increases in microsomal protein 
and cytochrome P^^q  expressed per gram of liver were not different in
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phenobarbitone and in 3,4 benzpyrene treated rats but since phenobarb­
itone administration was associated with an increased liver weight 
whereas 3,4 benzpyrene was not, there was a greater total increase in 
microsomal protein and cytochrome assocated with phenobarbitone
administration. Enzyme kinetics were performed using the activity of 
microsomal 0 -demethylation of p-nitroanisole as an indicator of overall 
liver microsomal metabolising activity although this particular enzyme 
is not involved in the biotransformation of lignocaine or of tocainide. 
Administration of phenobarbitone and 3,4 benzpyrene were associated with
increased V whereas K was unaltered indicating an increase in max m
enzyme activity without alteration substrate affinity (Table 4.4).
6.4.2 Enzyme induction and haemodynamic change
Since this work is concerned with the differing effects of drug 
metabolism and blood flow on drug kinetics the influence of 3,4 benzpyrene 
and of phenobarbitone on regional blood flow and in particular on 
hepatic blood flow were investigated (Chapter 4.2). It was also 
necessary to establish whether lignocaine or tocainide independently 
altered any haemodynamic parameters and the data for these drugs is 
conveniently considered at this point. The parameters measured were; 
mean arterial blood pressure, cardiac output and organ blood flow.
Changes in the weights of individual organs were also noted.
No change in mean arterial pressure or in cardiac output were 
found after administration of phenobarbitone, 3,4 benzpyrene, ligno­
caine or tocainide. Likewise, none of these drugs produced change in 
blood flow to or weight of the heart, lungs or kidneys. When liver 
blood flow and liver weight are considered no change was found after 
administration of 3,4 benzpyrene, lignocaine or tocainide. However, 
administration of phenobarbitone was associated with a significant
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increase in hepatosplanchnic (total liver) blood flow. With the 
radioactively labelled microsphere technique the two components of blood 
flow to the liver, namely hepatic arterial and portal flow are measured 
separately. It was found that the increase in hepa to splanchni c flow 
was entirely due to increased portal blood flow and in particular that 
portion of portal flow which came from the GI tract and pancreas, there 
being no increase in splenic blood flow. Because this increase in 
liver blood flow after phenobarbitone was associated with an increase 
in liver weight, the hepatic blood flow per gram of liver was not 
increased. Other workers who have used this technique have made the 
same findings in respect of changes in organ and in particular liver 
blood flow after 3,4 benzpyrene and phenobarbitone (Ohnhaus et al,
1971; Nies et al, 1976) . The absence of haemodynamic change after 
administration of lignocaine or of tocainide to rats is not unexpected 
and accords with the general findings of other workers using different 
techniques and different species (Chapter I). Benowitz et al (1974 a) , 
however, using the labelled microsphere technique found that infusion 
of lignocaine did cause changes in the distribution of cardiac output, 
the fraction going to hepatic artery, long bone and heart increasing 
at the expense of skeletal muscle. The present observations in rat 
contrast with these findings. Studies of the influence of tocainide 
on organ blood flow using the labelled microsphere technique have not 
been reported previously.
It is appreciated that a full analysis of the drug studied in 
this section would also include the effect on haemodynamics of the 
combinations of drugs used. Since no change in haemodynamic parameters 
was observed after 3,4 benzpyrene, lignocaine or tocainide, such a 
study was not undertaken for these drugs. However, because changes were 
observed after phenobarbitone, the effect of the combination of pheno­
barbitone followed by tocainide was studied and the same findings were
made as with phenobarbitone alone.
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6.4.3 Enzyme induction and pharmacokinetic change
It is apparent from Chapter 4 that enzyme induction brought about 
changes in the kinetics of lignocaine and tocainide. In this section 
these changes are considered as observation and their consequences are 
discussed. In a later section the change will be considered in relation 
to the prediction of pharmacokinetic models.
Intravenous administration
Lignocaine is a drug which undergoes high hepatic clearance and 
it would be anticipated that change in drug metabolism would have 
relatively less effect than change in blood flow especially when the 
drug is given intravenously. The observations support this in that 
change in metabolism alone (after 3,4 benzpyrene) caused no change in 
t^, AUC or CL. When phenobarbitone was given, however, AUC was sign- 
ficiantly reduced and CL increased but there was no change in t^. The 
changes after phenobarbitone presumably reflect the additional effect 
of change in blood flow caused by this drug but they could also be
due to a more intensive enzyme inducing effect.
Tocainide undergoes low hepatic extraction and consequently change 
in drug metabolism would be expected to have more marked effects on its 
kinetic than change in blood flow. Thus any effect observed after 
administration of phenobarbitone can presumably be ascribed to change 
in drug metabolism and not to change in liver blood flow. In effect 
both 3,4 benzpyrene and phenobarbitone caused AUC of tocainide to 
decrease and CL increased after intravenous administration. The 
changes were more marked after phenobarbitone and t^ was also reduced
with this drug. If the effect of increased blood flow may be ignored,
these changes presumably reflect a greater effect on the metabolism of 
tocainide when the rats were pretreated with phenobarbitone.
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Oral administration
When a drug is given by the oral route it must all pass through 
the liver once in order to reach the systemic circulation. This con+. 
trasts with intravenous administration for which in any single pass 
through the liver only drug in that part of cardiac output which 
supplies the liver (about 25%) is available for metabolism. For drugs 
which are highly cleared by the liver this difference in the fraction 
which is exposed to hepatic degradation depending on the route of 
administration is important and is expressed as extensive pre-systemic 
elimination by the oral route (first pass effect). With such drugs 
when factors governing elimination are altered the effects on kinetics 
are likely to be more marked when the drug is given by the oral route. 
The findings after oral administration of lignocaine to 3,4 benzpyrene 
treated rats were that although there was no change in t^ there was a 
significant reduction in AUC. After phenobarbitone there was an even 
greater reduction in AUC.
Significant changes were also observed after oral administration 
of tocainide in that with the enzyme inducers, both t^ and AUC were 
reduced, the effect on AUC being more marked with phenobarbitone. This 
may reflect a more potent effect in increasing drug metabolism with 
the latter drug.
Comparison with AUC after p.o. and i.v. administration allows 
calculation of a value for availability (F). For a highly extracted 
drug such as lignocaine changes in availability have relatively little 
practical consequence but in fact after both enzyme inducers F fell, 
the mean values being control 0.019, 3,4 benzpyrene 0.013 and phenobarb­
itone O.OlO. Tocainide is much less extracted in a single pass through 
the liver than lignocaine. Extraction of tocainide was also increased 
with reduced availability, the mean values for F being control 0.94,
3,4 benzpyrene 0.64 and phenobarbitone 0.63.
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Possible conséquences in clinical use
The findings may be extrapolated to the clinical use of these 
drugs. They imply that for lignocaine, a drug used almost exclusively 
by the intravenous route, since t^ does not change, the time to reach 
steady state (4 x tĵ ) would be unaltered by enzyme induction. CL was 
increased but not significantly so by 3,4 benzpyrene but was significantly 
increased by phenobarbitone. Thus following intravenous infusion it 
is possible that the concentration of lignocaine at steady state may 
be reduced in enzyme induced patients who would thus not receive the 
degree of protection expected from standard dosing regimens.(Perucca 
and Richens, 1979), although reduction in concentration of lignocaine 
would be mitigated by the fact that the primary metabolite MEGX is also 
pharmacologically active.
Tocainide may also be given by the intravenous route. The present 
data indicates that in the presence of enzyme induction CL is increased 
and thus the steady state blood concentration anticipated from standard 
dosing regimens would be reduced. The data for phenobarbitone (reduced 
t^) also suggest that steady state may be attained in a shorter time 
in enzyme induced subjects. The major use of tocainide, however, is oral 
and the data clearly show that although time to attain steady state is 
reduced (reduced t^), the major reduction is in AUC and is indicative 
of reduced blood concentration in the presence of enzyme induction. In 
patients o n  standard dosing lower than expected steady state concent*, 
trations would be acheived and such individuals may not be adequately 
protected against the risk of cardiac arrhythmia.
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6.5 Effects of reduction in blood flow on the kinetics of lignocaine 
and tocainide in rat
6.5.1 Liver blood flow
The various methods which have been used to measure liver blood
flow are reviewed in Chapter 1. In the present study the radioactively
labelled micro sphere method was used because it not only gave reliable
data for liver blood flow in rat but flow to other organs and the
fractional distribution of cardiac output can also be measured. The
values obtained for flow to liver and other major organs in the present
study are in good agreement with those of McDevitt and Nies (1976),
Hiley and Yates (1978). Liver blood flow,relative to tissue weight
-1 -1varies little between species being of the order of 1 ml.min .g, tiss 
and the findings in the present work are in accord with this (Neutze, 
Wyler and Rudolph, 1968; Sasaki and Wagner, 1971; Benowitz et al, 1974a; 
Yates et al, 1979).
Liver blood flow is an important determinant: of the elimination of 
many drugs, particularly those with high extraction ratio. Change in 
cardiac output or in distribution of the output to the liver cause 
variation in blood flow to this organ and may thus affect drug clearance. 
Factors that generally regulate cardiac output and its distribution have 
been summarized by Wilkinson (1975) . Exercise and thermal stress which 
increase cardiac output, caused about a 50% increase in human hepatic 
elimination of indocyanine green, a highly hepatic cleared substance 
(Rowell, Blackmen, Martin, Mazzarella and Bruce, 1965), whereas the 
hepatic clearance of antipyrine, a drug with a low hepatic extraction 
ratio, was unaffected by these stresses (Schartz, Sidell and Cucinell, 
1974). Other physiological variations e.g. changes in posture from the 
supine to upright position which decrease cardiac output, which leads 
to a significant reduction in flow to the liver were reported by
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Culbertson, Wilkins, Ingelfinger and Bradley (1951) to produce a two­
fold difference in the metabolism of aldosterone. Liver and heart 
disease may alter cardiac output and/or blood distribution leading to 
changes in hepatic blood flow. Thomson et al (1971) reported that 
there was about a 55% decrease in lignocaine clearance in patients with 
cardiac failure compared with normal. Other factors that cause hae- 
modynamic alterations are drugs. The clearance of d-propranolol was 
increased in the presence of glucagon in the monkey (Branch et al,
1973) because glucagon produced a dose-related increase in cardiac 
output and in total liver blood flow.
In the restrained monkey Benowitz et al (1974b) found that infu­
sion of isoprenaline lowered and infusion of noradrenaline raised 
steady state blood concentration of lignocaine due to alteration of 
liver blood flow. Branch et al (1974) demonstrated that phenobarbitone 
pretreatment caused an increase in the clearance of d-propranolol with 
reduction in t^. They estimated that only 43% of the increase in 
clearance was due to enzyme induction and that 57% was due to the fact, 
also found in the present work, that phenobarbitone increases liver 
blood flow. The same study also indicated that change in liver blood 
flow only played a minor role in the elimination of antipyrine a drug 
for which E - 0.2.
Branch et al (1973) demonstrated that when the pharmacologically
active dl-propranolol was given, cardiac output and liver blood flow
longer
were reduced and that the half life\and clearance of lignocaine 
were reduced, d-propranolol the pharmacologically inactive isomer 
caused no change in the kinetics of lignocaine indicating that the 
alteration in the kinetics were due to the effects of g-adrenoceptor 
blockade on haemodynamics. In similar studies with oxyphenbutazone 
a drug with low hepatic extraction the kinetic effects of 6 -adrenoceptor
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blockade were predictably less. The isomers of propranolol provide 
further evidence of effect of liver blood flow on drug clearance.
Nies et al (19731 found that in the monkey the clearance of dl-prop­
ranolol was about 25% less than that of d-propranolol an effect which 
may be attributed to the 6 -adrenoceptor antagonistic effect of the 
1 -isomer.
6.5.2 6 -adrenoceptor blockade, and organ blood flow
The labelled microsphere method permits an analysis of the blood 
flow to individual organ and also the fractional distribution of 
cardiac output. 6 -adrenoceptor blockade with sotalol in the present 
experiments brought about the expected decrease in cardiac output 
(26 %, p<0.02). This decrease was reflected in reduced blood flow 
received by all organs but was only statistically significant in the 
case of hepatic arterial flow. Blood flow to alimentary tract, pancreas 
and spleen were also reduced but not to a statistically significant 
degree. However, when hepatosplanchnic (hepatic arterial plus portal) 
flow was considered, blood flow was reduced by 29% which was statistically 
significant (p<0.05). Because the reduction in cardiac output was 
reflected in reduced blood flow to all organs the regional distribution 
of flow was not significantly altered by treatment with sotalol.
The effects of pentobarbitone anaesthesia per se was studied in 
dogs by Kaihara, van Heerden, Migita and Wagner (1968) in rats by Bell, 
Hiley and Yates (1977), using the microsphere distribution technique and 
in man by Goldberg (1970) using the Pick's method. All studies found that 
pentobarbitone did not affect splanchnic haemodynamics.
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6.5.3 ' Beta-adrenoceptor blockade and pharmacokinetic change
The present study has been concerned with lignocaine which is 
liver blood flow dependent for elimination and tocainide one which is 
not flow dependent. Thus it would be expected that altering liver 
blood flow would have different effects on the kinetics of these 
two drugs.
Blood flow was altered by administering a 6 -adrenoceptor anta­
gonist, since this is a convenient way to alter flow and one which is 
likely to be encountered in use in man. In the selection of a 6 -blocking 
agent it was necessary to find a drug which gave a depression in blood 
flow for a sufficient length of time to permit change in the kinetics 
of the two drugs to be observed. It was thus necessary to have a drug 
with a reasonaly long t^. Sotalol was selected because it has t^ of 
- 3 hours after intraperitoneal injection of 20 mg.kg in the rat 
(Ishizaki, Tawara and Oriuchi, 1977). Sotalol is also eliminated 
mainly by the kidney which is an added advantage because there is less 
chance of interaction between sotalol and lignocaine or tocainide both 
of which are eliminated by the liver.
The data may be dealt with either on observations or in relation 
to the changes in kinetics predicted by the pharmacokinetic models. In 
this section the data will be dealt with as observations and the 
implications of the findings on dosing are discussed.
- 1In initial experiments it was found that doses up to 50 mg.kg
did not have a sufficiently prolonged action for the proposed experi-
-1ments in the rat. Doses in excess of ICO mg.kg was lethal. Thus a 
-1dose of ICO mg.kg was selected and a regime in which sotalol was 
given intraperitoneally three times on the day before the experiment, 
then again 15 minutes before lignocaine or 30 minutes before tocainide 
and in case of tocainide on three further occassions was found to be 
satisfactory (Chapter 5.1). As was anticipated, when sotalol pre-
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treated rats were given lignocaine changes in kinetics were observed; 
after intravenous administration both t^ and AUC were increased and 
inconsequence drug clearance was reduced. Similar change occurred 
after oral administration with lengthening of t^ and increase in AUC.
The findings after tocainide were those that would be expected of 
a drug which has low hepatic extraction. There was a slight increase 
in AUC and lengthening of t^ after intravenous tocainide but the changes 
were not significant statistically. Increase in AUC and t^ also occurred 
after oral administration of tocainide but again the changes were not 
significant. It may be recalled that 20% of a dose of tocainide is 
eliminated by the kidney but this may be ignored because renal blood 
flow, showed only minor changes.
Possible consequences inclinical use
The finding can be extrapolated to man. It is possible that in 
patients who are fully g-blocked the haemodynamic and kinetic changes will 
be the similar as those made in the present work, i.e. lengthened/lignocaine t̂  ̂
and reduced clearance. This would imply that such patients receiving 
constant rate intravenous infusions of lignocaine would attain steady 
state after a longer time than would non-6 -blocked patients and because 
clearance is reduced, the ultimate steady state concentration attained 
would be higher than in non-6 -blocked patients. Thus unless the dosage 
scheme was modified patients receiving gadrenoceptor blocking drugs 
would run increased risk of toxicity from lignocaine infusion.
The findings are also of value for tocainide because they imply 
that even patients who are g-blocked would not show altered kinetics.
Thus normal dosing schedules for tocainide probably apply to patients 
taking 6 -blockers.
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6,6 Liver blood flow: comparison of results obtained by the
microsphere and by the lignocaine clearance methods
Two methods were used in this work to measure liver blood flow. 
This provides an opportunity to compare the results obtained with 
the lignocaine clearance and with the radioactively labelled micro­
sphere techniques when liver blood flow is altered by the experi­
mental conditions. Mean data for control and for 3,4 benzpyrene, 
phenobarbitone and sotalol pretreated rats are summarised in Table 
6.2.
The values for hepatic blood flow in control animals obtained 
by the two techniques were different being approximately three times . 
greater by the ncLcrosphere method. The reason for this difference is 
not clear. The data for the microsphere method agrees with previously 
published work by McDevitt and Nies (1976) and.Hiley and Yates (1978) 
but data for liver blood flow in rat using the lignocaine clearance 
technique have not been found in the literature. Anaesthesia (ether 
+ pentobarbitone) may have affected the results with the microsphere 
technique but this form of anaethesia is reported not to affect liver 
blood flow (Bell et al, 1977). Table 6.2 also shows that there 
was agreement between the two methods in the direction of change in 
liver blood flow under the influence of the various drugs used but 
the magnitude of the change was different being approximately two 
times greater when liver blood flow was calclulated by the lignocaine 
clearance techniqe. Thus the increase in liver blood flow after 
phenobarbitone was 39.7% by the microsphere method and 76.7% by the 
lignocaine clearance technique. The fall in liver blood flow after 
sotalol was 22.7% by the microsphere method but 50.9% by the ligno­
caine clearance technique.
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The two methods differ in approach to the estimation of liver 
blood flow, one depending on the clearance of a drug, the other on 
the arrest of microspheres in the hepatic microvasculature. The 
quantitative differences in the data obtained by the two techniques 
suggest that there are differences in what the two methods measure 
but the explanation for this is obscure.
Table 6.2 Comparison of mean liver blood flow calculated by the 
microsphere and by the lignocaine clearance methods in 
control and in treated rats
liver blood flow
by lignocaine clearance by microspheres
ml.min"! ml.min“l. % change 
1 0 0 g,bw”^
ml.min' ml.min 1 . 
1 0 0 g,bw~l
%change
control 5.28 1.26 — 20.74 4.06 —
3,4 benzpyrene 6.64 1.47 (+16.5) 17.9 4.16 (+2.5)
phenobarbitone 9.58 2.23 (+76.7) 27.13 5.67 (+39.7)
sotalol 2.45 0.62 (-50.9) 11.14 3.14 (-22.7)
6 .7 Observed values compared with predictions of Model I and Model II 
The observed values for various pharmacokinetic parameters 
derived in this work were compared with those predicted by Model I 
and Model II,
Change in liver blood flow
The definition of intrinsic clearance is the same with both models 
but the predicted value derived from a given extraction ratio does 
differ. Intrinsic clearance can be derived from each model from
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Table 1.2 in terms of blood flow and extraction as follows:
Model I CL. _ = QE
i=i
Model II CL. ^ = -Q . In (1-E)int
Using the value for E for lignocaine obtained from the mean of 
all intravenous and oral single dose studies (0.981), CLu^^ was 
calculated for each model. Taking the values for liver blood flow 
(corrected to 1 0 0  g, body weight) obtained by the lignocaine clearance 
and by the microsphere methods predicted values for E, AUC^ ^ , F and 
AUC were calculated for each model.P.O.
The predictions for the kinetics of lignocaine in control rats
were compared with the findings for rats which had received sotalol.
Since CL. ^ is independent of flow the value for CL. ^ calculated int int
for the control rats was used for predicting parameters for sotalol 
treated rats. The values for liver blood flow after treatment with 
sotalol (Table 6.3) were substituted to predict the kinetics of 
lignocaine in the sotalol treated rats. The data for lignocaine 
appears in Table 6.3. This shows that E did not change when flow 
was reduced and this is accurately predicted by both models. AUC^ ^ 
increased after sotalol treatment and Model I gave a closer prediction 
of this change than did Model II. Availability (F) was observed to 
reduce only marginally in the present work but both models predicted 
a much greater degree of fall. A marked discrepancy between the 
predictions of both models and the observed data occurs in AUCp.o.
This was observed to undergo a two fold increase when liver blood flow 
diminished but the predictions of Model I are that there would be 
no change and Model II predicts a reduction in AUCp.o.
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The influence of protein binding was ignored in these 
calculations because lignocaine exhibits non-restfictive binding 
i.e. E>fg.
Similar calculations were carried out for tocainide. It is
recognised that since tocainide exhibits restrictive binding i.e.
fg>E, alteration in binding could influence the findings. Since only
whole blood was assayed in the present work the fraction bound was
assumed to be constant at a value of 0.5 (Lalka et al, 1976). CL. ^int
in control animals was calculated from the mean of all intravenous
-1data and was related to the 50 mg.kg oral dose which was also the 
oral dose used in the studies with sotalol. The data are summarised 
in Table 6.4. This shows that for tocainide E increased by a fractor 
of 1.24 when blood flow was reduced by sotalol and this was predicted 
by both models. A slight increase in AUC^ ^ was observed after 
sotalol and was predicted by the models. Likewise the slight fall 
in F observed after sotalol was predicted. Only slight change was 
noted in AUC^ ^ and the predictions of both models agree with this.
Change in drug metabolism
Predictions in respect of lignocaine for Model I and Model II for
E, AUC. , F and AUC were made keeping liver blood flow constant i.v. p.o.
at the value for control rats and substituting the value for E obtained
after 3,4 benzpyrene treatment (0.986). The data appears in Table 6.5.
This shows that the reductions in AUC^ and AUC which occurredi.v. p.o.
with lignocaine after treatment with 3,4 benzpyrene were predicted by 
both models. Predictions for tocainide in rats treated with 3,4 benzpyrene 
were calculated taking the value for E obtained in that study (0.355) 
and assuming binding to be constant (f^ = 0.5). The data are shown in 
Table 6 .6 .
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This shows that increase in drug metabolism with 3,4 benzpyrene was
associated with an increase in E, a fall in AUC ̂ and a decrease inI.v.
AUC ^ all of which changes were predicted by both models.
Change in liver blood flow and in drug metabolism
The data for AUC. and AUC . for lignocaine and tocainide in I.v. p.o.
rats treated with phenobarbitone (i.e. change in liver blood flow and
enzyme induction) were calculated as previously described. Values for
CLu^^ after phenobarbitone treatment were calculated using the figures
for E obtained in that study (lignocaine E = 0.99, tocainide E = 0.369)
and in both instances the value for flow obtained in enzyme induced animals
was used. The value for flow measured after phenobarbitone treatment by
the lignocaine clearance and by the microsphere methods and the above
value for CL. were then used to calculate the data for area. The data int
are given in Table 6.7. This shows that for both AUC. and AUC theI.v. p.o.
predictions for lignocaine were accurate but the predictions for tocainide 
were less so.




3,4 benzpyrene 0.986 0. 355
phenobarbitone 0.990 0.369
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Summary of predictions by Model I and Model II
For a low hepatic clearance drug such as tocainide the models
predict changes in E, F and AUC with reasonable accuracy when blood
flow or metabolism are altered.
For a high hepatic clearance drug such as lignocaine, satisfactory
predictions of kinetics change are obtained when hepatic enzymes are
induced. When hepatic blood flow is changed the predictions for E
and AUC. are reasonably close to the observed changes but neither I.v.
model could predict the observed changes in AUC^ ^ for change in blood 
flow.
When blood flow and metabolism were changed the predictions for 
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p f—1 CN CN CN N* p CN O 00 LO m ĉ LO LO LO O en P en CN 00 o O OP P (—i 1—l
+1 +1 +1
m CD CD N* r~- LO LO TT 00 CN LO ro N* O CN CN LO Q O CN in LO en
N* iT) m 00 P un ■N* ro en m 00 f—1 LO ro TT ro en 0 d* en d* LO 00
LT»
CN- CN CN n LO p ro O 00 un in LO 00 r-~ 00 o O ro CN LO P d* ro O—1 P P (— i 1— 1 1—1 P
+1 +1 +1
p
p ro LOen r 1—1*H d*(U in O m O lO O en un O un O Q Q O Q in O in Q Q Q un f— 1
> 5 * CD CD CD CN CN +1
CN 00 O O O O 00 O +1 00 in O O O in +1m n m ro •d* N* m Tf ro -d* N* •N* ro en d* d» d* d* d* d* 1—1
>1 en en ro73 ro ro d*
O
m





cn Oo tn m O




























































LOcNcncoocnr^cNOcDO pi—I P  ro LO P  O  P  O  •
0 0 0 0 0 0 0 0 0  +1
enI—I
CN CN m LO m m d* CN in d* co m  CNO  CN p
O O O O P O O O O
in(nrocNcocoLominop OLOdLOLOr^CNLOP • • • • • • • • • • OP  O O O P O O O O + l
enLO
00 oC" p LO ro en CN LO d  00 p  p
enLO CN
P P O O c o p O O
O O O r o d P P O dpcNr~enroLOoop
LO en CN• « « oO +1
C N P O O d P O P O
inLO CN 00 O d P O O O' d O 00 CN ro P en LO LO r~- 00 ro LO CN
O LO CN f—t P en 00 r~ CN O LO P en 00 00 O ro CN
O Gro CN P P LO CN O 1—1 G +1 ro LO CN LO CN ro +1 r~» CN LO lO LO
un LO LO m  CN CN o ro d* d  d
O  m  O  O  00 p  m  00 ro d  ro ro







O  O  en r -  CN CN 00 CN ro
O O O O O O
LO d  O  LO d  00LO lO ro CN LO lO
O  O  O P  O O
00LO LO 00 O  LO lO roO  ro O  (N .
p  o  o  co o p  +1oCN
d  LO00 00 CN LO ro d  p  00 •
CN p  o ro p  p
CN CN 00 00 P  LO p  r- CN lo LO d
CN CN p  d  p oCN +1 LO d
G LO en en CN P CN S 00 LO CN 00 o LO 1—t en LO r~ LO r - O 1—1roLO ro LO G LO en LO 00 G O' r^ 00 en ro d ro CN en
O Od ro CN CN CN CN CN O +1 d LO ro LO CN d +1 en d en LO LO
in
O en G d P O p en 00 O G o 1—1 d LO ro 00 en CN en G 00
LO en ro LO CN p en fn CN LO lO LO CN LO 00 LO O CN d
G O O
LO d CN CN 2 LO d ro G +1Q LO 00 LO 00 LO LO +1d Or—1 LO 2 2 en +100
LO o  LO m  ro 00 ro 
d  d  d  d
LO 00 +1 
d  O  LO 
d
n










o gro en LOd
en
P O P ' —I P  P Sr-CN
00
ro G
ro00 d  O  rop  00 en CN •• • • • OCN CN P  CN +100
CN
ro00 00 en P  00 G  dO  O  00 00 LO r- .
d  p  CN ro CN CN +1LO 00
CN
r~»O  LO d  LO ro G  LO ro ro en ro d  «
ro ro +1lO P  ro d
en CN 00 P  G LO LO LO
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Lignocaine and tocainide blood concentration-time data after 
i.v. administration were fitted to prescribed functions using the 
non-linear least squares regression analysis programme "NONLIN" 
(Metzler, 1969). Preliminary analysis indicated that it was adequate 
to fit the lignocaine and tocainide I.V. bolus dose data by the sum 
of two exponentials.
The following parameters were calculated from the coefficients 
and exponents (a referring to the fast and 3 to the slow exponent) 
of the biexponential equation describing the lignocaine and tocainide 
intravenous data
* 1 2 - ’' 2 1 ’'e
Vp
S a ’ S ;
AUC
CL
Distribution volumes, VD , Vd and VD were calculatedextrap area ss









The blood concentration data of the drugs after single oral
administration were fitted by least squares linear regression analysis
to a mo no exponential equation. The estimated of k^ and t^ were
obtained graphically from semilogarithmic blood concentration curves
by the method described by Gibaldi (1975) and Wagner (1975)
(see Chapter I).
The areas under the blood concentration-time curve after oral
administration were calculated according to the trapezoidal rule
(Notari, 1975) and the infinite part of the curve was calculated as
C*/k, (C* = last measurable concentration, k_ = overall elimination d d
rate constant).
Systemic availability of orally administered lignocaine and 
tocainide was calculated according to the principles discussed 
previously (Chapter I) and shown in eq. (23) .
Systemic availability = AUC ,
eq. (23)AUC.
I . V .
Mean renal clearance of i.v. tocainide was calculated from the
blood level and urinary excretion data by the following relatinship
Mean renal clearance =
_______________ Total amount excreted in urine ^
Total area under blood concentration-time curve
The total body clearance (mean blood clearance) after i.v. and
oral administration was obtained from eq. (15) .
CL = Dose
AUC
The difference between total body and renal clearance was 
designated as the "nonrenal clearance".
eq. (15)
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Appendix 21 The nonlinear least square regression analysis 
programme "r:ONLIN"
i;’:A 00 0 : 3 11 3u:'!:cE r o u G i o u :
1 c r x c r . . î i gdl l
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[Dissolve 9.2 g potassium dihydrogen phosphate (KH^PO^)
44.0 g dipotassium hydrogen phosphate (K^HP0^.4H^0) 
11.2 g potassium chloride (KCl); 
in sufficient amount of de-ionised water to produce 1 0 0 0  ml. 
Adjust pH to 7.25 with 0.2 N HCl or NaOH
Appendix 23
Glycerol phosphate buffer (pH 7.25)
Dissolve 9.2 g potassium dihydrogen phosphate (KH^PO^)
44.0 g dipotassium hydrogen phosphate (K^HPO^ 4H^0) 
in sufficient amount of deionised water to produce 700 ml. 
Adjust pH to 7.25 with 0.2 N HCl or NaOH and then add 3.00 ml of 
glycerol to the mixture.
Appendix 24
Incubation mixture for p-nitroanisole O-demethylase activity 
assay.
Incubation mixture allowing for each sample:
0.25 ml 0.2 M Tris pH 7.2 
0.03 ml 0.1 M MgCl^
0.62 ml H^O 
0.3 mg NADH 
0.3 mg NADPH 
Titrate to pH 7.2 with 0.2 N NaOH if necessary.
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Appendix 25
Citrate buffer CpH 5.5)
Dissolve 7.14 g citric acid;
44.1 g sodium citrate; 
in 620 ml deionised water.
Adjust to pH 5.6 with 1 M citric acid solution.
Appendix 26
Nash reagent
Prepare fresh for each assay
3.75 g ammonium acetate;
0.05 ml acetylacetone; 
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